NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. GENERAL INFORMATION

Big Caring Group Bhd ("BCG" or the "Company") was incorporated in Malaysia under the Companies Act 1965 on 2 May 2013 as a private limited company under the name of Platinum Perspective Sdn. Bhd. and is deemed registered under the Act. The Company subsequently changed its name to Big Pharmacy Holdings Sdn. Bhd. on 12 November 2013 and thereafter to Big Caring Group Sdn. Bhd. on 3 January 2024. On 6 March 2026, the Company converted from a private limited company to a public limited liability company.

The registered office of the Company had changed from 3rd Floor, No. 17, Jalan Ipoh Kecil, 50350 Kuala Lumpur, Malaysia to No. D-09-02, Level 9, EXSIM Tower, Millerz Square @ Old Klang Road, Megan Legasi, No.357, Jalan Kelang Lama, 58000 Kuala Lumpur, W.P. Kuala Lumpur.

The principal place of business of the Company had changed from No. 19, Jalan 15/23, Taman Perindustrian Tiong Nam, Section 15, 40200 Shah Alam, Selangor Darul Ehsan to 8, Jalan Astana 3/KU2, Bandar Bukit Raja, 41050 Klang, Selangor.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION

The Accountants' Report comprises the Consolidated Financial Statements of the Company and its subsidiaries (collectively referred to as the "Group") for the financial years ended ("FYEs") 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026. The Consolidated Financial Statements of the Group consist of the audited financial statements of the Company and its subsidiaries and are prepared solely for inclusion in the Prospectus of the Company in connection with the listing of and quotation for the entire enlarged issued share capital of Big Caring Group Bhd on the Main Market of Bursa Malaysia Securities Berhad (the "Listing").

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows:

Company	Relevant Financial Years	Auditors
Plenitude Highlands Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Lucky Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Quantum Upstream Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
L&L Healthcare Supply Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Farmasi Maluri Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
LW Medical Associates Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy FC Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Aetos Pharma Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
BIG Pharmacy Healthcare Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Sarawak) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Northern) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy Avenue Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Southern) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Perak) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Sabah) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big KL Pharmacy Sdn. Bhd. (formerly known as Big Kok Lian Pharmacy Sdn. Bhd.)	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
AHC Medical Supplies Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Pharmacy (Melaka) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT


Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Quantum Upstream (Singapore) Pte. Ltd. ^	FYE 30 June 2023	Not audited
	FYE 30 June 2024	Not audited
	FYE 30 June 2025	Not audited
	FYE 30 June 2026	Not audited
Caring Pharmacy Group Sdn. Bhd. (formerly known as Caring Pharmacy Group Berhad) *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Medispec (M) Sdn. Bhd. *	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Your Physio Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT
Subsidiaries of BIG Pharmacy Healthcare Sdn. Bhd.		
MY Pharmacy Group Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Mercury Wellness Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd.		
Ting Alliance Sdn. Bhd. *	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiary of Quantum Upstream Sdn. Bhd.		
Yanling Assets Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of MY Pharmacy Group Sdn. Bhd.		
MY Pharmacy (M) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (Sentosa) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiaries of MY Pharmacy (M) Sdn. Bhd.		
MY Pharmacy Services Sdn. Bhd. *	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (Pelangi) Sdn. Bhd. *	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (Austin) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (NB) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (KT) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (Kota) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (JJ) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT


Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of MY Pharmacy Services Sdn. Bhd.		
MY Pharmacy (Pandan) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Pharmacy (Kulai) Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiaries of Mercury Wellness Sdn. Bhd.		
MP Wellness Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
G&T Pharma Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MYGS Venture Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
G&A Pharma Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MP Baitul Salam Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
GM Pharma Sdn. Bhd.	FYE 30 June 2023	BDO PLT
	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of Yanling Assets Sdn. Bhd.		
Yanling Holdings Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiaries of Yanling Holdings Sdn. Bhd.		
Yanling Natural Hygiene Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Asia Healthcare Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Dermarque Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
E-Pharma (M) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiary of Caring Pharmacy Group Sdn. Bhd. (formerly known as Caring Pharmacy Group Berhad)		
Caring Pharmacy Retail Management Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd.		
Caring Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Estore Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (Kinrara) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)		
Caring Pharmacy (RS) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Viva Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Belle Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Sterling Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Be Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MN Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (KLP) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring 'N' You Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy Always Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Ace Caring Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Stay Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)		
Caring Health Solutions Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (Ampang) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Vertex Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Preciouslife Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
WM Caring Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Big Caring Academy Sdn. Bhd. (formerly known as "Tonic Pharma Sdn. Bhd.") *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (MPLS) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (SW) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
MY Caring Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (ABM) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (SK) Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Victorie Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)		
One Caring Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Green Surge Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (JB Molek) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (Shah Alam) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Living Glory Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy (IDR) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Trio Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Mega Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Abundance Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Fuji Acre Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy Rising Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Trinity Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906050013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)		
Caring Clover Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Healthmark Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Evergreen Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Pharmacy Ascend Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Empire Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring T & T Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Link Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Caring Alliance Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
The Pill House Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Wellings Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Jom Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT


Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Held through Caring Evergreen Sdn. Bhd.:		
Maxi Caring Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Held through The Pill House Pharmacy Sdn. Bhd.:		
Wellings Pill House Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Held through Wellings Pill House Sdn. Bhd.:		
Wellings Pill House (TG) Pharmacy Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Blooming Health Pharmacy Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Realcare Pharmacy (K) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Health Town Pharmacy Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Green Trees Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Realcare Baby and Organic Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Nutrilife Pharmacy Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Pure Health Pharmacy Sdn. Bhd. * @	FYE 30 June 2024	BDO PLT
Sharing Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Simple Life Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Held through Wellings Pill House Sdn. Bhd.: (continued)		
Langkawi Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Amazinglife Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Pharmfresh Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Nutricient RX Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Super Health Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Healthy Care Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Healthy Point Pharmacy Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Held through Wellings Pharmacy Sdn. Bhd.:		
Masons Health Sdn. Bhd. *[&]	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
Wellings Selat Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Held through Jom Pharmacy Sdn. Bhd.:		
Medical Supplies (Sarawak) Sdn. Bhd. *	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Jom Pharmacy (Serian) Sdn. Bhd. *&	FYE 30 June 2024	BDO PLT
	FYE 30 June 2025	BDO PLT
Held through Medispec (M) Sdn. Bhd.:		
Vitamode Sdn Bhd*	FYE 30 June 2025	BDO PLT
	FYE 30 June 2026	BDO PLT
Medispec (S) Pte Ltd *	FYE 30 June 2025	Precursor Assurance LLP
	FYE 30 June 2026	Precursor Assurance LLP
Held through Your Physio Sdn. Bhd.:		
Our Physio Sdn. Bhd. * #	N/A	Y.H. Chang & Partners
	FYE 30 June 2026	BDO PLT
Spine Sports Stroke Rehab Specialist Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT
Your Physio Southern Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT
Held through Our Physio Sdn. Bhd.:		
Island Rehab Specialists Sdn. Bhd. * #	N/A	Y.H. Chang & Partners
	FYE 30 June 2026	BDO PLT
PT Pro Sdn. Bhd. * #	N/A	Y.H. Chang & Partners
	FYE 30 June 2026	BDO PLT
Held through Spine Sports Stroke Rehab Specialist Sdn. Bhd.:		
Pakar Fisio Dan Rehabilitasi Anda Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT
YB Physio Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT
Xin Rehab Specialist Sdn. Bhd. * #	N/A	OK Tan & Co. PLT
	FYE 30 June 2026	BDO PLT

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

2. BASIS OF PREPARATION (continued)

The relevant financial years of the audited financial statements used for the purpose of this Report and the statutory auditors of the respective companies within the Group are as follows: (continued)

Company	Relevant Financial Years	Auditors
Held through Spine Sports Stroke Rehab Specialist Sdn. Bhd.: **(continued)**		
Best Physio Sdn. Bhd. * #	N/A FYE 30 June 2026	OK Tan & Co. PLT BDO PLT
Your Physio Klang Sdn. Bhd. * #	N/A FYE 30 June 2026	OK Tan & Co. PLT BDO PLT
Caring Rehab Specialists Sdn. Bhd. * #	N/A FYE 30 June 2026	OK Tan & Co. PLT BDO PLT
YP Physio Sdn. Bhd. * #	N/A FYE 30 June 2026	OK Tan & Co. PLT BDO PLT

^ *Subsidiary is consolidated based on the unaudited financial statements as the subsidiary is not required to be audited for the FYEs 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026 under its country of incorporation. This subsidiary is not material to the Group.*
* *Subsidiaries are consolidated upon completion of acquisition.*
\# *Subsidiaries are consolidated based on the unaudited financial statements as at 30 June 2025 as the subsidiaries financial year end is 30 April 2025.*
@ *Subsidiaries have been struck off during the FYE 30 June 2025.*
& *Subsidiaries have been struck off during the FYE 30 June 2026.*

The audited financial statements of the Company and its subsidiaries for the relevant financial years reported above were not subject to any qualification or modification.

The Consolidated Financial Statements of the Group has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") and IFRS Accounting Standards.

The Consolidated Financial Statements of the Group has been prepared under the historical cost convention unless otherwise stated in the Consolidated Financial Statements.

The preparation of Consolidated Financial Statements in conformity with MFRS and IFRS Accounting Standards requires the Directors to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and contingent liabilities. In addition, the Directors are also required to exercise their judgement in the process of applying the accounting policies. The areas involving such judgements, estimates and assumptions are disclosed in the Note 4 to the Consolidated Financial Statements. Although these estimates and assumptions are based on the Directors' best knowledge of events and actions, actual results could differ from those estimates.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

3. ADOPTION OF NEW MFRSs AND AMENDMENTS TO MFRSs

3.1 New MFRSs adopted during the financial years

The Group adopted the following Standards of the MFRS Framework that were issued by the Malaysian Accounting Standards Board ("MASB") during the reporting periods:

Title	Effective Date
MFRS 17 *Insurance Contracts*	1 January 2023
Amendments to MFRS 17 *Initial Application of MFRS 17 and MFRS 9 – Comparative Information*	1 January 2023
Amendments to MFRS 101 *Disclosure of Accounting Policies*	1 January 2023
Amendments to MFRS 108 *Definition of Accounting Estimates*	1 January 2023
Amendments to MFRS 112 *Deferred tax related to Assets and Liabilities arising from a Single Transaction*	1 January 2023
Amendments to MFRS 112 *Income Taxes International Tax Reform - Pillar Two Model Rules*	See paragraph 98M of MFRS 112
Amendments to MFRS 16 *Lease Liability in a sale and leaseback*	1 January 2024
Amendments to MFRS 101 *Classification of Liabilities as Current or Non-current*	1 January 2024
Amendments to MFRS 101 *Non-current Liabilities with Covenants*	1 January 2024
Amendments to MFRS 107 and MFRS 7 *Supplier Finance Arrangements*	1 January 2024
Amendments to MFRS 121 *Lack of Exchangeability*	1 January 2025

Adoption of the above Standards and Amendments did not have any material effect on the financial performance or position of the Group.

3.2 New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2026

Title	Effective Date
Amendments to MFRS 9 and MFRS 7 *Amendments to the Classification and Measurement of Financial Instruments*	1 January 2026
Amendments to MFRS 9 and MFRS 7 *Contracts Referencing Nature-dependent Electricity*	1 January 2026
Annual Improvements to MFRS Accounting Standards - Volume 11	1 January 2026
MFRS 18 *Presentation and Disclosure in Financial Statements*	1 January 2027
MFRS 19 *Subsidiaries without Public Accountability: Disclosures*	1 January 2027
Amendment to MFRS 19 *Subsidiaries without Public Accountability: Disclosures*	1 January 2027
Amendments to MFRS 121 *Translation to a Hyperinflationary Presentation Currency*	1 January 2027
MFRS 20 *Regulatory Assets and Regulatory Liabilities*	1 January 2029
Amendments to the Fair Value Option for Investments in Associates and Joint Ventures (Amendments to MFRS 128 *Investments in Associates and Joint Ventures*)	Applicable when an entity first applies MFRS 18
Amendments to MFRS 10 and MFRS 128 *Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*	Deferred

The Group is in the process of assessing the impact of implementing these Standards and Amendments, since the effects would only be observable for future financial years.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS

4.1 Changes in estimates

Estimates are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Directors are of the opinion that there are no significant changes in estimates during the reporting period and at the end of the reporting period.

4.2 Critical judgements made in applying accounting policies

The following are judgements made by the management in the process of applying the accounting policies of the Group that have the most significant effect on the amounts recognised in the consolidated financial statements.

Deferred tax assets

Deferred tax assets are recognised for provisions and other temporary differences to the extent that it is probable that future taxable profits would be available against which the losses, capital allowances and other temporary differences could be utilised. Significant management's judgement is required to determine the amount of deferred tax assets that could be recognised, based on the likely timing and extent of future taxable profits together with future tax planning strategies.

4.3 Key sources of estimation uncertainty

The following are key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

(a) Impairment of property, plant and equipment and right-of-use assets

Management used forecasted cash flows and a value-in-use model to determine the recoverable amounts of the property, plant and equipment and right-of-use assets in certain subsidiaries/Cash Generating Units ("CGU") which have indication of impairment to assess if there is any impairment loss required on the property, plant and equipment and right-of-use assets.

The determination of whether or not an impairment loss is necessary involves significant judgements and estimates about the future results and key assumptions applied to cash flow projections of these CGUs in determining their recoverable amounts. These key assumptions include forecast growth in future revenues and operating profit margins, as well as determining an appropriate pre-tax discount rate and growth rates.

(b) Impairment of goodwill on consolidation

The Group determines whether goodwill on consolidation is impaired at least on an annual basis. This requires an estimation of the value-in-use of the subsidiaries to which goodwill is allocated. Estimating a value-in-use amount requires the management to make an estimate of the expected future cash flows from the subsidiaries and also to choose a suitable discount rate in order to calculate the present value of those cash flows.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

4. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS (continued)

4.3 Key sources of estimation uncertainty (continued)

(c) Impairment of intangible assets

The Group determines whether an asset is impaired by evaluating the extent to which the recoverable amount of an asset is less than its carrying amount. This evaluation is subject to changes such as market performance, economic and political situation of the country.

Recoverable amount is measured at the higher of the fair value less cost to sell for that asset and its value-in-use. The value-in-use is the net present value of the projected future cash flows derived from that asset discounted at an appropriate discount rate. For such discounted cash flows method, it involves the use of estimated future results and a set of assumptions to reflect its income and cash flows. Judgement has been used to determine the discount rate for the cash flows and the future growth of the business.

(d) Impairment of receivables

The impairment allowances for trade receivables are based on assumptions about risk of default and expected credit loss rates. The Group adopts judgement in making these assumptions and selecting inputs for computing such impairment loss, broadly based on the available customers' historical data, the existing market conditions including forward-looking estimates at end of the reporting period.

(e) Net realisable values of inventories

Reviews are made periodically by the management on damaged, obsolete and slow-moving inventories. These reviews require judgements and estimates. Inventories are written down when events or changes in circumstances indicate that the carrying amounts could not be recovered.

(f) Determination of the lease term of leases

The Group determines the lease term of a lease as the non-cancellable period of the lease, together with periods covered by an option to extend or to terminate the lease if the Group is reasonably certain to exercise the relevant options. The management has considered the relevant facts and circumstances that create an economic incentive for the Group to either exercise the option to extend the lease, or to exercise the option to terminate the lease. Any differences in expectations from the original estimates would impact the carrying amounts of the lease liabilities of the Group.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES

Details of the subsidiaries are as follows:

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Plenitude Highlands Sdn. Bhd.	60%	60%	60%	60%	Malaysia	Retail pharmacy, selling medicine, retail business and rice
Big Lucky Sdn. Bhd.	78%	78%	78%	78%	Malaysia	Retail pharmacy, selling medicine, retail business and rice
Quantum Upstream Sdn. Bhd.	*100%	*100%	[!]100%	100%	Malaysia	Distribute all kind of medication, pharmaceuticals, healthcare and cosmetic products
L&L Healthcare Supply Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Retail pharmacy, selling medicine and dispense prescription
Farmasi Maluri Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Retail pharmacy, selling medicine and dispense prescription
LW Medical Associates Sdn. Bhd.	*100%	*100%	[!]100%	100%	Malaysia	Provision of medical services
Big Pharmacy FC Sdn. Bhd.	100%	80%	80%	80%	Malaysia	Pharmacy chain retail and rice
Aetos Pharma Sdn. Bhd.	*100%	*100%	[!]100%	100%	Malaysia	Wholesale and distribution of imported and local pharmaceutical, healthcare and cosmetics products
BIG Pharmacy Healthcare Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Investment holding, pharmacy operator, retail business and rice
Big Pharmacy (Sarawak) Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Retail pharmacy and rice

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Big Pharmacy (Northern) Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Retail pharmacy and rice
Big Pharmacy Avenue Sdn. Bhd.	100%	100%	94%	94%	Malaysia	Retail pharmacy and rice
Big Pharmacy (Southern) Sdn. Bhd.	100%	79%	79%	79%	Malaysia	To deal in pharmaceutical products and rice
Big Pharmacy (Perak) Sdn. Bhd.	100%	100%	91%	91%	Malaysia	Retail pharmacy and rice
Big Pharmacy (Sabah) Sdn. Bhd.	100%	95%	95%	95%	Malaysia	Retail pharmacy and rice
Big KL Pharmacy Sdn. Bhd. (formerly known as Big Kok Lian Pharmacy Sdn. Bhd.)	100%	100%	90.6%	90.6%	Malaysia	Retail pharmacy, rice, rehabilitation products and tools
AHC Medical Supplies Sdn. Bhd.	60%	60%	60%	60%	Malaysia	Trading of medical and hospital equipment, pharmaceutical products and services, general trading and investment in shares
Big Pharmacy (Melaka) Sdn. Bhd.	100%	100%	86.3%	86.3%	Malaysia	Retail pharmacy and rice
Quantum Upstream (Singapore) Pte. Ltd.@	100%	100%	100%	100%	Singapore	Wholesale of medicinal and pharmaceutical products (western) and wholesale of medical, professional, scientific and precision equipment

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Caring Pharmacy Group Sdn. Bhd. (formerly known as Caring Pharmacy Group Berhad)	-	100%	100%	100%	Malaysia	Investment holding
Medispec (M) Sdn. Bhd.	-	-	89.3%	89.3%	Malaysia	Wholesale of pharmaceuticals products, medical machinery and equipment
Your Physio Sdn. Bhd.	-	-	57.1%[@]	57.1%	Malaysia	Engaged in provision of physiotherapy services and rehabilitation centre
Subsidiaries of BIG Pharmacy Healthcare Sdn. Bhd.						
MY Pharmacy Group Sdn. Bhd.	100%	100%	100%	100%	Malaysia	To deal in pharmaceutical products and rice
Mercury Wellness Sdn. Bhd.	51%	51%	51%	51%	Malaysia	Investment holding, wholesaling and retailing of pharmaceutical products, retail sale of rice
Subsidiaries of Big Pharmacy (Sarawak) Sdn. Bhd.						
Ting Alliance Sdn. Bhd.	70%	70%	70%	100%	Malaysia	Retail pharmacy and rice
Subsidiary of Quantum Upstream Sdn. Bhd.						
Yanling Assets Sdn. Bhd.	-	90%	90%	90%	Malaysia	Investment holding and provision of management services

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of MY Pharmacy Group Sdn. Bhd.						
MY Pharmacy (M) Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Investment holding
MY Pharmacy (Sentosa) Sdn. Bhd.	100%	100%	100%	100%	Malaysia	To deal in pharmaceutical products and rice
Subsidiaries of MY Pharmacy (M) Sdn. Bhd.						
MY Pharmacy Services Sdn. Bhd.	100%	100%	100%	100%	Malaysia	Investment holding
MY Pharmacy (Pelangi) Sdn. Bhd.	100%	100%	100%	100%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (Austin) Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (NB) Sdn. Bhd.	76%	76%	76%	76%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (KT) Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (Kota) Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (JJ) Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To deal in pharmaceutical products and rice

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of MY Pharmacy Services Sdn. Bhd.						
MY Pharmacy (Pandan) Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To deal in pharmaceutical products and rice
MY Pharmacy (Kulai) Sdn. Bhd.	80.4%	80.4%	80.4%	80.4%	Malaysia	To deal in pharmaceutical products and rice
Subsidiaries of Mercury Wellness Sdn. Bhd						
MP Wellness Sdn. Bhd.	51%	51%	51%	51%	Malaysia	To carry on the business of general importers and exporters, general merchant, hire purchase dealers, commission agents, manufacturer agents and representatives, manufacturers, processers, retailer, and wholesalers of and dealers including but limited to pharmaceutical and any health-related products, food and beverages, commodities, articles, products and merchandise of all kinds in a manufactured, semi manufactured or raw state and to buy and sell, barter, exchange or otherwise deal in the same
G&T Pharma Sdn. Bhd.	40.8%	40.8%	40.8%	40.8%	Malaysia	Wholesale of pharmaceutical and medical goods, buying, selling, renting and operating of self-owned or leased real estate-land and retail sale of rice
MYGS Venture Sdn. Bhd.	48.5%	48.5%	48.5%	48.5%	Malaysia	Retailing of pharmaceutical products, retail sale of rice

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Mercury Wellness Sdn. Bhd (continued)						
G&A Pharma Sdn. Bhd.	40.8%	40.8%	40.8%	40.8%	Malaysia	To carry on the business of general importers and exporters, general merchant, hire-purchase dealers, commission agents, manufacturers agents and representatives, manufacturers, processors, retailers and wholesaler of and dealers including but not limited to pharmaceutical and any health related products, food and beverages, commodities, articles, products and merchandise of all kinds in a manufactured, semi-manufactured or raw state and to buy and sell, barter, exchange or otherwise deal in the same, retail sale of rice
MP Baitul Salam Sdn. Bhd.	45.9%	45.9%	45.9%	45.9%	Malaysia	Stores specialised in retail sale of pharmaceuticals, medical and orthopedic goods, buying, selling, renting and operating of self-owned or leased real estate - land and retail sale of rice

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Mercury Wellness Sdn. Bhd (continued)						
GM Pharma Sdn. Bhd.	48.5%	48.5%	48.5%	48.5%	Malaysia	To carry on the business of general importers and exporters, general merchant, hire-purchase dealers, commission agents, manufacturers agents and representatives, manufacturers, processors, retailers and wholesaler of and dealers including but not limited to pharmaceutical and any health-related products, food and beverages, commodities, articles, products and merchandise of all kinds in a manufactured, semi manufactured or raw state and to buy and sell, barter, exchange or otherwise deal in the same
Subsidiaries of Yanling Assets Sdn. Bhd.						
Yanling Holdings Sdn. Bhd.*	-	54%	54%	90%	Malaysia	Investment holding
Subsidiaries of Yanling Holdings Sdn. Bhd.						
Yanling Natural Hygiene Sdn. Bhd.	-	54%	54%	90%	Malaysia	Manufacturing health products, provide laboratory test, product registration and research and development
Asia Healthcare Sdn. Bhd.	-	54%	54%	90%	Malaysia	Trading of health and skincare products
Dermarque Sdn. Bhd.	-	54%	54%	90%	Malaysia	Manufacturer of skincare products
E-Pharma (M) Sdn. Bhd.	-	54%	54%	90%	Malaysia	Manufacturing health products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiary of Caring Pharmacy Group Sdn. Bhd. (formerly known as Caring Pharmacy Group Berhad)						
Caring Pharmacy Retail Management Sdn. Bhd.	-	100%	100%	100%	Malaysia	Investment holding and the provision of management services as well as warehousing and distribution of pharmaceutical, healthcare and personal care products, along with various foodstuffs including, but not limited to, rice and grains products
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd.						
Caring Pharmacy Sdn. Bhd.	-	100%	100%	100%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Estore Sdn. Bhd.	-	100%	100%	100%	Malaysia	Internet sales and warehouse sales of healthcare and personal care products
Caring Pharmacy (Kinrara) Sdn. Bhd.	-	100%	100%	100%	Malaysia	Investment holding and property investment
Caring Pharmacy (RS) Sdn. Bhd.	-	100%	100%	100%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Viva Caring Sdn. Bhd.	-	73.3%	73.3%	73.3%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Belle Sdn. Bhd.[%]	-	100%	-	-	Malaysia	Dormant
Sterling Pharmacy Sdn. Bhd.	-	51%	51%	51%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Be Caring Sdn. Bhd. ^	-	75.5%	75.5%	87.8%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
MN Pharmacy Sdn. Bhd.	-	80%	80%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy (KLP) Sdn. Bhd.	-	80%	80%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Caring 'N' You Pharmacy Sdn. Bhd.^	-	60%	60%	100%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy Always Sdn. Bhd.	-	100%	70%	70%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Ace Caring Pharmacy Sdn. Bhd.	-	75.5%	75.5%	75.5%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Stay Caring Sdn. Bhd.	-	70%	70%	70%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Health Solutions Sdn. Bhd.	-	100%	70%	70%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff but not limited to rice and grains products
Caring Pharmacy (Ampang) Sdn. Bhd.	-	100%	100%	100%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Vertex Pharmacy Sdn. Bhd.^	-	75.5%	75.5%	87.8%	Malaysia	Community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Preciouslife Pharmacy Sdn. Bhd.^	-	70%	70%	85%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
WM Caring Pharmacy Sdn. Bhd.	-	80%	80%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Big Caring Academy Sdn. Bhd. (formerly known as Tonic Pharma Sdn. Bhd.)	-	100%	100%	100%	Malaysia	To provide training and consultancy services for any business interests and other related activities
Caring Pharmacy (MPLS) Sdn. Bhd.^	-	60%	60%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy (SW) Sdn. Bhd.	-	51%	51%	51%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
MY Caring Pharmacy Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Pharmacy (ABM) Sdn. Bhd.	-	80%	80%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy (SK) Sdn. Bhd. [%]	-	100%	-	-	Malaysia	Dormant
Victorie Caring Sdn. Bhd.	-	85%	85%	85%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
One Caring Pharmacy Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Green Surge Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy (JB Molek) Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, along with various foodstuffs including, but not limited to, rice and grains products
Caring Pharmacy (Shah Alam) Sdn. Bhd.	-	100%	100%	100%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Living Glory Sdn. Bhd.	-	51%	51%	51%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Pharmacy (IDR) Sdn. Bhd.	-	68.2%	68.2%	68.2%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Trio Sdn. Bhd.	-	86.5%	86.5%	86.5%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Mega Caring Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Abundance Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operating a pharmacy including retailing of pharmaceutical, healthcare and personal care products
Fuji Acre Sdn. Bhd.	-	86.7%	86.7%	86.7%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy Rising Sdn. Bhd.	-	61%	61%	61%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Trinity Sdn. Bhd.	-	59.5%	59.5%	59.5%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Clover Sdn. Bhd. ^	-	60%	60%	80%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Caring Healthmark Sdn. Bhd.	-	75%	75%	75%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Evergreen Sdn. Bhd.	-	70%	70%	70%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring Pharmacy Ascend Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceuticals, healthcare and personal care products
Caring Empire Sdn. Bhd.	-	59.5%	59.5%	59.5%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products
Caring T & T Sdn. Bhd.^	-	75%	75%	87.5%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Subsidiaries of Caring Pharmacy Retail Management Sdn. Bhd. (continued)						
Caring Link Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Caring Alliance Sdn. Bhd.	-	60%	60%	60%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products, all kinds of foodstuff including but not limited to rice and grains products
Realcare Baby and Organic Sdn. Bhd.	-	-	100%	100%	Malaysia	Trading in all kind of baby products and rice
The Pill House Pharmacy Sdn. Bhd.#	-	67%	67%	93.8%	Malaysia	Investment holding company
Wellings Pharmacy Sdn. Bhd. #	-	60%	60%	92.4%	Malaysia	Dealer in pharmaceutical products
Jom Pharmacy Sdn. Bhd.	-	60%	60%	60%	Malaysia	Pharmacy
Held through Caring Evergreen Sdn. Bhd.:						
Maxi Caring Sdn. Bhd.^	-	42%	42%	56%	Malaysia	Operation of community pharmacy including retailing of pharmaceutical, healthcare and personal care products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Held through The Pill House Pharmacy Sdn. Bhd.:						
Wellings Pill House Sdn. Bhd.	-	67%	67%	93.8%	Malaysia	Investment holding
Held through Wellings Pill House Sdn. Bhd.:						
Wellings Pill House (TG) Pharmacy Sdn. Bhd. [%]	-	67%	-	-	Malaysia	Dormant
Blooming Health Pharmacy Sdn. Bhd. [%]	-	67%	-	-	Malaysia	Dormant
Realcare Pharmacy (K) Sdn. Bhd.	-	67%	67%	93.8%	Malaysia	To operate a pharmacy and to provide a warehouse supplies, warehouse management services and transportation of goods between original and destination to its related companies
Health Town Pharmacy Sdn. Bhd. [%]	-	67%	-	-	Malaysia	Dormant
Green Trees Pharmacy Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Sales of pharmaceutical products
Nutrilife Pharmacy Sdn. Bhd. [%]	-	67%	-	-	Malaysia	Dormant
Pure Health Pharmacy Sdn. Bhd. [%]	-	67%	-	-	Malaysia	Dormant
Sharing Pharmacy Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Sales of pharmaceuticals products

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Held through Wellings Pill House Sdn. Bhd.: (continued)						
Simple Life Pharmacy Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Sales of pharmaceuticals products
Langkawi Pharmacy Sdn. Bhd.	-	40.2%	40.2%	56.3%	Malaysia	Sales of pharmaceutical products
Amazinglife Pharmacy Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Sales of pharmaceutical products
Realcare Baby and Organic Sdn. Bhd.	-	67%	-	-	Malaysia	Trading in all kind of baby product
Pharmfresh Pharmacy Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Sales of pharmaceutical products
Nutricient RX Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Stores specialised in retail sale of pharmaceuticals, medical and orthopaedic goods
Super Health Sdn. Bhd.	-	34.2%	34.2%	47.8%	Malaysia	Stores specialised in retail sale of pharmaceuticals, medical and orthopaedic goods
Healthy Care Pharmacy Sdn. Bhd.	-	34.2%	40.2%	47.8%	Malaysia	Stores specialised in retail sale of pharmaceuticals, medical and orthopaedic goods
Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.)	-	40.2%	67%	65.7%	Malaysia	Export and import of biotech pharmaceuticals

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Held through Wellings Pill House Sdn. Bhd.: (continued)						
Healthy Point Pharmacy Sdn. Bhd.	-	46.9%	46.9%	65.7%	Malaysia	Stores specialised in retail sale of pharmaceuticals, medical and orthopaedic goods, export and import of biotech pharmaceuticals
Held through Wellings Pharmacy Sdn. Bhd.:						
Masons Health Sdn. Bhd. +	-	60%	60%	-	Malaysia	Other retail sale in non-specialised stores N.E.C.
Wellings Selat Sdn. Bhd.	-	36%	36%	55.4%	Malaysia	Store specialised in retail sale of pharmaceuticals, medical and orthopaedic goods
Held through Jom Pharmacy Sdn. Bhd.:						
Medical Supplies (Sarawak) Sdn. Bhd.	-	60%	60%	60%	Malaysia	Marketing and distribution of pharmaceuticals and healthcare products
Jom Pharmacy (Serian) Sdn. Bhd. +	-	60%	60%	-	Malaysia	Dormant
Held through Medispec (M) Sdn. Bhd.:						
Vitamode Sdn. Bhd.	-	-	89.3%	89.3%	Malaysia	Dormant
Medispec (S) Pte Ltd @	-	-	89.3%	89.3%	Singapore	Dormant

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Held through Your Physio Sdn. Bhd.:						
Our Physio Sdn. Bhd.	-	-	40.1%@	40.1%	Malaysia	Physiotherapy services and rehabilitation centre
Spine Sports Stroke Rehab Specialist Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
Your Physio Southern Sdn. Bhd.	-	-	29.1%@	43.1%	Malaysia	Physiotherapy and occupational therapy services
Horizon Academy Sdn. Bhd.	-	-	-	57.1%	Malaysia	To provide training and consultancy services in physiotherapy and related skills and the company shall have full capacity to carry out its current and intended business objectives
Held through Our Physio Sdn. Bhd.:						
Island Rehab Specialist Sdn. Bhd.	-	-	40.1%@	40.1%	Malaysia	Physiotherapy services and rehabilitation centre
PT Pro Sdn. Bhd.	-	-	40.1%@	40.1%	Malaysia	Physiotherapy services and rehabilitation centre
Held through Spine Sports Stroke Rehab Specialist Sdn. Bhd.:						
Pakar Fisio Dan Rehabilitasi Anda Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
YB Physio Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
Xin Rehab Specialist Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
Best Physio Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

Details of the subsidiaries are as follows: (continued)

Name of company	Effective interest in equity held 2023	2024	2025	2026	Country of incorporation/ Principal place of business	Principal activities
Held through Spine Sports Stroke Rehab Specialist Sdn. Bhd.: (continued)						
Your Physio Klang Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
Caring Rehab Specialist Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services
YP Physio Sdn. Bhd.	-	-	50.7%@	50.7%	Malaysia	Physiotherapy and occupational therapy services

* The shares were held in trust by appointed persons on behalf of Big Caring Group Bhd.
@ Not audited by BDO PLT or member firms of BDO International.
! During FYE 2025, the shares that were previously held in trust by appointed person on behalf of Big Caring Group Bhd were transferred to Big Caring Group Bhd.
Caring Pharmacy Retail Management Sdn. Bhd. ("CPRM") entered into a put and call option agreement with the vendor for the remaining 33% and 40% stake in The Pill House Pharmacy Sdn. Bhd. ("TPH") and Wellings Pharmacy Sdn. Bhd. ("Wellings") respectively. This option, which is treated as contingent consideration of the acquisition, effectively gives CPRM a present ownership of 100% in TPH and Wellings. CPRM has exercised the option to acquire an additional stake in the financial year ended 30 June 2026 and will exercise its option to acquire the remaining stake in the financial year ending 30 June 2028.
^ The Group entered into a put and call option agreement with the seller for 10% to 20% of the remaining shareholdings in the subsidiaries respectively. This option, which is treated as contingent consideration of the acquisition, effectively gives the Group a present ownership interest including the 10% to 20% of remaining shareholdings.
• During the financial year ended 30 June 2026, the non-controlling shareholders of Yanling Holdings Sdn. Bhd. ("YHSB") expressed their intention to exercise the put and call option arrangement in respect of their remaining equity interest in YHSB within the next twelve (12) months. Consequently, Yanling Assets Sdn. Bhd. ("YASB"), a subsidiary of the Group, recognised contingent consideration of RM150,285,152. The option arrangement effectively provides YASB with a present ownership interest of 100% in YHSB.
% Strike off during the financial year ended 30 June 2025.
+ Strike off during the financial year ended 30 June 2026.

All the other subsidiaries are audited by BDO PLT.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(a) All components of non-controlling interests shall be measured at their acquisition-date fair value, unless another measurement basis is required by MFRSs. The choice of measurement basis is made on a combination-by-combination basis. Subsequent to initial recognition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent change in equity.

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group.

(i) Summarised statements of financial position

	Big Lucky Sdn. Bhd. RM	Plenitude Highlands Sdn. Bhd. RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
At 30 June 2023						
Non-current assets	6,761,144	8,657,421	10,294,512	16,752,298	13,536,689	56,002,064
Current assets	11,257,097	14,305,457	10,976,729	25,933,835	13,370,819	75,843,937
Total assets	18,018,241	22,962,878	21,271,241	42,686,133	26,907,508	131,846,001
Non-current liabilities	3,962,837	4,199,035	3,041,589	10,853,190	7,416,298	29,472,949
Current liabilities	6,530,313	15,174,422	5,369,801	13,087,768	8,567,398	48,729,702
Total liabilities	10,493,150	19,373,457	8,411,390	23,940,958	15,983,696	78,202,651
Net assets	7,525,091	3,589,421	12,859,851	18,745,175	10,923,812	53,643,350
Equity attributable to owners of the parent	5,869,571	2,153,653	7,715,911	9,560,039	7,646,668	32,945,842
Non-controlling interests	1,655,520	1,435,768	5,143,940	9,185,136	3,277,144	20,697,508
Total equity	7,525,091	3,589,421	12,859,851	18,745,175	10,923,812	53,643,350

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(ii) Summarised statements of profit or loss and other comprehensive income

	Big Lucky Sdn. Bhd. RM	Plenitude Highlands Sdn. Bhd. RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2023						
Revenue	42,956,792	40,699,889	18,299,736	89,015,086	15,357,746	206,329,249
Profit for the year	2,421,389	1,273,261	562,699	4,678,969	576,539	9,512,857
Other comprehensive income	-	-	-	-	-	-
Total comprehensive income	2,421,389	1,273,261	562,699	4,678,969	576,539	9,512,857
Profit attributable to:						
- owners of the parent	1,888,683	763,957	337,619	2,364,226	403,577	5,758,062
- non-controlling interests	532,706	509,304	225,080	2,314,743	172,962	3,754,795
Total comprehensive income attributable to:						
- owners of the parent	1,888,683	763,957	337,619	2,364,226	403,577	5,758,062
- non-controlling interests	532,706	509,304	225,080	2,314,743	172,962	3,754,795

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(iii) Summarised statements of cash flows

	Big Lucky Sdn. Bhd. RM	Plenitude Highlands Sdn. Bhd. RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2023						
Net cash from/(used in):						
- operating activities	1,545,857	4,520,213	(1,102,222)	1,075,940	1,566,880	7,606,668
- investing activities	(858,182)	(3,200,706)	(37,452)	724,568	(894,313)	(4,266,085)
- financing activities	(806,343)	(716,016)	334,516	(1,633,805)	(393,860)	(3,215,508)
Net (decrease)/increase in cash and cash equivalents	(118,668)	603,491	(805,158)	166,703	278,707	125,075
Cash and cash equivalents at beginning of the year	972,332	718,886	902,609	2,290,921	-	4,884,748
Cash and cash equivalents at end of the year	853,664	1,322,377	97,451	2,457,624	278,707	5,009,823

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(iv) Summarised statements of financial position

	Caring Pharmacy Group* RM	The Pill House Pharmacy Group RM	Yanling Assets Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
At 30 June 2024							
Non-current assets	251,194,058	21,598,139	75,678,925	10,152,975	18,767,862	10,754,539	388,146,498
Current assets	343,550,557	58,421,755	39,785,245	11,473,592	30,049,874	27,449,206	510,730,229
Total assets	594,744,615	80,019,894	115,464,170	21,626,567	48,817,736	38,203,745	898,876,727
Non-current liabilities	117,860,007	11,763,217	16,184,018	2,854,482	12,042,118	6,226,530	166,930,372
Current liabilities	337,446,889	45,923,287	23,344,467	5,975,791	14,420,012	19,182,903	446,293,349
Total liabilities	455,306,896	57,686,504	39,528,485	8,830,273	26,462,130	25,409,433	613,223,721
Net assets	139,437,719	22,333,390	75,935,685	12,796,294	22,355,606	12,794,312	285,653,006
Equity attributable to owners of the parent	134,882,390	20,011,724	53,291,481	7,677,776	11,401,359	8,956,018	236,220,748
Non-controlling interests	4,555,329	2,321,666	22,644,204	5,118,518	10,954,247	3,838,294	49,432,258
Total equity	139,437,719	22,333,390	75,935,685	12,796,294	22,355,606	12,794,312	285,653,006

*Excluding The Pill House Pharmacy Sdn. Bhd. Group, Wellings Pharmacy Sdn. Bhd. Group and Jom Pharmacy Sdn. Bhd. Group.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(v) Summarised statements of profit or loss and other comprehensive income

	Caring Pharmacy Group* RM	The Pill House Pharmacy Group RM	Yanling Assets Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2024							
Revenue	565,494,057	133,790,683	48,722,628	16,311,259	97,900,802	54,624,531	916,843,960
Profit/(Loss) for the year	13,242,120	4,845,054	7,674,859	(63,557)	3,640,431	2,868,851	32,207,758
Other comprehensive income	-	-	-	-	-	-	-
Total comprehensive income/(loss)	13,242,120	4,845,054	7,674,859	(63,557)	3,640,431	2,868,851	32,207,758
Profit/(Loss) attributable to:							
- owners of the parent	11,081,227	4,110,843	3,544,271	(38,134)	1,838,443	2,008,196	22,544,846
- non-controlling interests	2,160,893	734,211	4,130,588	(25,423)	1,801,988	860,655	9,662,912
Total comprehensive income/(loss) attributable to:							
- owners of the parent	11,081,227	4,110,843	3,544,271	(38,134)	1,838,443	2,008,196	22,544,846
- non-controlling interests	2,160,893	734,211	4,130,588	(25,423)	1,801,988	860,655	9,662,912

*Excluding The Pill House Pharmacy Sdn. Bhd. Group, Wellings Pharmacy Sdn. Bhd. Group and Jom Pharmacy Sdn. Bhd. Group.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(vi) Summarised statements of cash flows

	Caring Pharmacy Group* RM	The Pill House Pharmacy Group RM	Yanling Assets Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2024							
Net cash from/(used in):							
- operating activities	51,634,316	(11,317,512)	7,143,474	158,336	3,477,353	6,587,189	57,683,156
- investing activities	(3,525,473)	446,060	(51,355,364)	(33,712)	(2,277,766)	(1,685,721)	(58,431,976)
- financing activities	(71,098,787)	(7,055,106)	53,302,851	(641,665)	(1,889,835)	(1,150,300)	(28,532,842)
Net (decrease)/increase in cash and cash equivalents	(22,989,944)	(17,926,558)	9,090,961	(517,041)	(690,248)	3,751,168	(29,281,662)
Cash and cash equivalents at beginning of the year	71,768,515	37,732,284	25,792	97,451	2,457,624	278,707	112,360,373
Cash and cash equivalents at end of the year	48,778,571	19,805,726	9,116,753	(419,590)	1,767,376	4,029,875	83,078,711

*Excluding The Pill House Pharmacy Sdn. Bhd. Group, Wellings Pharmacy Sdn. Bhd. Group and Jom Pharmacy Sdn. Bhd. Group.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(vii) Summarised statements of financial position

	Caring Pharmacy Group RM	Yanling Assets Group RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
At 30 June 2025								
Non-current assets	295,062,870	80,762,353	13,192,713	26,148,190	9,945,540	19,607,581	14,903,443	459,622,690
Current assets	903,732,127	31,596,466	99,671,576	5,773,180	13,550,245	36,396,518	22,467,448	1,113,187,560
Total assets	1,198,794,997	112,358,819	112,864,289	31,921,370	23,495,785	56,004,099	37,370,891	1,572,810,250
Non-current liabilities	226,119,508	14,533,607	3,443,844	3,525,408	2,665,661	13,094,305	7,025,945	270,408,278
Current liabilities	903,757,313	15,707,684	37,829,106	3,849,663	8,376,917	20,106,339	13,516,330	1,003,143,352
Total liabilities	1,129,876,821	30,241,291	41,272,950	7,375,071	11,042,578	33,200,644	20,542,275	1,273,551,630
Net assets	68,918,176	82,117,528	71,591,339	24,546,299	12,453,207	22,803,455	16,828,616	299,258,620
Equity attributable to owners of the parent	53,474,769	62,077,024	47,956,850	12,025,973	7,427,074	9,383,120	11,179,971	203,524,781
Non-controlling interests	15,443,407	20,040,504	23,634,489	12,520,326	5,026,133	13,420,335	5,648,645	95,733,839
Total equity	68,918,176	82,117,528	71,591,339	24,546,299	12,453,207	22,803,455	16,828,616	299,258,620

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(viii) Summarised statements of profit or loss and other comprehensive income

	Caring Pharmacy Group RM	Yanling Assets Group RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2025								
Revenue	1,838,293,810	72,178,812	58,482,913	1,736,058	17,263,972	110,223,855	66,970,856	2,165,150,276
Profit/(Loss) for the year	114,053,457	8,281,842	6,154,599	404,670	(343,087)	5,016,057	6,034,504	139,602,042
Other comprehensive income	-	-	-	-	-	-	-	-
Total comprehensive income/(loss)	114,053,457	8,281,842	6,154,599	404,670	(343,087)	5,016,057	6,034,504	139,602,042
Profit/(Loss) attributable to:								
- owners of the parent	103,607,791	7,453,658	5,493,423	230,905	(205,852)	319,767	3,624,093	120,523,785
- non-controlling interests	10,445,666	828,184	661,176	173,765	(137,235)	4,696,290	2,410,411	19,078,257
Total comprehensive income/(loss) attributable to:								
- owners of the parent	103,607,791	7,453,658	5,493,423	230,905	(205,852)	319,767	3,624,093	120,523,785
- non-controlling interests	10,445,666	828,184	661,176	173,765	(137,235)	4,696,290	2,410,411	19,078,257

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(ix) Summarised statements of cash flows

	Caring Pharmacy Group RM	Yanling Assets Group RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Ting Alliance Sdn. Bhd. RM	Total RM
2025								
Net cash from/(used in):								
- operating activities	363,486,688	1,300,431	3,494,269	757,093	(1,799,317)	12,088,530	4,641,059	383,968,753
- investing activities	(154,042,528)	(8,635,652)	604,937	(30,642)	(68,570)	1,061,080	1,508,501	(159,602,874)
- financing activities	(159,021,313)	(12,236)	1,119,170	(128,707)	1,646,583	(6,670,222)	(2,472,723)	(165,539,448)
Net increase/(decrease) in cash and cash equivalents	50,422,847	(7,347,457)	5,218,376	597,744	(221,304)	6,479,388	3,676,837	58,826,431
Cash and cash equivalents at beginning of the year	80,626,539	9,116,753	10,675,487	4,228,471	(419,590)	1,767,376	4,029,875	110,024,911
Effects of exchange rate changes on cash and cash equivalents	-	(5,165)	173,872	-	-	-	-	168,707
Cash and cash equivalents at end of the year	131,049,386	1,764,131	16,067,735	4,826,215	(640,894)	8,246,764	7,706,712	169,020,049

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(x) Summarised statements of financial position

	Caring Pharmacy Group RM	Yanling Assets Group[2] RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Total RM
At 30 June 2026							
Non-current assets	364,234,143	82,431,721	15,304,175	37,405,884	10,151,127	20,687,316	530,214,366
Current assets	990,774,223	60,630,766	122,991,137	10,113,761	17,099,012	41,086,994	1,242,695,893
Total assets	1,355,008,366	143,062,487	138,295,312	47,519,645	27,250,139	61,774,310	1,772,910,259
Non-current liabilities	171,427,075	13,711,772	2,847,540	10,087,246	2,617,197	13,966,668	214,657,498
Current liabilities	999,817,635	183,451,641	30,475,530	7,670,918	11,078,708	15,717,681	1,248,212,113
Total liabilities	1,171,244,710	197,163,413	33,323,070	17,758,164	13,695,905	29,684,349	1,462,869,611
Net assets	183,763,656	(54,100,926)	104,972,242	29,761,481	13,554,234	32,089,961	310,040,648
Equity attributable to owners of the parent	156,556,358	(51,233,378)	77,749,870	14,913,018	8,087,691	16,307,739	222,381,298
Non-controlling interests	27,207,298	(2,867,548)	27,222,372	14,848,463	5,466,543	15,782,222	87,659,350
Total equity	183,763,656	(54,100,926)	104,972,242	29,761,481	13,554,234	32,089,961	310,040,648

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(xi) Summarised statements of profit or loss and other comprehensive income

	Caring Pharmacy Group RM	Yanling Assets Group RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Total RM
2026							
Revenue	1,965,546,608	114,746,885	196,448,340	28,736,704	22,087,493	130,486,382	2,458,052,412
Profit for the year	120,218,895	16,066,697	33,376,962	6,968,756	1,101,025	9,286,508	187,018,843
Other comprehensive income	-	-	3,941	-	-	-	3,941
Total comprehensive income	120,218,895	16,066,697	33,380,903	6,968,756	1,101,025	9,286,508	187,022,784
Profit attributable to:							
- owners of the parent	107,434,240	5,425,445	29,790,918	3,292,364	660,615	4,686,199	151,289,781
- non-controlling interests	12,784,655	10,641,252	3,586,044	3,676,392	440,410	4,600,309	35,729,062
Total comprehensive income attributable to:							
- owners of the parent	107,434,240	5,425,445	29,794,436	3,292,364	660,615	4,686,199	151,293,299
- non-controlling interests	12,784,655	10,641,252	3,586,467	3,676,392	440,410	4,600,309	35,729,485

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

(xii) Summarised statements of cash flows

	Caring Pharmacy Group RM	Yanling Assets Group RM	Medispec (M) Group RM	Your Physio Group RM	AHC Medical Supplies Sdn. Bhd. RM	Mercury Wellness Group RM	Total RM
2026							
Net cash from/(used in):							
- operating activities	71,661,382	13,220,177	22,384,543	10,941,899	2,290,217	11,883,560	132,381,778
- investing activities	(39,524,375)	(3,990,279)	(3,748,028)	(6,527,787)	(32,660)	(12,075,191)	(65,898,320)
- financing activities	27,288,559	(1,938,539)	(6,552,078)	(3,440,672)	(1,995,452)	(2,233,302)	11,128,516
Net increase/(decrease) in cash and cash equivalents	59,425,566	7,291,359	12,084,437	973,440	262,105	(2,424,933)	77,611,974
Cash and cash equivalents at beginning of the year	131,049,386	1,764,131	16,067,735	4,826,215	(640,894)	8,246,764	161,313,337
Effects of exchange rate changes on cash and cash equivalents	-	-	6,407	-	-	-	6,407
Cash and cash equivalents at end of the year	190,474,952	9,055,490	28,158,579	5,799,655	(378,789)	5,821,831	238,931,718

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(b) Summarised information of companies with non-controlling interests that are material to the Group is set out below. The summarised financial information presented below is the amount before inter-company elimination. The non-controlling interests of the other companies are not material to the Group. (continued)

[1] The 2026 financial information relating to Ting Alliance Sdn. Bhd. ("TASB") has not been presented following the Group's acquisition of the remaining 30% equity interest in TASB on 18 July 2025. As a result, TASB became a wholly owned subsidiary of the Group, and the related non-controlling interests were not material to the Group.

[2] Included in the Yanling Assets Group's current liabilities is a purchase consideration payable of RM150,285,152 to the non-controlling shareholders of Yanling Holdings Sdn. Bhd. ("YHSB"), in relation to the put and call option arrangements over the remaining equity interests in YHSB. Following the non-controlling shareholders of YHSB's indication of their intention to exercise the options within the next twelve (12) months, the recognition of this financial liability resulted in a corresponding reduction in equity attributable to the owners of the Company.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries

During the financial year ended 30 June 2023

(i) On 17 January 2023, a subsidiary of the Company, Big Pharmacy (Sarawak) Sdn. Bhd. subscribed for 70 ordinary shares at an issue price of RM1 per share in Ting Alliance Sdn. Bhd., a company incorporated in Malaysia for a total cash consideration of RM70. Big Pharmacy (Sarawak) Sdn. Bhd. entered into a share purchase agreement with three (3) individuals to acquire shares, representing 70% of equity interest in Ting Alliance Sdn. Bhd. for a total cash consideration of RM27,964,176.

(ii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM5,955,730 and the acquisition was completed during the financial year ended 30 June 2023.

(iii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Betong) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM324,582 and the acquisition was completed during the financial year ended 30 June 2023.

(iv) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Bintulu) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM498,075 and the acquisition was completed during the financial year ended 30 June 2023.

(v) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Limbang) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM511,238 and the acquisition was completed during the financial year ended 30 June 2023.

(vi) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (MJC) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM384,392 and the acquisition was completed during the financial year ended 30 June 2023.

(vii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Mukah) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM352,528 and the acquisition was completed during the financial year ended 30 June 2023.

(viii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Samarindah) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM337,274 and the acquisition was completed during the financial year ended 30 June 2023.

(ix) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered entered into an assets transfer agreement with Antares Pharma (Saratok) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM339,235 and the acquisition was completed during the financial year ended 30 June 2023.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2023 (continued)

(x) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Sarikei) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM498,013 and the acquisition was completed during the financial year ended 30 June 2023.

(xi) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Antares Pharma (Sri Aman) Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM482,496 and the acquisition was completed during the financial year ended 30 June 2023.

(xii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Ting Pharmacy Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM453,166 and the acquisition was completed during the financial year ended 30 June 2023.

(xiii) On 15 May 2023, a subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd., Ting Alliance Sdn. Bhd. entered into an assets transfer agreement with Sejingkat Pharmacy Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM210,444 and the acquisition was completed during the previous financial year.

(xiv) The fair value of the identifiable assets and liabilities acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition of Ting Alliance Sdn. Bhd. RM
Property, plant and equipment	7	2,176,364
Inventories		8,170,809
Total fair value of identifiable assets		10,347,173
Less: Non-controlling interests		(3,104,152)
Add: Goodwill arising from acquisition	9	20,721,155
Purchase consideration		27,964,176
Purchase consideration payable		(27,964,176)
Net cash outflow to the Group on acquisition		-

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2024

(i) On 10 August 2023, a subsidiary of the Company, Quantum Upstream Sdn. Bhd. had subscribed for 1 ordinary share in the share capital of Yanling Assets Sdn. Bhd. ("YASB"), representing 100% equity interest in YASB for a cash consideration of RM1.

(ii) On 15 August 2023, YASB, a subsidiary of the Company's subsidiary, Quantum Upstream Sdn. Bhd., had entered into a sale and purchase agreement with two (2) individuals to acquire 60 ordinary shares in Yanling Holdings Sdn. Bhd. ("YHSB"), representing 60% of the issued share capital of YHSB for a total purchase consideration of RM62,893,056.

The purchase consideration is to be settled in the following manner:
i. a sum of RM55,064,700 upon the delivery and/or procurement of the transaction documents; and
ii. a sum of RM7,828,356 upon satisfaction of earn-out payment.

Earn-out payment is stipulated to the two (2) individuals if YHSB adjusted profit after tax and minority interest for the financial year ended 30 April 2024 or ending 30 April 2025, whichever earlier, is equivalent to RM7,000,000 or more.

The acquisition of YHSB was completed on 30 October 2023.

Following the completion of the acquisition, YHSB has become an indirect subsidiary of Quantum Upstream Sdn. Bhd.. Accordingly, Asia Healthcare Sdn. Bhd., Yanling Natural Hygiene Sdn. Bhd., Dermaque Sdn. Bhd. and E-Pharma (M) Sdn. Bhd., wholly-owned subsidiaries of YHSB, have also become indirect subsidiaries of the Company.

On 26 September 2023, YASB increased its paid-up share capital from 1 to 1,000 ordinary shares, which Quantum Upstream Sdn. Bhd. subscribed additional 899 ordinary shares for a consideration of RM899. Pursuant to that, the effective ownership interest of Quantum Upstream Sdn. Bhd. in YASB has decreased from 100% to 90%.

On 4 December 2023, YASB further increased its paid-up share capital from 1,000 to 54,901,000 ordinary shares, which Quantum Upstream Sdn. Bhd. subscribed additional 49,410,000 ordinary shares for a consideration of RM49,410,000. Pursuant to that, the effective ownership interest of Quantum Upstream Sdn. Bhd. in YASB remained at 90%.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2024 (continued)

(iii) The fair value of the identifiable assets and liabilities acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition of YHSB RM
Property, plant and equipment	7	5,632,126
Intangible assets	9	369,404
Right-of-use assets	10	21,440,083
Trade and other receivables		17,272,798
Inventories		11,136,740
Cash and cash equivalents		7,115,146
Other assets		447,855
Borrowings		(17,992,195)
Trade and other payables		(11,712,004)
Lease liabilities	10	(1,612,127)
Deferred tax liabilities	12	(2,121,187)
Total fair value of identifiable assets		29,976,639
Less: Non-controlling interests		(13,359,826)
Deferred tax impact (trademarks)	12	(1,080,957)
Add: Goodwill arising from acquisition	9	42,853,215
Identified intangible assets (trademarks)	9	4,503,985
Purchase consideration		62,893,056
Cash and cash equivalents of the subsidiaries acquired		(7,115,146)
Contingent consideration not paid (Note 20(l))		(7,828,356)
Net cash outflow to the Group on acquisition		47,949,554

(iv) On 21 September 2023, the Company had entered into a sale and purchase agreement with Convenience Shopping (Sabah) Sdn. Bhd. and Motivasi Optima Sdn. Bhd. to acquire 217,706,400 ordinary shares in Caring Pharmacy Group Sdn. Bhd. (formerly known as Caring Pharmacy Group Berhad) ("CPGB'), representing 100% of the issued share capital of CPGB for a total purchase consideration of RM889,019,339. The acquisition was completed on 29 December 2023.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2024 (continued)

(v) The fair value of the identifiable assets and liabilities acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition of CPGB RM
Property, plant and equipment	7	39,824,801
Investment properties	8	19,752,986
Intangible assets	9	72,324,709
Right-of-use assets	10	142,946,292
Trade and other receivables		49,214,406
Inventories		233,543,448
Cash and cash equivalents		67,072,181
Deferred tax assets	12	3,855,038
Other assets		68,610,520
Borrowings		(61,361,815)
Trade and other payables		(369,880,700)
Lease liabilities	10	(123,900,310)
Deferred tax liabilities	12	(5,350,638)
Total fair value of identifiable assets		136,650,918
Less: Non-controlling interests		(5,522,436)
Deferred tax impact (trademarks)	12	(117,110,000)
Deferred tax impact (dealership rights)	12	(1,511,000)
Add: Goodwill arising from acquisition	9	382,259,857
Identified intangible assets (trademarks)	9	487,957,000
Identified intangible assets (dealership rights)	9	6,295,000
Purchase consideration		889,019,339
Cash and cash equivalents of the subsidiaries acquired		(126,285,248)
Contingent consideration not paid (Note 20(l))		(38,327,510)
Net cash outflow to the Group on acquisition		724,406,581

During the financial year ended 30 June 2025

(i) On 24 January 2025, the Company had entered into a sale and purchase agreement with Premier Vitality Sdn. Bhd. and two (2) individuals to acquire 892,572 ordinary shares in Medispec (M) Sdn. Bhd.("MEM"), representing 89.3% of the issued share capital of MEM for a total purchase consideration of RM249,441,000. The acquisition was completed on 28 February 2025.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2025 (continued)

(ii) The fair value of the identifiable assets and liabilities acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition of MEM RM
Property, plant and equipment	7	17,627,407
Right-of-use assets	10	129,733
Trade and other receivables		38,755,833
Inventories		31,729,610
Cash and cash equivalents		11,010,698
Current tax assets		750,832
Borrowings		(6,739,929)
Trade and other payables		(18,543,489)
Current tax liabilities		(3,161,766)
Lease liabilities	10	(1,848,698)
Deferred tax liabilities	12	(783,015)
Total fair value of identifiable assets		68,927,216
Less: Non-controlling interests		(22,973,313)
Deferred tax impact (distribution rights)	12	(39,804,108)
Deferred tax impact (trademarks)	12	(5,978,102)
Add: Goodwill arising from acquisition	9	58,510,100
Identified intangible assets (distribution rights)	9	165,850,450
Identified intangible assets (trademarks)	9	24,908,757
Purchase consideration		249,441,000
Cash and cash equivalents of the subsidiaries acquired		(11,010,698)
Net cash outflow to the Group on acquisition		238,430,302

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(c) Acquisition of subsidiaries (continued)

During the financial year ended 30 June 2025 (continued)

(iii) On 20 March 2025, the Company had entered into a sale and purchase agreement with three (3) individuals to acquire 180,570 ordinary shares in Your Physio Sdn. Bhd.("YPSB"), representing 57.1% of the issued share capital of YPSB for a total purchase consideration of RM32,760,000. The acquisition was completed on 30 May 2025.

(iv) The fair value of the identifiable assets and liabilities acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition of YPSB RM
Property, plant and equipment	7	1,711,429
Goodwill	9	19,919,000
Right-of-use assets	10	4,314,213
Trade and other receivables		17,161,565
Inventories		104,288
Cash and cash equivalents		4,228,471
Trade and other payables		(18,597,318)
Current tax liabilities		(399,760)
Lease liabilities	10	(4,545,635)
Deferred tax liabilities	12	(13,400)
Total fair value of identifiable assets		23,882,853
Less: Non-controlling interests		(12,026,360)
Deferred tax impact (customer relationships)	12	(518,955)
Deferred tax impact (trademarks)	12	(783,521)
Add: Goodwill arising from acquisition	9	16,779,002
Identified intangible assets (customer relationships)	9	2,162,312
Identified intangible assets (trademarks)	9	3,264,669
Purchase consideration		32,760,000
Cash and cash equivalents of the subsidiaries acquired		(4,228,471)
Net cash outflow to the Group on acquisition		28,531,529

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(d) Acquisition of outlets

During the financial year ended 30 June 2023

(i) On 14 July 2022, a subsidiary of the Company, Big Pharmacy (Sabah) Sdn. Bhd., entered into an assets transfer agreement with Kinabalu Pharmacy (Donggongon) Sdn. Bhd. to acquire its assets of four outlets for a total consideration of RM4,220,267. The acquisition was completed during the financial year ended 30 June 2023.

(ii) On 8 November 2022, a subsidiary of the Company, Big Pharmacy (Northern) Sdn. Bhd., entered into an assets transfer agreement with Eco Pharmacy to acquire its assets of an outlet for a total consideration of RM2,531,308. The acquisition was completed during the financial year ended 30 June 2023.

(iii) On 10 November 2022, a subsidiary of the Company, Big Pharmacy (Sabah) Sdn. Bhd., entered into an assets transfer agreement with Daily Care Pharmacy Sdn Bhd to acquire its assets of an outlet for a total consideration of RM233,852. The acquisition was completed during the financial year ended 30 June 2023.

(iv) On 26 April 2023, a subsidiary of the Company, Big Pharmacy (Perak) Sdn. Bhd., entered into an assets transfer agreement with Caribbean Healthcare Sdn. Bhd. to acquire its assets of an outlet for a total consideration of RM7,191,484. The acquisition was completed during the financial year ended 30 June 2023.

(v) The fair value of the above identifiable assets acquired and the effects on cash flows arising from the acquisitions were as follows:

	Note	At date of acquisition RM
Property, plant and equipment	7(b)	157,512
Inventories		4,210,889
Total fair value of identifiable assets		4,368,401
Add: Goodwill arising from acquisition	9	9,808,509
Purchase consideration/Net cash outflow to the Group on acquisition		14,176,910

During the financial year ended 30 June 2024

(i) On 24 July 2023, a subsidiary of the Company, Big Pharmacy (Perak) Sdn. Bhd., entered into a supplementary asset transfer agreement with Caribbean Healthcare Sdn. Bhd. for an additional cash consideration of RM49,000 to acquire an outlet. The amount had been fully settled during the financial year ended 30 June 2024.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(d) Acquisition of outlets (continued)

During the financial year ended 30 June 2025

(i) On 7 January 2025, a subsidiary of the Company, Wellings Selat Sdn. Bhd. has entered into a business sale agreement with Jecki Medical Supplies Sdn. Bhd. for an outlet for a cash consideration of RM40,000 as a goodwill gesture.

During the financial year ended 30 June 2026

(i) On 25 July 2025 a subsidiary of the Company, Big Pharmacy (Perak) has entered into an asset sale agreement with E3 Farmasi Sdn. Bhd. for an outlet for a cash consideration of RM40,000.

(ii) On 6 January 2026, a subsidiary of the Company, LW Medical Associates Sdn. Bhd. has entered into an asset purchase agreement with Deenadirah Healthcare Sdn. Bhd. for a clinic for a cash consideration of RM130,000. The assets acquired comprised plant and equipment of RM59,000 and licences and panel registration of RM70,800.

(e) Acquisition and subscription of interest in existing subsidiaries

During the financial year ended 30 June 2023

(i) On 31 October 2022, a subsidiary of the Group, My Pharmacy (JJ) Sdn. Bhd. had acquired the remaining 40% equity interest in My Pharmacy (Kulai) Sdn. Bhd. for a total cash consideration of RM150,000. Consequently, the effective shareholding interest of the Group in My Pharmacy (Kulai) Sdn. Bhd. increased from 60% to 80.4%.

(ii) On 13 January 2023, the Company had acquired additional 29,999 shares in Big Pharmacy (Sabah) Sdn. Bhd., an existing direct subsidiary, equivalent to 29,999 total shares issued by Big Pharmacy (Sabah) Sdn. Bhd. for a total cash consideration of RM29,999. There is no change in the effective shareholding interest of the Company during the financial year ended 30 June 2023.

During the financial year ended 30 June 2024

(i) On 18 July 2023, a subsidiary of the Group, Ting Alliance Sdn. Bhd., increased its issued share capital from RM100 to RM10,344,767 by way of the issuance of 1,000,000 new ordinary shares for total consideration of RM10,344,667 for the purpose of increasing the working capital of Ting Alliance Sdn. Bhd..

Subsequently on 29 February 2024, a subsidiary of the Group, Ting Alliance Sdn. Bhd. has undertaken a capital reduction exercise under Section 117(4) of Companies Act 2016 by RM995,845 via cancellation of the paid-up share capital which is unpresented by available assets. Upon completion of the capital reduction exercise, the Company's effective shareholding interest in Ting Alliance Sdn. Bhd. remained at 70%.

(ii) On 1 October 2023, Big Pharmacy (Southern) Sdn. Bhd. increased its paid-up share capital from 1 to 2,000,000 ordinary shares, which the Company subscribed additional 1,579,999 ordinary shares for a consideration of RM1,579,999. Pursuant to that, the effective shareholding interest of the Company in Big Pharmacy (Southern) Sdn. Bhd. has decreased from 100% to 79%.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(e) Acquisition and subscription of interest in existing subsidiaries (continued)

During the financial year ended 30 June 2024 (continued)

(iii) On 5 January 2024, Big Pharmacy (Sabah) Sdn. Bhd. increased its paid-up share capital from 30,000 to 10,000,000 ordinary shares, which the Company subscribed additional 9,470,000 ordinary shares for a consideration of RM9,470,000. Pursuant to that, the effective ownership interest of the Company in Big Pharmacy (Sabah) Sdn. Bhd. has decreased from 100% to 95%.

(iv) On 13 June 2024, the Company acquired additional 99,999 shares in Big Pharmacy FC Sdn. Bhd., an existing direct subsidiary, equivalent to 99,999 total shares issued by Big Pharmacy FC Sdn. Bhd. for a total cash consideration of RM99,999.

Subsequently on 24 June 2024, Big Pharmacy FC Sdn. Bhd. further increased its paid-up share capital from 100,000 to 1,200,000 ordinary shares, which the Company subscribed additional 860,000 ordinary shares for a consideration of RM860,000. Pursuant to that, the effective ownership interest of the Company in Big Pharmacy FC Sdn. Bhd. has decreased from 100% to 80%.

During the financial year ended 30 June 2025

(i) On 25 July 2024, Big Pharmacy (Melaka) Sdn. Bhd., an existing direct subsidiary of the Company, increased its issued and paid-up share capital from 1 to 4,000,001 ordinary shares, which the Company subscribed for 3,450,000 new ordinary shares for a total cash consideration of RM3,450,000. Upon completion of the share subscriptions, the Company's equity interest in Big Pharmacy (Melaka) Sdn. Bhd. decreased from 100% to 86.3%.

(ii) On 28 October 2024, the Company subscribed for 249,999 new ordinary shares in Big Pharmacy (Sarawak) Sdn. Bhd., an existing direct subsidiary, for a total cash consideration of RM249,999. Accordingly, the issued and paid-up ordinary share capital of Big Pharmacy (Sarawak) Sdn. Bhd. increased from RM1 to RM250,000. Upon completion of the share subscriptions, the Company's equity interest in Big Pharmacy (Sarawak) Sdn. Bhd. remained at 100%.

(iii) On 27 February 2025, Yanling Assets Sdn. Bhd., a subsidiary of the Company, increased its issued and paid-up share capital from 54,901,000 to 57,201,000 ordinary shares, which Quantum Upstream Sdn. Bhd. subscribed additional 2,070,000 ordinary shares for a consideration of RM2,070,000. Pursuant to that, the effective ownership interest of the Company in Yanling Assets Sdn. Bhd. has remained at 90%.

(iv) On 3 April 2025, the Company subscribed for 2,998 new ordinary shares in Quantum Upstream Sdn. Bhd., an existing direct subsidiary, for a total cash consideration of RM2,998. Accordingly, the issued and paid-up ordinary share capital of Quantum Upstream Sdn. Bhd. increased from RM2 to RM3,000. Upon completion of the share subscriptions, the Company's equity interest in Quantum Upstream Sdn. Bhd. remained at 100%.

(v) On 23 April 2025, the Company acquired 35,000 ordinary shares, representing 70% of the total issued shares in LW Medical Associates Sdn. Bhd. for a total consideration of RM Nil. The shares were previously held in trust by appointed persons on behalf of the Company. Upon completion of the share transfer, the Company's equity interest in LW Medical Associates Sdn. Bhd. remained at 100%.



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(e) Acquisition and subscription of interest in existing subsidiaries (continued)

During the financial year ended 30 June 2025 (continued)

(vi) On 9 May 2025, the Company acquired 1 ordinary share, representing 100% of the total issued shares in Aetos Pharma Sdn. Bhd. for a total consideration of RM Nil. The shares were previously held in trust by appointed persons on behalf of the Company. Upon completion of the share transfer, the Company's effective shareholding interest in Aetos Pharma Sdn. Bhd. remained at 100%.

(vii) On 29 April 2025, the Company acquired 2 ordinary shares, representing 0.06% of the total issued shares in Quantum Upstream Sdn. Bhd. for a total consideration of RM Nil. The shares were previously held in trust by appointed persons on behalf of the Company. Upon completion of the share transfer, the Company's equity interest in Quantum Upstream Sdn. Bhd. remained at 100%.

(viii) On 19 June 2025, Big Pharmacy Avenue Sdn. Bhd., an existing direct subsidiary of the Company, increased its issued and paid-up share capital from 1 to 7,000,000 ordinary shares, which the Company subscribed additional 6,579,999 ordinary shares for a consideration of RM6,579,999. Pursuant to that, the effective ownership interest of the Company in Big Pharmacy Avenue Sdn. Bhd. has decreased from 100% to 94%.

(ix) On 19 June 2025, Big Pharmacy (Perak) Sdn. Bhd., an existing direct subsidiary of the Company, increased its issued and paid-up share capital from 1 to 10,000,000 ordinary shares, which the Company subscribed additional 9,099,999 ordinary shares for a consideration of RM9,099,999. Pursuant to that, the effective ownership interest of the Company in Big Pharmacy (Perak) Sdn. Bhd. has decreased from 100% to 91%.

(x) On 19 June 2025, Big KL Pharmacy Sdn. Bhd. (formerly known as Big Kok Lian Pharmacy Sdn. Bhd.), an existing direct subsidiary of the Company, increased its issued and paid-up share capital from 1 to 1,600,000 ordinary shares, which the Company subscribed additional 1,449,999 ordinary shares for a consideration of RM1,449,999. Pursuant to that, the effective ownership interest of the Company in Big KL Pharmacy Sdn. Bhd. (formerly known as Big Kok Lian Pharmacy Sdn. Bhd.) has decreased from 100% to 90.6%.

During the financial year ended 30 June 2026

(i) On 18 July 2025, Big Pharmacy (Sarawak) Sdn. Bhd., a subsidiary of the Company, had entered into a sale and purchase agreement with three (3) individuals to acquire 300,030 ordinary shares in Ting Alliance Sdn. Bhd. ("TASB"), representing 30% of the total issued and paid-up share capital of TASB for a total purchase consideration of RM17,522,630.

Following the completion of the acquisition, TASB became a wholly-owned subsidiary of Big Pharmacy (Sarawak) Sdn. Bhd.

(ii) On 24 October 2025 and 13 January 2026, CPRM, a subsidiary of the Company, acquired an additional 20,000 ordinary shares on each date in Caring 'N' You Pharmacy Sdn. Bhd. for total cash considerations of RM65,000 and RM131,300, respectively. These acquisitions increased the Group's effective equity interest in Caring 'N' You Pharmacy Sdn. Bhd. from 60% to 80% and subsequently from 80% to 100%, resulting in Caring 'N' You Pharmacy Sdn. Bhd. becoming a wholly owned subsidiary of the Group.

(iii) On 5 January 2026, a subsidiary of the Company, CPRM, had acquired 15,000 additional number of shares in Preciouslife Pharmacy Sdn. Bhd. for a total purchase consideration of RM1,113,100. The acquisition of shares has increased the effective interest of Preciouslife Pharmacy Sdn. Bhd. from 70% to 85%.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(e) Acquisition and subscription of interest in existing subsidiaries (continued)

During the financial year ended 30 June 2026 (continued)

(iv) On 5 January 2026, a subsidiary of the Company, CPRM, had acquired 12,250 additional number of shares in Vertex Pharmacy Sdn. Bhd. for a total purchase consideration of RM3,185,300. The acquisition of shares has increased the effective interest of Vertex Pharmacy Sdn. Bhd. from 75.5% to 87.8%.

(v) On 6 January 2026, a subsidiary of the Company, Your Physio Sdn. Bhd. had acquired 1,000 additional number of shares in Your Physio Southern Sdn. Bhd. for a total purchase consideration of RM350,000. The acquisition has increased the effective interest of Your Physio Southern Sdn. Bhd. from 29.1% to 43.1%.

(vi) On 13 January 2026, a subsidiary of the Company, CPRM, had acquired 12,250 additional number of shares in Be Caring Sdn. Bhd. for a total purchase consideration of RM148,824. The acquisition of shares has increased the effective interest of Be Caring Sdn. Bhd. from 75.5% to 87.8%.

(vii) On 13 January 2026, a subsidiary of the Company, CPRM, had acquired 20,000 additional number of shares in Caring Clover Sdn. Bhd. for a total purchase consideration of RM44,000. The acquisition of shares has increased the effective interest of Caring Clover Sdn. Bhd. from 60% to 80%.

(viii) On 13 January 2026, a subsidiary of the Company, CPRM had acquired 20,000 additional number of shares in Caring Pharmacy (MPLS) Sdn. Bhd. for a total purchase consideration of RM317,600. The acquisition of shares has increased the effective interest of Caring Pharmacy (MPLS) Sdn. Bhd. from 60% to 80%.

(ix) On 14 January 2026, a subsidiary of the Company, CPRM had acquired 12,500 additional number of shares in Caring T & T Sdn. Bhd. for a total purchase consideration of RM343,200. The acquisition of shares has increased the effective interest of Caring T & T Sdn. Bhd. from 75% to 87.5%.

(x) On 11 February 2026, a subsidiary of CPRM, Caring Evergreen Sdn. Bhd. had acquired 20,700 additional number of ordinary shares in Maxi Caring Sdn. Bhd. for a total purchase consideration of RM1,493,400. This acquisition had increased the effective interest of Maxi Caring Sdn. Bhd. from 42% to 56%.

(xi) On 3 March 2026, a subsidiary of the Company, CPRM had acquired 209,974 additional number of shares in TPH for a total purchase consideration of RM37,367,400. The acquisition of shares had increased the effective interest of TPH from 67% to 93.8%. Accordingly, the Group's effective equity interests in the subsidiaries of TPH were adjusted accordingly.

(xii) On 13 March 2026, a subsidiary of the Company, CPRM had acquired 323,668 additional number of ordinary shares in Wellings for a total purchase consideration of RM40,312,200. The acquisition of shares had increased the effective interest of Wellings from 60% to 92.4%.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(e) Acquisition and subscription of interest in existing subsidiaries (continued)

During the financial year ended 30 June 2026 (continued)

(xiii) During the financial year, the non-controlling shareholders of Yanling Holdings Sdn. Bhd. ("YHSB") expressed their intention to exercise the put and call option arrangements in respect of their remaining equity interest in YHSB within the next twelve (12) months. Consequently, Yanling Assets Sdn. Bhd. recognised contingent consideration of RM150,285,152. The option arrangement effectively provides YASB with a present ownership interest of 100% in YHSB. Accordingly, the Group's effective equity interests in YHSB were adjusted accordingly.

(f) Changes in the group structure

During the financial year ended 30 June 2024

(i) On 29 February 2024, a subsidiary of the Company, CPRM had subscribed 13,500 additional number of ordinary shares in Caring Trio Sdn. Bhd. ("Trio") with total purchase consideration of RM23,220. This subscription had increased the effective shareholding interest of Trio from 59.5% to 73.3%.

(ii) On 29 February 2024, a subsidiary of the Company, CPRM had subscribed 13,334 additional number of ordinary shares in Viva Caring Sdn. Bhd. ("Viva") with total purchase consideration of RM54,136. This subscription had increased the controlling interest of Viva from 60% to 73%.

(iii) On 31 May 2024, a subsidiary of the Company, CPRM had subscribed 13,500 additional number of ordinary shares in Trio with total purchase consideration of RM23,220. This subscription had increased the controlling interest of Trio from 73.3% to 86.5%.

During the financial year ended 30 June 2025

(i) On 30 July 2024, a subsidiary of the Company, CPRM had acquired 100% equity interest in Realcare Baby And Organic Sdn. Bhd from its subsidiary, Wellings Pill House Sdn. Bhd. for a cash consideration of RM179,156.

(ii) On 27 December 2024, a subsidiary of the Company, Wellings Pill House Sdn. Bhd. had subscribed 40,000 additional number of ordinary shares in Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.)("GNPSB") for a total purchase consideration of RM40,000. This subscription had increased the controlling interest of GNPSB from 40.2% to 67%.

(iii) On 3 April 2025, a subsidiary of the Company, CPRM had disposed of a total of 30,000 ordinary shares in Caring Health Solutions Sdn. Bhd. for a total cash consideration of RM30,000. Consequently, the effective shareholding interest of CPRM in Caring Health Solutions Sdn. Bhd. decreased from 100% to 70%.

(iv) On 27 June 2025, a subsidiary of the Company, CPRM had disposed of a total of 30,000 ordinary shares in Caring Pharmacy Always Sdn. Bhd. for a total cash consideration of RM30,000. Consequently, the effective shareholding interest of CPRM in Caring Pharmacy Always Sdn. Bhd. decreased from 100% to 70%.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(f) Changes in the group structure (continued)

During the financial year ended 30 June 2025 (continued)

(v) On 30 June 2025, Caring Pharmacy (ABM) Sdn. Bhd. increased its paid-up share capital from 400,000 to 1,300,000 ordinary shares, which CPRM subscribed additional 720,000 ordinary shares for a consideration of RM720,000. Pursuant to that, the effective ownership interest of CPRM in Caring Pharmacy (ABM) Sdn. Bhd. remained at 80%.

(vi) On 30 June 2025, Caring Evergreen Sdn. Bhd. ("Evergreen") increased its paid-up share capital from 100,000 to 106,800 ordinary shares, which CPRM subscribed additional 4,816 ordinary shares for a consideration of RM4,816,000. Pursuant to that, the effective ownership interest of CPRM in Evergreen remained at 70%.

(vii) On 30 June 2025, Caring Health Solutions Sdn. Bhd. increased its paid-up share capital from 100,000 to 500,000 ordinary shares, which CPRM subscribed additional 280,000 ordinary shares for a consideration of RM280,000. Pursuant to that, the effective ownership interest of CPRM in Caring Health Solutions Sdn. Bhd. remained at 70%.

(viii) On 30 June 2025, Jom Pharmacy Sdn. Bhd. increased its paid-up share capital from 600,000 to 607,900 ordinary shares, which CPRM subscribed additional 4,740 ordinary shares for a consideration of RM4,740,000. Pursuant to that, the effective ownership interest of CPRM in Jom Pharmacy Sdn. Bhd. remained at 60%.

(ix) On 30 June 2025, Living Glory Sdn. Bhd. increased its paid-up share capital from 100,000 to 1,000,000 ordinary shares, which CPRM subscribed additional 459,000 ordinary shares for a consideration of RM459,000. Pursuant to that, the effective ownership interest of CPRM in Living Glory Sdn. Bhd. remained at 51%.

(x) On 30 June 2025, Caring Pharmacy Rising Sdn. Bhd. increased its paid-up share capital from 200,000 to 1,000,000 ordinary shares, which CPRM subscribed additional 488,000 ordinary shares for a consideration of RM488,000. Pursuant to that, the effective ownership interest of CPRM in Caring Pharmacy Rising Sdn. Bhd. remained at 61%.

(xi) On 30 June 2025, WM Caring Pharmacy Sdn. Bhd. increased its paid-up share capital from 100,000 to 300,000 ordinary shares, which CPRM subscribed additional 160,000 ordinary shares for a consideration of RM160,000. Pursuant to that, the effective ownership interest of CPRM in WM Caring Pharmacy Sdn. Bhd. remained at 80%.

(xii) On 30 June 2025, a subsidiary of Evergreen, Maxi Caring Sdn. Bhd. increased its paid-up share capital from 100,000 to 103,500 ordinary shares, which Evergreen subscribed additional 2,100 ordinary shares for a consideration of RM2,100,000. Pursuant to that, the effective ownership interest of the Group in Maxi Caring Sdn. Bhd. remained at 42%.

During the financial year ended 30 June 2026

(i) On 21 August 2025, Wellings Pill House Sdn. Bhd., had disposed of 30,000 of the ordinary shares of Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.) for a total consideration of RM30,000. Pursuant to that, the effective ownership interest of the Group in Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.) becomes 65.7%.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(f) Changes in the group structure (continued)

During the financial year ended 30 June 2026 (continued)

(ii) On 1 October 2025, Wellings Pill House Sdn. Bhd., had acquired additional 280,000 of the ordinary shares of Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.), representing 70% of the 400,000 ordinary shares allotted, for a total consideration of RM280,000. Pursuant to that, the effective ownership interest of the Group in Golden North Pharmacy Sdn. Bhd. (formerly known as Ambergreen Pharmacy Sdn. Bhd.) remains at 65.7%.

(iii) On 13 March 2026, a subsidiary of the Company, Your Physio Sdn. Bhd., had incorporated Horizon Academy Sdn. Bhd. and subscribed to 1,000 of its ordinary shares for a total consideration of RM1,000. Pursuant to that, Horizon Academy Sdn. Bhd. becomes a wholly owned subsidiary of Your Physio Sdn. Bhd. The effective ownership interest of the Group in Horizon Academy Sdn. Bhd. becomes 57.1%.

(g) Incorporation of subsidiaries

During the financial year ended 30 June 2023

On 14 July 2022, the Company subscribed for one (1) ordinary share at an issue price of RM1 per share in Big Pharmacy (Melaka) Sdn. Bhd., a company incorporated in Malaysia for a total consideration of RM1.

(h) Winding up/dissolution of subsidiaries

During the financial year ended 30 June 2025

(i) On 19 March 2025, Caring Belle Sdn. Bhd., a wholly-owned subsidiary of CPRM, had been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, CPRM received a total consideration on a first return of surplus assets of RM60,000.

(ii) On 19 March 2025, Caring Pharmacy (SK) Sdn. Bhd., a wholly-owned subsidiary of CPRM, had been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, CPRM received a total consideration on a first return of surplus assets of RM45,000.

(iii) On 19 March 2025, Health Town Pharmacy Sdn. Bhd., a wholly-owned subsidiary of Wellings Pill House Sdn. Bhd. ("WPH"), has been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, WPH received a total consideration on a first return of surplus assets of RM70,000.

(iv) On 19 March 2025, Blooming Health Pharmacy Sdn. Bhd., a wholly-owned subsidiary of WPH, has been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, WPH received a total consideration on a first return of surplus assets of RM70,000.

(v) On 19 March 2025, Nutrilife Pharmacy Sdn. Bhd., a wholly-owned subsidiary of WPH, has been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, WPH received a total consideration on a first return of surplus assets of RM70,000.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

5. LIST OF SUBSIDIARIES (continued)

(h) Winding up/dissolution of subsidiaries (continued)

During the financial year ended 30 June 2025 (continued)

(vi) On 19 March 2025, Pure Health Pharmacy Sdn. Bhd., a wholly-owned subsidiary of WPH has been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, WPH received a total consideration on a first return of surplus assets of RM200,000.

(vii) On 19 March 2025, Wellings Pill House (TG) Sdn. Bhd., a wholly-owned subsidiary of WPH has been struck off upon passing of a resolution of a member's voluntary winding up. Upon completion of the striking off, WPH received a total consideration on a first return of surplus assets of RM200,000.

During the financial year ended 30 June 2026

(i) As at the end of the current financial year, Jom Pharmacy (Serian) Sdn. Bhd., a wholly-owned subsidiary of Jom Pharmacy Sdn. Bhd., had been struck off upon passing of a resolution of a member's voluntary winding up.

(ii) On 18 August 2025, Mason Health Sdn. Bhd., a wholly-owned subsidiary of Wellings, had been struck off upon passing of a resolution of a member's voluntary winding up.

(i) The Group reviews the investments in subsidiaries for impairment when there is an indication of impairment.

The recoverable amounts of the investments in subsidiaries are assessed by reference to the fair value less cost to sell of the underlying assets or the value-in-use of the respective subsidiaries.

The value-in-use is the net present value of the projected cash flows derived from the business operations of the respective subsidiaries discounted at an appropriate pre-tax discount rate. For such discounted cash flow method, it involves the use of estimated future results and a set of assumptions to support their income and cash flows. Judgement had also been used to determine the pre-tax discount rate for the cash flows and the future growth rate of the business of the entities.

6. OPERATING SEGMENTS

The Group has arrived at two (2) reportable segments that are organised and managed separately based on information reported internally to the Management and the Board of Directors. The reportable segments are summarised as follows:

Retail: Sale of pharmaceutical, healthcare, beauty, general merchandise, and other related products through a network of pharmacy retail outlets, e-commerce platforms, and corporate sales channels.

Others: Manufacturing, importing, marketing, distributing and wholesaling of healthcare, pharmaceutical and nutraceutical products, as well as the provision of physiotherapy, tele-consultation and other healthcare related services.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

The accounting policies of operating segments are the same as those described in the respective notes to the consolidated financial statements. The Group evaluates performance on the basis of profit or loss from operations before tax. These policies have been applied consistently throughout the current and previous financial years.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

Segment revenue and expenses include inter-segment revenue that are eliminated on consolidation. Segment results exclude the effects of transfer between segments.

The inter-segment assets are adjusted against the segment assets to arrive at total assets reported in the consolidated statements of financial position.

The inter-segment liabilities are adjusted against the segment liabilities to arrive at total liabilities reported in the consolidated statements of financial position.

2023	**Retail RM**	**Others RM**	**Elimination and adjustment RM**	**Total RM**
Revenue				
Revenue from external customers	1,089,146,699	21,504,726	-	1,110,651,425
Inter-segment revenue	170,516	70,546,605	(70,717,121)	-
Total revenue	**1,089,317,215**	**92,051,331**	**(70,717,121)**	**1,110,651,425**
Interest income	2,164,773	8,755	-	2,173,528
Finance costs	(11,324,918)	(350,421)	78,244	(11,597,095)
Net finance expense	**(9,160,145)**	**(341,666)**	**78,244**	**(9,423,567)**
Amortisation and depreciation of:				
- Intangible assets	(29,137)	-	-	(29,137)
- Property, plant and equipment	(12,631,029)	(321,921)	-	(12,952,950)
- Investment properties	(57,279)	(52,000)	-	(109,279)
- Right-of-use assets	(25,189,735)	(188,384)	184,194	(25,193,925)
Segment profit before tax	**53,933,003**	**12,295,491**	**(7,387,776)**	**58,840,718**
Tax expense	(14,446,817)	(3,199,724)	-	(17,646,541)
Other material non-cash items:				
Impairment losses on trade and other receivables	(100,071)	-	-	(100,071)
Reversal of impairment losses on trade and other receivables	405,636	-	-	405,636
Inventories written back, net	4,265,461	-	-	4,265,461
Property, plant and equipment written off	(453,650)	-	-	(453,650)
Gain on reassessment and modification of lease, net	244,200	-	-	244,200

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2023	**Retail RM**	**Others RM**	**Elimination and adjustment RM**	**Total RM**
Additions to non-current assets other than financial instruments, goodwill and deferred tax assets				
- Property, plant and equipment	42,875,650	218,292	-	43,093,942
- Right-of-use assets	73,390,299	190,802	-	73,581,101
Segment assets	**948,584,003**	**100,698,078**	**(321,669,518)**	**727,612,563**
Goodwill on consolidation	12,798,426	-	47,960,550	60,758,976
Segment liabilities	**773,746,182**	**73,980,980**	**(279,246,340)**	**568,480,822**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906006013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2024	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Revenue				
Revenue from external customers	2,112,422,658	58,936,802	-	2,171,359,460
Inter-segment revenue	163,756	112,399,815	(112,563,571)	-
Total revenue	**2,112,586,414**	**171,336,617**	**(112,563,571)**	**2,171,359,460**
Interest income	3,690,581	24,139	-	3,714,720
Finance costs	(37,870,587)	(2,454,438)	110,231	(40,214,794)
Net finance expenses	**(34,180,006)**	**(2,430,299)**	**110,231**	**(36,500,074)**
Amortisation and depreciation of:				
- Intangible assets	(1,561,579)	(131,943)	(3,147,500)	(4,841,022)
- Property, plant and equipment	(22,796,359)	(1,259,383)	-	(24,055,742)
- Investment properties	(320,221)	(52,000)	-	(372,221)
- Right-of-use assets	(46,789,278)	(880,676)	-	(47,669,954)
Segment profit before tax	**134,050,946**	**26,201,346**	**(79,045,232)**	**81,207,060**
Tax expense	(25,538,018)	(7,122,724)	(755,500)	(33,416,242)
Other material non-cash items:				
Impairment losses on trade and other receivables	(124)	(227,296)	-	(227,420)
Reversal of impairment losses on:				
- Property, plant and equipment	82,876	-	-	82,876
- Right-of-use assets	154,273	-	-	154,273
- Trade and other receivables	7,299	-	-	7,299
Inventories written (down)/back, net	(325,099)	353,107	-	28,008
Inventories written off	(120,062)	-	-	(120,062)
Bad debts written off	(410,938)	-	-	(410,938)
Property, plant and equipment written off	(1,206,826)	-	-	(1,206,826)
Gain on disposal of property, plant and equipment	106,411	-	-	106,411
Gain on fair value of quoted equity instruments	218,887	-	-	218,887
Gain/(Loss) on reassessment and modification of lease, net	594,379	-	(622,396)	(28,017)

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2024 (continued)	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Additions to non-current assets other than financial instruments, goodwill and deferred tax assets				
- Property, plant and equipment	27,042,386	2,728,273	39,924	29,810,583
- Investment properties	1,800,000	-	-	1,800,000
- Right-of-use assets	56,531,591	88,442	618,946	57,238,979
- Intangible assets	234,867	15,800	-	250,667
Segment assets	**2,741,839,078**	**283,593,234**	**(565,185,590)**	**2,460,246,722**
Goodwill	53,569,605	42,853,215	430,919,252	527,342,072
Segment liabilities	**2,177,653,190**	**175,536,688**	**(312,231,672)**	**2,040,958,206**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2025	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Revenue				
Revenue from external customers	3,281,761,882	130,264,774	-	3,412,026,656
Inter-segment revenue	164,865	168,029,930	(168,194,795)	-
Total revenue	3,281,926,747	298,294,704	(168,194,795)	3,412,026,656
Interest income	5,717,466	188,592	-	5,906,058
Finance costs	(68,869,693)	(3,636,950)	6,194,935	(66,311,708)
Net finance expense	**(63,152,227)**	**(3,448,358)**	**6,194,935**	**(60,405,650)**
Amortisation and depreciation of:				
- Intangible assets	(1,433,285)	(216,277)	(3,173,242)	(4,822,804)
- Property, plant and equipment	(23,461,355)	(2,161,118)	-	(25,622,473)
- Investment properties	(500,137)	(52,000)	-	(552,137)
- Right-of-use assets	(68,445,393)	(1,544,080)	-	(69,989,473)
Segment profit before tax	338,178,772	53,387,445	(172,242,283)	219,323,934
Tax expense	(61,975,321)	(15,091,754)	761,678	(76,305,397)
Other material non-cash items:				
Impairment losses on:				
- Property, plant and equipment	(1,026,665)	-	-	(1,026,665)
- Investment properties	(137,000)	-	-	(137,000)
- Intangible assets	(936,354)	(1,404)	-	(937,758)
- Right-of-use assets	(1,706,576)	-	-	(1,706,576)
- Trade and other receivables	(1,178,508)	(250,351)	-	(1,428,859)
Reversal of impairment losses on trade and other receivables	39,462	315,825	-	355,287
Inventories written down, net	(1,151,011)	(985,410)	-	(2,136,421)
Inventories written off	(944,789)	(625,092)	-	(1,569,881)
Bad debts written off	(148,644)	(345,371)	-	(494,015)
Property, plant and equipment written off	(2,409,503)	(8,560)	-	(2,418,063)
Prepayment written off	-	(645,475)	-	(645,475)
Gain on disposal of:				
- Property, plant and equipment	105,047	36,867	-	141,914
- Investment properties	185,728	-	-	185,728
- Quoted equity instruments	3,607	-	-	3,607
Gain on fair value of quoted equity instruments	32,960	-	-	32,960

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2025 (continued)	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Other material non-cash items: (continued)				
Gain on reassessment and modification of leases	1,404,507	88	-	1,404,595
Under provision of restoration cost	(436,353)	-	-	(436,353)
Unrealised gain/(loss) on foreign exchange, net	627	(215,495)	-	(214,868)
Share of loss in associates	(3,505)	-	(8,660)	(12,165)
Additions to non-current assets other than financial instruments, goodwill and deferred tax assets				
- Property, plant and equipment	78,280,433	7,127,464	-	85,407,897
- Investment properties	950,000	-	-	950,000
- Intangible assets	3,919,840	603,874	-	4,523,714
- Right-of-use assets	53,524,621	1,370,202	-	54,894,823
Segment assets	3,766,414,932	436,221,578	(1,031,765,214)	3,170,871,296
Investments in associates	5,673,694	-	21,341	5,695,035
Goodwill	52,673,251	62,772,215	506,208,354	621,653,820
Segment liabilities	3,109,733,703	224,974,548	(692,617,704)	2,642,090,547

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906006013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2026	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Revenue				
Revenue from external customers	3,738,090,208	285,901,310	-	4,023,991,518
Inter-segment revenue	319,475	341,961,134	(342,280,609)	-
Total revenue	3,738,409,683	627,862,444	(342,280,609)	4,023,991,518
Interest income	15,364,676	339,107	(10,022,234)	5,681,549
Finance costs	(83,898,175)	(14,813,673)	10,226,827	(88,485,021)
Net finance expense	(68,533,499)	(14,474,566)	204,593	(82,803,472)
Amortisation and depreciation of:				
- Intangible assets	(1,989,996)	(161,988)	(308,902)	(2,460,886)
- Property, plant and equipment	(30,000,396)	(3,431,894)	-	(33,432,290)
- Investment properties	(498,822)	(52,000)	-	(550,822)
- Right-of-use assets	(79,003,743)	(4,030,708)	2,092,437	(80,942,014)
Segment profit before tax	255,576,322	152,473,530	(55,845,770)	352,204,082
Tax expense	(79,369,266)	(41,085,387)	74,137	(120,380,516)
Other material non-cash items:				
Impairment losses on:				
- Property, plant and equipment	(558,628)	(66,104)	-	(624,732)
- Right-of-use assets	(1,799,962)	(108,694)	-	(1,908,656)
- Trade and other receivables	(1,243,261)	(149,021)	-	(1,392,282)
Reversal of impairment losses on trade and other receivables	428,213	184,825	-	613,038
Inventories written down, net	(1,947,878)	(3,978,895)	-	(5,926,773)
Inventories written off	-	(531,635)	-	(531,635)
Bad debts written off	(100,295)	(109,846)	-	(210,141)
Property, plant and equipment written off	(796,403)	(29,290)	-	(825,693)
Gain on disposal of:				
- Property, plant and equipment	87,231	-	-	87,231
- Quoted equity instruments	8,710	-	-	8,710
Gain on fair value of quoted equity instruments	74,152	-	-	74,152

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

2026 (continued)	**Retail RM**	**Others RM**	**Elimination and adjustments RM**	**Total RM**
Other material non-cash items: (continued)				
Gain/(Loss) on reassessment and modification of leases	423,573	(14,740)	-	408,833
Over provision of restoration cost	1,925,328	-	-	1,925,328
Unrealised gain/(loss) on foreign exchange, net	1,545,757	(349,130)	-	1,196,627
Share of profit from associates	76,333	-	(19,333)	57,000
Additions to non-current assets other than financial instruments, goodwill and deferred tax assets				
- Property, plant and equipment	62,496,297	11,280,850	-	73,777,147
- Intangible assets	4,336,172	386,740	-	4,722,912
- Right-of-use assets	76,850,834	9,889,533	(12,554,624)	74,185,743
Segment assets	3,594,982,143	509,984,751	(628,445,806)	3,476,521,088
Investments in associates	5,946,147	-	(27,992)	5,918,155
Goodwill	52,697,783	62,772,215	506,208,353	621,678,351
Segment liabilities	2,833,114,420	341,384,361	(257,108,074)	2,917,390,707

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. OPERATING SEGMENTS (continued)

(a) Geographical information

The business activities of the Group predominantly located in Malaysia.

In presenting information on the basis of geographical areas, segment revenue is based on the region and country of operations. Segment assets are based on the geographical location of the assets of the Group.

	2023 RM	2024 RM	2025 RM	2026 RM
Revenue from external customers				
Malaysia	1,105,541,729	2,164,129,770	3,403,276,906	4,019,039,928
Singapore	5,109,696	6,956,729	7,923,928	3,090,448
Brunei	-	-	703,538	1,680,032
Hong Kong	-	131,247	-	-
Kenya	-	127,529	122,094	38,338
United States	-	14,185	-	13,314
Australia	-	-	190	-
Thailand	-	-	-	129,458
	1,110,651,425	2,171,359,460	3,412,026,656	4,023,991,518
Locations of the assets				
Malaysia				
- Non-current assets	360,865,692	1,591,880,686	1,972,723,636	2,055,908,616
- Current assets	366,715,043	868,334,208	1,197,989,306	1,420,484,728
	727,580,735	2,460,214,894	3,170,712,942	3,476,393,344
Singapore				
- Non-current assets	-	-	-	-
- Current assets	31,828	31,828	158,354	127,744
	31,828	31,828	158,354	127,744
	727,612,563	2,460,246,722	3,170,871,296	3,476,521,088

(b) Major customers

There are no major customers with revenue equal or more than ten per centum (10%) of the Group's revenue throughout the reporting financial years. As such, information on major customers is not presented.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT

2023 Carrying amount	Balance as at 1.7.2022 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Disposals RM	Written off RM	Reclassification RM	Reclassification from right-of-use assets (Note 10) RM	Depreciation charge for the financial year RM	Balance as at 30.6.2023 RM
Air conditioners	2,075,854	105,269	1,907,013	(1,071)	(7,062)	18,639	-	(759,606)	3,339,036
Buildings	2,891,639	-	-	-	-	-	-	(62,708)	2,828,931
Freehold land	39,316,841	-	-	-	-	-	-	-	39,316,841
Furniture, fittings and office equipment	31,381,355	901,762	27,795,777	(3,780)	(251,625)	94,728	-	(8,451,168)	51,467,049
Motor vehicles	624,223	75,110	19,310	-	-	-	187,418	(206,132)	699,929
Plant and machinery	191,202	-	132,010	-	-	-	-	(37,683)	285,529
Renovations	11,349,634	1,094,223	13,239,832	-	(194,963)	(113,367)	-	(3,435,653)	21,939,706
	87,830,748	2,176,364	43,093,942	(4,851)	(453,650)	-	187,418	(12,952,950)	119,877,021

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

	<---------- As at 30.6.2023 ---------->			
	Cost RM	Accumulated depreciation RM	Accumulated impairment RM	Carrying amount RM
Air conditioners	5,631,449	(1,977,463)	(314,950)	3,339,036
Buildings	3,343,419	(514,488)	-	2,828,931
Freehold land	39,316,841	-	-	39,316,841
Furniture, fittings and office equipment	77,816,008	(24,288,584)	(2,060,375)	51,467,049
Motor vehicles	1,783,480	(1,083,551)	-	699,929
Plant and machinery	348,169	(62,640)	-	285,529
Renovations	31,804,600	(9,564,683)	(300,211)	21,939,706
	160,043,966	(37,491,409)	(2,675,536)	119,877,021

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

2024 Carrying amount	Balance as at 1.7.2023 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Disposals RM	Written off RM	Reclassification from intangible assets (Note 9) RM	Reclassification to right-of-use assets (Note 10) RM	Reclassification to investment properties (Note 8) RM	Depreciation charge for the financial year RM	Reversal of impairment RM	Balance as at 30.6.2024 RM
Air conditioners	3,339,036	77,660	1,736,655	(33,753)	(78,094)	-	-	-	(1,055,514)	-	3,985,990
Buildings	2,828,931	16,465,789	507,167	-	-	-	-	(2,340,847)	(351,706)	-	17,109,334
Freehold land	39,316,841	-	-	-	-	-	-	-	-	-	39,316,841
Furniture, fittings and office equipment	51,467,049	17,572,063	17,165,523	(345,876)	(548,495)	6,600	-	(39,924)	(14,767,876)	33,213	70,542,277
Motor vehicles	699,929	338,966	1,059,047	(28,814)	-	-	(289,425)	-	(1,166,143)	-	613,560
Plant and machinery	285,529	2,605,196	1,246,863	-	-	-	-	-	(570,584)	-	3,567,004
Renovations	21,939,706	7,833,562	7,842,561	(77,445)	(580,237)	-	-	-	(6,064,342)	49,663	30,943,468
Medical and laboratory equipment	-	563,691	227,485	-	-	-	-	-	(79,577)	-	711,599
Capital work-in-progress	-	-	25,282	-	-	-	-	-	-	-	25,282
	119,877,021	45,456,927	29,810,583	(485,888)	(1,206,826)	6,600	(289,425)	(2,380,771)	(24,055,742)	82,876	166,815,355

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

	<---------- As at 30.6.2024 ---------->			
	Cost **RM**	**Accumulated depreciation** **RM**	**Accumulated impairment** **RM**	**Carrying amount** **RM**
Air conditioners	7,512,376	(3,526,386)	-	3,985,990
Buildings	19,264,433	(2,155,099)	-	17,109,334
Freehold land	39,316,841	-	-	39,316,841
Furniture, fittings and office equipment	137,687,730	(67,128,445)	(17,008)	70,542,277
Motor vehicles	3,338,860	(2,725,300)	-	613,560
Plant and machinery	10,883,227	(7,316,223)	-	3,567,004
Renovations	61,745,446	(30,801,978)	-	30,943,468
Medical and laboratory equipment	1,301,455	(589,856)	-	711,599
Capital work-in-progress	25,282	-	-	25,282
	281,075,650	(114,243,287)	(17,008)	166,815,355

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

2025 Carrying amount	Balance as at 1.7.2024 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Disposals RM	Written off RM	Reclassification RM	Reclassification to right-of-use assets (Note 10) RM	Reclassification from investment properties (Note 8) RM	Depreciation charge for the financial year RM	Impairment loss for the financial year RM	Balance as at 30.6.2025 RM
Air conditioners	3,985,990	-	-	-	-	(3,985,990)	-	-	-	-	-
Buildings	17,109,334	8,823,000	-	-	-	(6,840,607)	-	3,191,505	(302,156)	-	21,981,076
Freehold land	39,316,841	4,326,999	-	-	-	6,840,607	-	-	-	-	50,484,447
Furniture, fittings and office equipment	70,542,277	3,547,984	19,441,124	(82,398)	(1,745,000)	4,005,947	-	-	(16,693,130)	(461,904)	78,554,900
Motor vehicles	613,560	2,097,403	109,044	(1)	-	-	(1,612,999)	-	(532,531)	-	674,476
Plant and machinery	3,567,004	66,947	893,731	-	(133)	-	-	-	(731,137)	-	3,796,412
Renovations	30,943,468	476,503	9,309,262	(1,391)	(672,930)	5,325	(1,785,912)	-	(6,930,295)	(564,761)	30,779,269
Medical and laboratory equipment	711,599	-	67,707	-	-	-	-	-	(107,152)	-	672,154
Warehouse automation	-	-	12,395,424	-	-	-	-	-	(103,295)	-	12,292,129
Warehouse	-	-	26,733,249	-	-	-	-	-	(222,777)	-	26,510,472
Capital work-in-progress	25,282	-	16,458,356	-	-	(25,282)	-	-	-	-	16,458,356
	166,815,355	19,338,836	85,407,897	(83,790)	(2,418,063)	-	(3,398,911)	3,191,505	(25,622,473)	(1,026,665)	242,203,691

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

	<---------- As at 30.6.2025 ---------->			
	Cost RM	**Accumulated depreciation** RM	**Accumulated impairment** RM	**Carrying amount** RM
Buildings	25,755,236	(3,774,160)	-	21,981,076
Freehold land	50,484,447	-	-	50,484,447
Furniture, fittings and office equipment	162,471,697	(83,437,885)	(478,912)	78,554,900
Motor vehicles	5,768,362	(5,093,886)	-	674,476
Plant and machinery	12,007,347	(8,210,935)	-	3,796,412
Renovations	74,973,786	(43,629,756)	(564,761)	30,779,269
Medical and laboratory equipment	1,369,162	(697,008)	-	672,154
Warehouse automation	12,395,424	(103,295)	-	12,292,129
Warehouse	26,733,249	(222,777)	-	26,510,472
Capital work-in-progress	16,458,356	-	-	16,458,356
	388,417,066	(145,169,702)	(1,043,673)	242,203,691

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

2026 Carrying amount	Balance as at 1.7.2025 RM	Additions RM	Disposals RM	Written off RM	Reclassification RM	Reclassification to right-of-use assets (Note 10) RM	Reclassification from intangible assets (Note 9) RM	Depreciation charge for the financial year RM	Impairment loss for the financial year RM	Balance as at 30.6.2026 RM
Buildings	21,981,076	15,156,716	-	-	(1,576,914)	-	-	(768,524)	-	34,792,354
Freehold land	50,484,447	1,980,000	-	-	1,633,333	-	-	-	-	54,097,780
Furniture, fittings and office equipment	78,554,900	33,145,638	(116,715)	(642,101)	1,356,149	-	321,906	(20,846,275)	(165,753)	91,607,749
Motor vehicles	674,476	320,166	(17,817)	-	10,588	-	-	(365,697)	-	621,716
Plant and machinery	3,796,412	3,011,688	-	(1,367)	1,996,119	-	-	(986,060)	(10,621)	7,806,171
Renovations	30,779,269	19,265,118	(94,133)	(182,225)	1,581,711	(271,111)	106,272	(8,555,055)	(448,358)	42,181,488
Medical and laboratory equipment	672,154	81,368	-	-	(123,374)	-	-	(102,053)	-	528,095
Warehouse automation	12,292,129	813,290	-	-	-	-	-	(1,259,020)	-	11,846,399
Warehouse	26,510,472	3,163	-	-	11,580,744	-	-	(549,606)	-	37,544,773
Capital work-in-progress	16,458,356	-	-	-	(16,458,356)	-	-	-	-	-
	242,203,691	73,777,147	(228,665)	(825,693)	-	(271,111)	428,178	(33,432,290)	(624,732)	281,026,525

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

	<---------- As at 30.6.2026 ---------->			
	Cost **RM**	**Accumulated depreciation** **RM**	**Accumulated impairment** **RM**	**Carrying amount** **RM**
Buildings	39,393,499	(4,601,145)	-	34,792,354
Freehold land	54,097,780	-	-	54,097,780
Furniture, fittings and office equipment	199,924,712	(107,549,188)	(767,775)	91,607,749
Motor vehicles	5,945,839	(5,324,123)	-	621,716
Plant and machinery	16,557,321	(8,740,529)	(10,621)	7,806,171
Renovations	89,116,969	(46,037,324)	(898,157)	42,181,488
Medical and laboratory equipment	1,315,531	(787,436)	-	528,095
Warehouse automation	13,208,714	(1,362,315)	-	11,846,399
Warehouse	38,469,345	(924,572)	-	37,544,773
	458,029,710	(175,326,632)	(1,676,553)	281,026,525

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

(a) All items of property, plant and equipment are initially measured at cost. After initial recognition, property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

Depreciation is calculated to write down the cost of the assets to their residual values on a straight line basis over their estimated useful lives. The principal depreciation period and annual rates used are as follows:

Air conditioners	10% to 20%
Buildings	2%
Furniture, fittings and office equipment	10% to 40%
Motor vehicles	20%
Plant and machinery	10% to 20%
Renovations	10% to 20%
Medical and laboratory equipment	10% to 20%
Warehouse automation	10%
Warehouse	10%

Freehold land has unlimited useful life and is not depreciated.

Capital work-in-progress represents renovation. Capital work-in-progress are not depreciated until such time when the assets are available for use.

(b) During the financial year, the Group made the following cash payments to purchase property, plant and equipment:

	2023 RM	2024 RM	2025 RM	2026 RM
Purchase of property, plant and equipment	43,093,942	29,810,583	85,407,897	73,777,147
Provision for restoration costs capitalised (Note 20(g))	(774,226)	(798,765)	-	-
Acquisition of outlets (Note 5(d))	(157,512)	-	-	(59,000)
Cash payments on purchase of property, plant and equipment	42,162,204	29,011,818	85,407,897	73,718,147

(c) For the purpose of impairment assessment, recoverable amount of property, plant and equipment is determined based on a "value-in-use" of each Cash Generating Unit ("CGU").

Value-in-use of the CGUs is determined by discounting the future cash flows to be generated from continuing use of the CGUs. Management considered consecutive losses in certain outlets after their gestation period of two (2) to three (3) financial years as one of the indicators of impairment. Management has made estimates about the future results and key assumptions applied to cash flow projections of the CGUs in determining the recoverable amount using the value-in-use model. These key assumptions include forecast growth in future revenues and operating profit margins, as well as determining an appropriate pre-tax discount rate and growth rates.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. PROPERTY, PLANT AND EQUIPMENT (continued)

(c) (continued)

During the financial year, management has determined that the recoverable amounts of certain property, plant and equipment of the loss-making outlets are lower than their carrying amounts. Accordingly, the Group has recognised impairment losses on certain property, plant and equipment amounted to RM624,732 (2025: RM1,026,665, 2024: RM Nil, 2023: RM Nil) within operating and administrative expenses in the consolidated statements of profit or loss and other comprehensive income. The pre-tax discount rate applied on the cash flow projections in determining the recoverable amounts is 7% (2025: 7%, 2024: 5%, 2023: 5%).

With regard to the assessment of value-in-use of the CGUs, management believes that no reasonably possible change in any of the above key assumptions would cause the carrying amounts of the CGUs to further materially exceed their recoverable amounts.

(d) In the FYE 30 June 2024, the Group recognised a reversal of impairment losses on certain property, plant and equipment amounted to RM82,876 within other operating income in the consolidated statements of profit or loss and other comprehensive income.

(e) As at the end of the reporting period, freehold land and buildings, warehouse and capital work-in-progress of the Group with a total carrying amount of RM90,918,575 (2025: RM85,327,102, 2024: RM53,110,386, 2023: RM39,744,417) has been charged to a licensed bank for credit facilities granted to the Group as disclosed in Note 19(b) to the consolidated financial statements.

8. INVESTMENT PROPERTIES

2023 **Carrying amount**	**Balance as at 1.7.2022** **RM**	**Depreciation charge for the financial year** **RM**	**Balance as at 30.6.2023** **RM**
Buildings, at cost	10,127,893	(109,279)	10,018,614

	As at 30.6.2023			
	Cost **RM**	**Accumulated depreciation** **RM**	**Accumulated impairment** **RM**	**Carrying amount** **RM**
Buildings	10,719,738	(645,290)	(55,834)	10,018,614

2024 **Carrying amount**	**Balance as at 1.7.2023** **RM**	**Acquisition from subsidiaries (Note 5(c))** **RM**	**Additions** **RM**	**Reclassification from property, plant and equipment (Note 7)** **RM**	**Depreciation charge for the financial year** **RM**	**Balance as at 30.6.2024** **RM**
Buildings, at cost	10,018,614	19,752,986	1,800,000	2,380,771	(372,221)	33,580,150

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

8. INVESTMENT PROPERTIES (continued)

	As at 30.6.2024			
2024	**Cost RM**	**Accumulated depreciation RM**	**Accumulated impairment RM**	**Carrying amount RM**
Buildings	36,816,778	(3,180,794)	(55,834)	33,580,150

2025	**Balance as at 1.7.2024 RM**	**Additions RM**	**Reclassification to property, plant and equipment (Note 7) RM**	**Depreciation charge for the financial year RM**	**Disposal RM**	**Impairment loss RM**	**Balance as at 30.6.2025 RM**
Carrying amount							
Buildings, at cost	33,580,150	950,000	(3,191,505)	(552,137)	(1,239,272)	(137,000)	29,410,236

	As at 30.6.2025			
2025	**Cost RM**	**Accumulated depreciation RM**	**Accumulated impairment RM**	**Carrying amount RM**
Buildings	32,901,311	(3,298,241)	(192,834)	29,410,236

2026	**Balance as at 1.7.2025 RM**	**Depreciation charge for the financial year RM**	**Balance as at 30.6.2026 RM**
Carrying amount			
Buildings, at cost	29,410,236	(550,822)	28,859,414

	As at 30.6.2026			
2026	**Cost RM**	**Accumulated depreciation RM**	**Accumulated impairment RM**	**Carrying amount RM**
Buildings	32,901,311	(3,849,063)	(192,834)	28,859,414

(a) Investment properties are initially measured at cost, which includes transaction costs. After initial recognition, investment properties are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

Depreciation is calculated to write off the cost of the investment properties to their residual values on a straight line basis over their estimated useful life. The principal depreciation period is as follows:

Buildings 50 years

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

8. INVESTMENT PROPERTIES (continued)

(b) During the financial year, management has determined that the recoverable amounts of certain investment properties are lower than their carrying amounts. Accordingly, the Group has recognised an impairment loss amounted to RM Nil (2025: RM137,000, 2024: RM Nil, 2023: RM Nil) within operating and administrative expenses in the consolidated statements of profit or loss and other comprehensive income.

(c) Investment properties with a total carrying amount of RM27,346,067 (2025: RM27,863,554, 2024: RM33,139,007, 2023: RM9,567,648) are charged to a financial institution for banking facilities granted to the Group as disclosed in Note 19(b) to the financial statements.

(d) The Level 2 fair value of investment properties of the Group are RM41,300,000 (2025: RM42,947,843, 2024: RM38,200,850, 2023: RM11,557,467). The fair value is determined by the Directors based on market values for similar properties in the same vicinity obtained from property agencies. There is no transfer between levels in the hierarchy during the financial year.

(e) The following are recognised in the consolidated statements of profit or loss in respect of investment properties:

	2023 RM	2024 RM	2025 RM	2026 RM
Leasing and rental income	104,567	562,197	1,392,071	1,233,275
Quit rent and maintenance	(37,733)	(95,678)	(384,675)	(58,183)

9. INTANGIBLE ASSETS

2023 Carrying amount	Balance as at 1.7.2022 RM	Additions RM	Amortisation charge for the financial year RM	Balance as at 30.6.2023 RM
Software development cost	67,145	-	(29,137)	38,008
Goodwill	30,229,312	30,529,664	-	60,758,976
	30,296,457	30,529,664	(29,137)	60,796,984

	|---------- As at 30.6.2023 ----------|		
	Cost RM	Accumulated amortisation RM	Accumulated impairment RM	Carrying amount RM
Software development cost	197,267	(159,259)	-	38,008
Goodwill	60,909,186	-	(150,210)	60,758,976
	61,106,453	(159,259)	(150,210)	60,796,984

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

2024 Carrying amount	Balance as at 1.7.2023 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Reclassification to property, plant and equipment (Note 7) RM	Amortisation charge for the financial year RM	Balance as at 30.6.2024 RM
Software development cost	38,008	-	15,800	-	(30,322)	23,486
Computer software	-	7,482,697	234,867	(6,600)	(1,657,367)	6,053,597
Trademarks	-	514,931,567	-	-	(5,833)	514,925,734
Dealership rights	-	8,313,654	-	-	(3,147,500)	5,166,154
Goodwill	60,758,976	465,835,251	747,845	-	-	527,342,072
	60,796,984	996,563,169	998,512	(6,600)	(4,841,022)	1,053,511,043

	As at 30.6.2024			
	Cost RM	Accumulated amortisation RM	Accumulated impairment RM	Carrying amount RM
Software development cost	213,067	(189,581)	-	23,486
Computer software	18,297,849	(12,148,808)	(95,444)	6,053,597
Trademarks	514,966,577	(40,843)	-	514,925,734
Dealership rights	8,313,654	(3,147,500)	-	5,166,154
Goodwill	527,492,282	-	(150,210)	527,342,072
	1,069,283,429	(15,526,732)	(245,654)	1,053,511,043

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

2025 Carrying amount	Balance as at 1.7.2024 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Written off RM	Impairment loss for the financial year RM	Amortisation charge for the financial year RM	Balance as at 30.6.2025 RM
Software development cost	23,486	-	-	(296)	-	(10,945)	12,245
Computer software	6,053,597	-	3,980,774	-	(1,404)	(1,608,326)	8,424,641
Customer relationships	-	2,162,312	-	-	-	(25,742)	2,136,570
Trademarks	514,925,734	28,173,426	542,940	-	-	(30,291)	543,611,809
Dealership rights	5,166,154	-	-	-	-	(3,147,500)	2,018,654
Distribution rights	-	165,850,450	-	-	-	-	165,850,450
Goodwill	527,342,072	95,208,102	40,000	-	(936,354)	-	621,653,820
	1,053,511,043	291,394,290	4,563,714	(296)	(937,758)	(4,822,804)	1,343,708,189

	As at 30.6.2025			
	Cost RM	Accumulated amortisation RM	Accumulated impairment RM	Carrying amount RM
Software development cost	15,800	(3,555)	-	12,245
Computer software	22,278,623	(13,757,134)	(96,848)	8,424,641
Customer relationships	2,162,312	(25,742)	-	2,136,570
Trademarks	543,682,944	(71,135)	-	543,611,809
Dealership rights	8,313,654	(6,295,000)	-	2,018,654
Distribution rights	165,850,450	-	-	165,850,450
Goodwill	622,740,384	-	(1,086,564)	621,653,820
	1,365,044,167	(20,152,566)	(1,183,412)	1,343,708,189

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

2026 Carrying amount	Balance as at 1.7.2025 RM	Acquisition of outlets (Note 5(d)) RM	Additions RM	Reclassification to property, plant and equipment (Note 7) RM	Amortisation charge for the financial year RM	Balance as at 30.6.2026 RM
Software development cost	12,245	-	-	-	(2,370)	9,875
Computer software	8,424,641	-	4,516,641	(428,178)	(2,072,871)	10,440,233
Customer relationships	2,136,570	-	-	-	(308,902)	1,827,668
Trademarks	543,611,809	-	181,740	-	(72,023)	543,721,526
Dealership rights	2,018,654	-	-	-	-	2,018,654
Distribution rights	165,850,450	-	-	-	-	165,850,450
Licenses and panel registration	-	70,800	-	-	(4,720)	66,080
Goodwill	621,653,820	-	24,531	-	-	621,678,351
	1,343,708,189	70,800	4,722,912	(428,178)	(2,460,886)	1,345,612,837

	As at 30.6.2026			
	Cost RM	Accumulated amortisation RM	Accumulated impairment RM	Carrying amount RM
Software development cost	15,800	(5,925)	-	9,875
Computer software	26,367,086	(15,830,005)	(96,848)	10,440,233
Customer relationships	2,162,312	(334,644)	-	1,827,668
Trademarks	543,864,684	(143,158)	-	543,721,526
Dealership rights	8,313,654	(6,295,000)	-	2,018,654
Distribution rights	165,850,450	-	-	165,850,450
Licenses and panel registration	70,800	(4,720)	-	66,080
Goodwill	622,764,915	-	(1,086,564)	621,678,351
	1,369,409,701	(22,613,452)	(1,183,412)	1,345,612,837

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

(a) Intangible assets are initially measured at cost. After initial recognition, intangible assets are carried at cost less accumulated amortisation and accumulated impairment losses, if any.

(b) Intangible assets with finite lives are amortised on a straight-line basis over the estimated economic useful lives and are assessed for any indication that the asset could be impaired. If any such indication exists, the entity shall estimate the recoverable amount of the asset. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. The amortisation expense on intangible assets with finite lives is recognised in profit or loss and is included within the operating and administrative expenses line item.

(c) Intangible asset has an indefinite useful life when based on the analysis of all the relevant factors, there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows to the Group. Intangible assets with indefinite useful lives are tested for impairment annually and wherever there is an indication that the carrying amount may be impaired. Such intangible assets are not amortised.

(d) Amortisation is calculated to write off the cost of the assets to their residual values on a straight-line basis over their estimated useful lives. Trademarks and dealership rights amounted to RM698,219 and RM Nil (2025: RM588,502 and RM Nil, 2024: RM75,853 and RM5,166,154, 2023: RM Nil and RM Nil) respectively have finite useful lives. The principal annual amortisation periods are as follows:

Software development cost	5 years
Computer software	3 to 7 years
Customer relationships	7 years
Trademarks	10 years
Dealership rights	2 years
Licenses and panel registration	7 years

The residual values, useful lives and amortisation methods are reviewed at the end of each reporting period.

(e) Allocation of goodwill, trademarks, dealership rights and distribution rights

Goodwill, trademarks, dealership rights and distribution rights with indefinite useful lives have been allocated to the Cash Generating Units ("CGUs") of the Group that has been identified according to business segments as follows:

	Retail			
	2023	**2024**	**2025**	**2026**
	RM	**RM**	**RM**	**RM**
Goodwill	58,402,988	482,132,869	481,236,515	481,261,046
Trademarks	-	510,345,896	510,345,896	510,345,896
Dealership rights	-	-	2,018,654	2,018,654
	58,402,988	992,478,765	993,601,065	993,625,596

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

(e) Allocation of goodwill, trademarks, dealership rights and distribution rights (continued)

Goodwill, trademarks and distribution rights with indefinite useful lives have been allocated to the Cash Generating Units ("CGUs") of the Group that has been identified according to business segments as follows: (continued)

	Others			
	2023	**2024**	**2025**	**2026**
	RM	**RM**	**RM**	**RM**
Goodwill	2,355,988	45,209,203	140,417,305	140,417,305
Trademarks	-	4,503,985	32,677,411	32,677,411
Distribution rights	-	-	165,850,450	165,850,450
	2,355,988	49,713,188	338,945,166	338,945,166

(f) The goodwill, trademarks, dealership rights and distribution rights of the Group amounted to RM621,678,351, RM543,023,307, RM2,018,654 and RM165,850,450 (2025: RM621,653,820, RM543,023,307, RM2,018,654 and RM165,850,450, 2024: RM527,342,072, RM514,849,881 and RM Nil, 2023: RM60,758,976, RM Nil and RM Nil) respectively have indefinite useful lives and are tested for impairment annually and wherever there is an indication that the carrying amount may be impaired.

(g) Goodwill, trademarks, dealership rights and distribution rights

Goodwill recognised in a business combination is an asset at the acquisition date and is initially measured at cost being the excess of the sum of the consideration transferred, the amount of any non-controlling interest in the acquiree and the fair value of the acquirer's previously held equity interest (if any) in the entity over net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed.

After initial recognition, goodwill is measured at cost less accumulated impairment losses, if any. Goodwill is not amortised but instead tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying amount could be impaired. Objective events that would trigger a more frequent impairment review include adverse industry or economic trends, significant restructuring actions, significantly lowered projections of profitability, or a sustained decline in the acquiree's market capitalisation.

Trademarks, dealership rights and distribution rights with indefinite useful lives are tested for impairment annually and wherever there is an indication that the carrying amounts may be impaired.

For the purpose of impairment testing, the recoverable amount of the CGUs is determined based on a "value-in-use" calculation. The value-in-use of the CGUs is determined by discounting the future cash flows to be generated from continuing use of the CGUs. The value-in-use is derived based on management's cash flow projections for five (5) (2025: five (5), (2024: five (5), 2023: five (5)) financial years from 2027 to 2031 (2025: 2026 to 2030, 2024: 2025 to 2029, 2023: 2024 to 2028) and a terminal value thereafter. Management has made significant judgements and estimates about the future results and key assumptions applied to cash flow projections of the CGUs in determining the recoverable amount using the value-in-use model.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. INTANGIBLE ASSETS (continued)

(g) Goodwill, trademarks, dealership rights and distribution rights (continued)

The key assumptions used in the value-in-use calculations are as follows:

	2023	2024	2025	2026
Retail				
Anticipated annual revenue growth rates	7%	7% to 8%	7%	1% to 25%
Profit margins	19%	21%	20%	17% to 31%
Pre-tax discount rate	5.84%	10.00%	7.50%	5% to 7%
Terminal value	Zero growth	Zero growth	Zero growth	Zero growth
Others				
Anticipated annual revenue growth rates	7%	7% to 42%	5% to 34%	5% to 68%
Profit margins	23%	37%	7% to 70%	28% to 65%
Pre-tax discount rate	5.84%	5.84%	6.54% to 10.10%	7% to 12.50%
Terminal value	2%	2%	2%	0% to 3%

(i) The anticipated annual revenue growth rates used in the cash flow projections of the CGUs are determined based on historical sales and adjusted for expected efficiency improvements, market and economic conditions, and the supply and demand factors, where applicable.

(ii) Profit margins are projected based on the historical profit margin achieved for the products.

(iii) The pre-tax discount rate used reflects the overall weighted average cost of capital of the Group adjusted for specific risks relating to the relevant community pharmacy business.

The values assigned to the key assumptions represent management's assessment of future trends in the community pharmacy business and are based on both external sources and internal historical data.

Based on these assumptions, an impairment loss of RM Nil (2025: RM936,354, 2024: RM Nil, 2023: RM Nil) is recognised in relation to goodwill as the recoverable amount determined is lower than the carrying amounts of the CGUs. Management is of the view that no impairment loss is required in relation to trademarks and distribution rights as the recoverable amounts determined are higher than the carrying amounts of the CGUs.

With regard to the assessment of value-in-use of the goodwill, trademarks and distribution rights, management believes that no reasonably possible change in the above key assumptions would cause the carrying amounts of the CGUs to materially exceed their recoverable amounts.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES

The Group as lessee

Right-of-use assets

2023 Carrying amount	Balance as at 1.7.2022 RM	Additions RM	Reclassification to property, plant and equipment (Note 7) RM	Reassessment and modification RM	Depreciation charge for the financial year RM	Balance as at 30.6.2023 RM
Buildings	121,610,056	73,330,421	-	(4,297,031)	(24,771,193)	165,872,253
Motor vehicles	1,617,301	245,337	(187,418)	-	(409,942)	1,265,278
Office equipment	42,205	5,343	-	(29,504)	(12,790)	5,254
	123,269,562	73,581,101	(187,418)	(4,326,535)	(25,193,925)	167,142,785

2024 Carrying amount	Balance as at 1.7.2023 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Reclassification from property, plant and equipment (Note 7) RM	Reassessment and modification RM	Reversal of impairment RM	Depreciation charge for the financial year RM	Balance as at 30.6.2024 RM
Leasehold land	-	22,949,246	-	-	-	-	(161,586)	22,787,660
Buildings	165,872,253	139,571,919	56,417,023	-	(6,975,061)	154,273	(46,738,233)	308,302,174
Motor vehicles	1,265,278	890,268	821,956	289,425	-	-	(636,733)	2,630,194
Office equipment	5,254	87,792	-	-	-	-	(38,038)	55,008
Plant and machinery	-	300,677	-	-	-	-	(37,701)	262,976
Air conditioners	-	586,473	-	-	-	-	(57,663)	528,810
	167,142,785	164,386,375	57,238,979	289,425	(6,975,061)	154,273	(47,669,954)	334,566,822

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

Right-of-use assets (continued)

2025 Carrying amount	Balance as at 1.7.2024 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Reclassification from property, plant and equipment (Note 7) RM	Reassessment and modification RM	Impairment loss for the financial year RM	Depreciation charge for the financial year RM	Balance as at 30.6.2025 RM
Leasehold land	22,787,660	-	-	-	-	-	(258,874)	22,528,786
Buildings	308,302,174	4,443,946	54,208,049	1,785,912	20,853,701	(1,706,576)	(68,491,835)	319,395,371
Motor vehicles	2,630,194	-	686,774	1,612,999	-	-	(1,061,909)	3,868,058
Office equipment	55,008	-	-	-	-	-	(34,523)	20,485
Plant and machinery	262,976	-	-	-	-	-	(56,551)	206,425
Air conditioners	528,810	-	-	-	-	-	(85,781)	443,029
	334,566,822	4,443,946	54,894,823	3,398,911	20,853,701	(1,706,576)	(69,989,473)	346,462,154

2026 Carrying amount	Balance as at 1.7.2025 RM	Additions RM	Reclassification from property, plant and equipment (Note 7) RM	Reassessment and modification RM	Impairment loss RM	Depreciation charge for the financial year RM	Balance as at 30.6.2026 RM
Leasehold land	22,528,786	-	-	-	-	(258,875)	22,269,911
Buildings	319,395,371	73,987,133	271,111	51,471,967	(1,908,656)	(79,280,681)	363,936,245
Motor vehicles	3,868,058	181,329	-	-	-	(1,209,657)	2,839,730
Office equipment	20,485	17,281	-	-	-	(19,437)	18,329
Plant and machinery	206,425	-	-	-	-	(56,551)	149,874
Air conditioners	443,029	-	-	(52)	-	(116,813)	326,164
	346,462,154	74,185,743	271,111	51,471,915	(1,908,656)	(80,942,014)	389,540,253

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

Lease liabilities 2023 Carrying amount	Balance as at 1.7.2022 RM	Additions RM	Reassessment and modification RM	Lease concessions RM	Lease payments RM	Interest expense RM	Balance as at 30.6.2023 RM
Buildings	124,828,841	73,544,323	(4,539,272)	(75,883)	(28,254,068)	6,134,392	171,638,333
Motor vehicles	1,470,210	6,798	-	-	(467,028)	49,271	1,059,251
Office equipment	44,710	5,343	(31,463)	-	(13,976)	642	5,256
	126,343,761	73,556,464	(4,570,735)	(75,883)	(28,735,072)	6,184,305	172,702,840

2024 Carrying amount	Balance as at 1.7.2023 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Reassessment and modification RM	Lease payments RM	Interest expense RM	Balance as at 30.6.2024 RM
Buildings	171,638,333	124,342,089	56,417,023	(6,947,044)	(53,967,993)	9,629,183	301,111,591
Motor vehicles	1,059,251	374,010	925,199	-	(649,713)	76,823	1,785,570
Office equipment	5,256	92,853	-	-	(42,878)	4,111	59,342
Plant and machinery	-	366,923	-	-	(83,102)	5,867	289,688
Air conditioners	-	336,562	-	-	(107,088)	16,410	245,884
	172,702,840	125,512,437	57,342,222	(6,947,044)	(54,850,774)	9,732,394	303,492,075

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

Lease liabilities (continued)

2025 Carrying amount	Balance as at 1.7.2024 RM	Acquisition of subsidiaries (Note 5(c)) RM	Additions RM	Reassessment and modification RM	Lease payments RM	Interest expense RM	Balance as at 30.6.2025 RM
Buildings	301,111,591	4,677,073	53,479,589	18,962,307	(77,208,276)	12,896,381	313,918,665
Motor vehicles	1,785,570	1,717,260	639,200	-	(973,856)	153,121	3,321,295
Office equipment	59,342	-	-	-	(38,923)	3,105	23,524
Plant and machinery	289,688	-	-	-	(70,682)	7,077	226,083
Air conditioners	245,884	-	-	-	(160,632)	16,069	101,321
	303,492,075	6,394,333	54,118,789	18,962,307	(78,452,369)	13,075,753	317,590,888

2026 Carrying amount	Balance as at 1.7.2025 RM	Additions RM	Reassessment and modification RM	Lease payments RM	Interest expense RM	Balance as at 30.6.2026 RM
Buildings	313,918,665	71,426,642	50,818,204	(89,676,213)	15,555,205	362,042,503
Motor vehicles	3,321,295	185,000	-	(1,171,267)	130,629	2,465,657
Office equipment	23,524	17,281	-	(21,891)	1,222	20,136
Plant and machinery	226,083	-	-	(155,322)	7,448	78,209
Air conditioners	101,321	-	-	(75,990)	3,642	28,973
	317,590,888	71,628,923	50,818,204	(91,100,683)	15,698,146	364,635,478

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

Lease liabilities (continued)

	2023 RM	2024 RM	2025 RM	2026 RM
Represented by:				
Current liabilities	24,047,904	63,672,181	67,102,328	77,675,390
Non-current liabilities	148,654,936	239,819,894	250,488,560	286,960,088
	172,702,840	303,492,075	317,590,888	364,635,478
Lease liabilities owing to:				
Financial institutions	1,059,251	2,361,828	3,666,374	2,583,226
Non-financial institutions	171,643,589	301,130,247	313,924,514	362,052,252
	172,702,840	303,492,075	317,590,888	364,635,478

(a) The right-of-use assets are initially measured at cost, which comprise the initial amount of the lease liabilities adjusted for any lease payments made at or before the commencement date of the leases.

After initial recognition, right-of-use assets are stated at cost less accumulated depreciation and any accumulated impairment losses, and adjusted for any re-measurement of the lease liabilities.

The right-of-use assets are depreciated on the straight-line basis over the earlier of the estimated useful lives of the right-of-use assets or the end of the lease term. The lease terms of right-of-use assets are as follows:

Leasehold land	3 - 99 years
Buildings	1 - 17 years
Motor vehicles	5 years
Office equipment	5 years
Plant and machinery	5 years
Air conditioners	5 years

(b) The Group has certain leases of buildings and office equipment with lease term of twelve (12) months or less, and low value leases of buildings of RM20,000 and below. The Group applies the "short-term lease" and "lease of low-value assets" exemptions for these leases.

(c) For the purpose of impairment assessment, recoverable amount of right-of-use assets is determined based on a "value-in-use" of each CGU.

Value-in-use of the CGUs is determined by discounting the future cash flows to be generated from continuing use of the CGUs. Management considered consecutive losses in certain outlets after their gestation periods of two (2) to three (3) financial years as one of the indicators of impairment. Management has made estimates about the future results and key assumptions applied to cash flow projections of the CGUs in determining the recoverable amount using the value-in-use model. These key assumptions include forecast growth in future revenues and operating profit margins, as well as determining an appropriate pre-tax discount rate and growth rates.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

(c) (continued)

During FYE 2026, management has determined that the recoverable amounts of certain right-of-use assets of the loss-making outlets are lower than their carrying amounts. Accordingly, the Group has recognised impairment losses on certain right-of-use assets amounted to RM1,908,656 (2025: RM1,706,576, 2024: RM Nil, 2023: RM Nil) within operating and administrative expenses in the consolidated statements of profit or loss and other comprehensive income. The pre-tax discount rate applied on the cash flow projections in determining the recoverable amounts is 7% (2025: 7%, 2024: 5%, 2023: 5%).

With regard to the assessment of value-in-use of the CGUs, management believes that no reasonably possible change in any of the above key assumptions would cause the carrying amounts of the CGUs to further materially exceed their recoverable amounts.

(d) During FYE 2024, the Group recognised a reversal of impairment losses on certain right-of-use assets amounted to RM154,273 within other operating income in the consolidated statements of profit or loss and other comprehensive income.

(e) The following are the amounts recognised in profit or loss:

	2023 RM	2024 RM	2025 RM	2026 RM
Included in operating and administrative expenses:				
Depreciation charge of right-of-use assets	25,193,925	47,669,954	69,989,473	80,942,014
Expenses relating to short-term leases	847,675	4,573,063	2,755,615	9,402,025
Expenses relating to low-value assets	6,219	6,219	116,813	1,367,313
Loss on reassessment and modification of leases	-	28,017	-	-
Included in finance costs:				
Interest expense on lease liabilities	6,184,305	9,732,394	13,075,753	15,698,146
Included in other operating income:				
Gain on reassessment and modification of leases	(244,200)	-	(1,404,595)	(408,833)

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

(e) The following are the amounts recognised in profit or loss: (continued)

	2023 RM	2024 RM	2025 RM	2026 RM
Impairment losses of right-of-use assets (included in operating and administrative expenses)	-	-	1,706,576	1,908,656
Reversal of impairment of right-of-use assets (included in other operating income)	-	(154,273)	-	-
Variable lease payments based on sales (included in operating and administrative expenses)	-	3,547,593	9,278,883	9,772,510
Variable lease payments arising from COVID-19 lease concessions (included in other operating income)	(75,883)	-	-	-
	31,912,041	65,402,967	95,518,518	118,681,831

(f) Some leases of retail outlets contain variable lease payments that are based on sales that the Group makes at the outlets. Fixed and variable rental payments were at follows:

Group	Fixed payments RM	Variable payments RM	Total payments RM	Estimated annual impact on rent of a 1% increase in sales RM
2026				
Leases with lease payments based on sales	91,100,683	9,772,510	100,873,193	97,725
2025				
Leases with lease payments based on sales	78,452,369	9,278,883	87,731,252	92,789
2024				
Leases with lease payments based on sales	54,850,774	3,547,593	58,398,367	35,476
2023				
Leases with lease payments based on sales	28,735,072	-	28,735,072	-

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906006013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

(g) The following are total cash outflows for leases as a lessee:

	2023 RM	2024 RM	2025 RM	2026 RM
Included in net cash from operating activities:				
Payment relating to short-term leases and low value assets	853,894	4,579,282	2,872,428	10,769,338
Interest paid in relation to lease liabilities	6,184,305	9,732,394	13,075,753	15,698,146
Payment relating to variable lease payments not included in the measurement of lease liabilities	-	3,547,593	9,278,883	9,772,510
Included in net cash from investing activities:				
Purchase of right-of-use assets	24,637	186,182	47,575	31,827
Included in net cash used in financing activities:				
Payment of lease liabilities	28,735,072	54,850,774	78,452,369	91,100,683
	35,797,908	72,896,225	103,727,008	127,372,504

(h) Management exercises significant judgement in determining the incremental borrowing rates whenever the implicit rates of interest in a lease are not readily determinable as well as the lease terms. The incremental borrowing rates used are based on prevailing market borrowing rates over similar lease terms, of similar value as the right-of-use asset in a similar economic environment.

The Group has lease contracts that include extension and termination options. These options are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.

(i) As at the end of the reporting period, certain land and buildings of the Group with a total carrying amount of RM30,526,588 (2025: RM31,633,652, 2024: RM27,651,964, 2023: RM Nil) have been charged to a bank for credit facilities granted to the Group as disclosed in Note 19(b) to the consolidated financial statements respectively.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

(j) The following are the undiscounted potential future rental payments that are not included in the lease term:

	Within 5 years RM	More than 5 years RM	Total RM
30 June 2023			
Extension options expected not to be exercised	-	-	-
30 June 2024			
Extension options expected not to be exercised	5,015,352	1,082,209	6,097,561
30 June 2025			
Extension options expected not to be exercised	4,932,852	1,708,813	6,641,665
30 June 2026			
Extension options expected not to be exercised	1,285,320	397,980	1,683,300

(k) The table below summarises the maturity profile of the lease liabilities of the Group at end of the reporting period based on contractual undiscounted repayment obligations as follows:

30 June 2023	**Weighted average incremental borrowing rate per annum %**	**Within 1 year RM**	**1 - 5 years RM**	**Over 5 years RM**	**Total RM**
Lease liabilities					
Fixed rate	3.84 - 4.55	30,310,355	106,814,278	63,223,697	200,348,330
30 June 2024					
Lease liabilities					
Fixed rate	2.12 - 5.10	73,402,217	194,050,117	65,155,968	332,608,302
30 June 2025					
Lease liabilities					
Fixed rate	2.16 - 8.00	79,055,094	225,051,633	59,640,589	363,747,316
30 June 2026					
Lease liabilities					
Fixed rate	2.16 - 8.00	94,606,144	254,050,893	74,770,323	423,427,360

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessee (continued)

(l) Sensitivity analysis for fixed rate lease liabilities at the end of the reporting period is not presented as it is not affected by changes in interest rate.

(m) During the financial year, the Group made the following cash payments to purchase right-of-use assets:

	2023 RM	2024 RM	2025 RM	2026 RM
Additions of right-of-use assets	73,581,101	57,238,979	54,894,823	74,185,743
Reclassification from property, plant and equipment (Note 7)	-	289,425	-	-
Financed by lease liabilities	(73,556,464)	(57,342,222)	(54,118,789)	(71,628,923)
Provision for restoration costs capitalised (Note 20(g))	-	-	(796,393)	(2,524,993)
Recognised in profit or loss	-	-	67,934	-
Cash payments on purchase of right-of-use assets	24,637	186,182	47,575	31,827

(n) Reconciliation of liabilities arising from financing activities

The table below details the changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statements of cash flows as cash flows from financing activities.

	2023 RM	2024 RM	2025 RM	2026 RM
At beginning of financial year	126,343,761	172,702,840	303,492,075	317,590,888
Cash flows:				
- Payments of lease liabilities	(22,550,767)	(45,118,380)	(65,376,616)	(75,402,537)
- Payments of lease interests	(6,184,305)	(9,732,394)	(13,075,753)	(15,698,146)
	(28,735,072)	(54,850,774)	(78,452,369)	(91,100,683)
Non-cash flows changes:				
- Additions of right-of-use assets	73,556,464	57,342,222	54,118,789	71,628,923
- Acquisition of subsidiaries (Note 5(c))	-	125,512,437	6,394,333	-
- Lease concessions	(75,883)	-	-	-
- Reassessment and modification	(4,570,735)	(6,947,044)	18,962,307	50,818,204
- Interest expenses (Note 22)	6,184,305	9,732,394	13,075,753	15,698,146
At end of financial year	172,702,840	303,492,075	317,590,888	364,635,478

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES (continued)

The Group as lessor

The Group has entered into non-cancellable lease agreements on certain properties for terms of between two (2) to six (6) years (2025: two (2) to six (6) years, 2024: two (2) to six (6) years, 2023: two (2) to six (6) years) and renewable at the end of the lease period. The monthly rental consists of a fixed base rent.

The Group has aggregate future minimum lease receivables as at the end of each reporting period as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Less than one (1) year	154,650	97,550	288,876	138,406
Later than one (1) year and not later than five (5) years	127,500	85,150	199,367	15,429
Later than five (5) years	6,000	-	-	-
	288,150	182,700	488,243	153,835

11. INVESTMENTS IN ASSOCIATES

	2023 RM	2024 RM	2025 RM	2026 RM
Unquoted shares, at cost	-	-	5,707,200	5,873,320
Share of post acquisition reserves	-	-	(12,165)	44,835
	-	-	5,695,035	5,918,155

(a) Investments in associates are measured at cost less impairment losses in the separate financial statements of the Group and accounted for using equity method in the consolidated financial statements.

(b) During the financial year ended 30 June 2026, a subsidiary of the Company, Caring Pharmacy Retail Management Sdn. Bhd., fulfilled RM2,000,000 of its outstanding subscription commitment in Data Flows Sdn. Bhd. pursuant to the tranche payment schedule stipulated in the Subscription Agreement dated 21 May 2025. The Group's equity interest remained unchanged at 30%. The increase in the carrying amount of the investment during the financial year represented the unwinding of discount on the outstanding subscription commitment recognised at present value in the previous financial year.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

11. INVESTMENTS IN ASSOCIATES (continued)

(c) The details of the associates are as follows:

Name of company	Country of incorporation/ Principal place of business	Effective interest in equity				Principal activities
		2023 %	2024 %	2025 %	2026 %	
Axelton Healthcare Sdn. Bhd. (AHSB) [3]	Malaysia	-	50	50	50	Import, sale and distribution of pharmaceutical, medical, cosmetic and related items
Data Flows Sdn. Bhd. ("DFSB") [1] [2]	Malaysia	-	-	30.07	30.07	Provision of software, platforms development and technology consultancy.

[1] Not audited by BDO PLT or BDO Member Firms
[2] Equity accounted based on management accounts for the financial year ended 30 June 2025
[3] In the previous financial years, the shares were held in trust by appointed persons on behalf of Big Caring Group Bhd. During the financial year ended 30 June 2026, the shares were transferred and registered under Big Caring Group Bhd.

(d) DFSB has a financial year end of 31 December, which is not conterminous with the Group. The unaudited financial statements of DFSB for financial period ended 30 June 2026 and 30 June 2025 have been used in applying the equity method of accounting. The use of the unaudited financial statements is not expected to have any significant effects on the consolidated financial statements of the Group.

(e) The summarised financial information of the associates are as follows:

	DFSB RM	AHSB RM	Total RM
2026			
Assets and liabilities			
Non-current assets	613,554	-	613,554
Current assets	7,511,539	4,391	7,515,930
Non-current liabilities	-	-	-
Current liabilities	(422,392)	(43,938)	(466,330)
Net assets/(liabilities)	7,702,701	(39,547)	7,663,154
Results			
Revenue	4,870,921	-	4,870,921
Profit/(Loss) for the financial year	335,263	(39,547)	295,716
Total comprehensive profit/(loss)	335,263	(39,547)	295,716

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

11. INVESTMENTS IN ASSOCIATES (continued)

(e) The summarised financial information of the associates are as follows: (continued)

	DFSB RM	AHSB RM	Total RM
2026			
Cash flows			
Cash flows from:			
- operating activities	11,671	(37,802)	(26,131)
- investing activities	(1,874,670)	10,000	(1,864,670)
- financing activities	(123,552)	-	(123,552)
Net decrease in cash and cash equivalents	(1,986,551)	(27,802)	(2,014,353)

	DFSB RM	AHSB RM	Total RM
2025			
Assets and liabilities			
Non-current assets	13,858	-	13,858
Current assets	7,379,413	32,193	7,411,606
Non-current liabilities	-	-	-
Current liabilities	(161,232)	(32,193)	(193,425)
Net assets	7,232,039	-	7,232,039
Results			
Revenue	257,333	10,652	267,985
Loss for the financial year	(16,034)	(34,639)	(50,673)
Total comprehensive loss	(16,034)	(34,639)	(50,673)
Cash flows			
Cash flows from:			
- operating activities	332,441	(31,303)	301,138
- investing activities	(4,040,258)	-	(4,040,258)
- financing activities	2,312,606	60,000	2,372,606
Net (decrease)/increase in cash and cash equivalents	(1,395,211)	28,697	(1,366,514)

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

11. INVESTMENTS IN ASSOCIATES (continued)

(f) The reconciliation of net assets/(liabilities) of the associates to the carrying amount of the investments in associates is as follows:

	DFSB RM	AHSB RM	Total RM
2026			
Share of net assets of the associates	2,316,202	-	2,316,202
Goodwill	3,571,952	-	3,571,952
Effect arising from transfer of shares from trustee	-	30,001	30,001
Carrying amount in the consolidated statements of financial position	5,888,154	30,001	5,918,155
Share of results of the associates			
Share of profit/(loss) of the associates	76,333	(19,333)	57,000
Share of total comprehensive income/(loss) of the associates	76,333	(19,333)	57,000

	DFSB RM	AHSB RM	Total RM
2025			
Share of net assets of the associates	2,174,674	-	2,174,674
Goodwill	3,520,361	-	3,520,361
Carrying amount in the consolidated statements of financial position	5,695,035	-	5,695,035
Share of results of the associates			
Share of loss of the associates	(3,505)	(8,660)	(12,165)
Share of total comprehensive loss of the associates	(3,505)	(8,660)	(12,165)

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

12. DEFERRED TAX ASSETS/(LIABILITIES)

(a) The deferred tax assets and liabilities are made up of the following:

	2023 RM	2024 RM	2025 RM	2026 RM
As at beginning of financial year	(1,053,728)	1,292,531	124,002,315	168,886,961
Acquisition of subsidiaries (Note 5(c))	-	123,318,744	47,881,101	-
Recognised in profit or loss (Note 24)	2,346,259	(608,960)	(2,996,455)	1,517,137
As at end of financial year	1,292,531	124,002,315	168,886,961	170,404,098
Presented after appropriate offsetting as follows:				
Deferred tax assets	(2,949,934)	(3,108,075)	(4,773,399)	(4,399,923)
Deferred tax liabilities	4,242,465	127,110,390	173,660,360	174,804,021
	1,292,531	124,002,315	168,886,961	170,404,098

(b) The components and movements of deferred tax assets and liabilities during the financial year prior to offsetting are as follows:

Deferred tax assets	**Provisions RM**	**Others RM**	**Total RM**
At 1 July 2022	(3,003,482)	(928,554)	(3,932,036)
Recognised in profit or loss	1,208,476	(226,374)	982,102
At 30 June 2023, prior to offsetting	(1,795,006)	(1,154,928)	(2,949,934)
Offsetting			-
At 30 June 2023			(2,949,934)
At 1 July 2023	(1,795,006)	(1,154,928)	(2,949,934)
Acquisition of subsidiaries	-	(4,135,781)	(4,135,781)
Recognised in profit or loss	(914,816)	(102,963)	(1,017,779)
At 30 June 2024, prior to offsetting	(2,709,822)	(5,393,672)	(8,103,494)
Offsetting			4,995,419
At 30 June 2024			(3,108,075)

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

12. DEFERRED TAX ASSETS/(LIABILITIES) (continued)

(b) The components and movements of deferred tax assets and liabilities during the financial year prior to offsetting are as follows: (continued)

Deferred tax assets (continued)	**Provisions RM**	**Others RM**	**Total RM**
At 1 July 2024	(2,709,822)	(5,393,672)	(8,103,494)
Acquisition of subsidiaries	-	(425,875)	(425,875)
Recognised in profit or loss	(795,928)	(263,881)	(1,059,809)
At 30 June 2025, prior to offsetting	(3,505,750)	(6,083,428)	(9,589,178)
Offsetting			4,815,779
At 30 June 2025			(4,773,399)
At 1 July 2025	(3,505,750)	(6,083,428)	(9,589,178)
Recognised in profit or loss	(469,162)	(3,067,294)	(3,536,456)
At 30 June 2026, prior to offsetting	(3,974,912)	(9,150,722)	(13,125,634)
Offsetting			8,725,711
At 30 June 2026			(4,399,923)

Deferred tax liabilities	**Property, plant and equipment RM**	**Trademarks RM**	**Dealership and distribution rights RM**	**Other RM**	**Total RM**
At 1 July 2022	2,877,308	-	-	1,000	2,878,308
Recognised in profit or loss	1,355,157	-	-	9,000	1,364,157
At 30 June 2023, prior to offsetting	4,232,465	-	-	10,000	4,242,465
Offsetting					-
At 30 June 2023					4,242,465

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

12. DEFERRED TAX ASSETS/(LIABILITIES) (continued)

(b) The components and movements of deferred tax assets and liabilities during the financial year prior to offsetting are as follows: (continued)

Deferred tax liabilities	Property, plant and equipment RM	Trademarks RM	Dealership and distribution rights RM	Other RM	Total RM
At 1 July 2023	4,232,465	-	-	10,000	4,242,465
Acquisition of subsidiaries	708,016	122,033,365	1,511,000	3,202,144	127,454,525
Recognised in profit or loss	1,166,319	-	(755,500)	(2,000)	408,819
At 30 June 2024, prior to offsetting	6,106,800	122,033,365	755,500	3,210,144	132,105,809
Offsetting					(4,995,419)
At 30 June 2024					127,110,390
At 1 July 2024	6,106,800	122,033,365	755,500	3,210,144	132,105,809
Acquisition of subsidiaries	1,222,290	6,761,623	39,804,108	518,955	48,306,976
Recognised in profit or loss	(1,186,365)	-	(761,678)	11,397	(1,936,646)
At 30 June 2025, prior to offsetting	6,142,725	128,794,988	39,797,930	3,740,496	178,476,139
Offsetting					(4,815,779)
At 30 June 2025					173,660,360
At 1 July 2025	6,142,725	128,794,988	39,797,930	3,740,496	178,476,139
Recognised in profit or loss	6,079,601	-	-	(1,026,008)	5,053,593
At 30 June 2026, prior to offsetting	12,222,326	128,794,988	39,797,930	2,714,488	183,529,732
Offsetting					(8,725,711)
At 30 June 2026					174,804,021

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

12. DEFERRED TAX ASSETS/(LIABILITIES) (continued)

(c) The amounts of temporary differences for which no deferred tax assets have been recognised in the consolidated statements of financial position are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Unabsorbed capital allowances	5,839,880	6,308,992	5,054,400	8,742,330
Unused tax losses:				
- expires by 30 June 2028	2,774,791	3,443	3,443	-
- expires by 30 June 2030	161,472	168,403	102,716	-
- expires by 30 June 2031	1,071,865	1,139,444	1,114,558	330,977
- expires by 30 June 2032	1,521,631	1,079,599	1,113,599	380,067
- expires by 30 June 2033	4,800,116	7,380,304	5,283,586	3,244,894
- expires by 30 June 2034	-	2,633,006	5,146,121	3,168,964
- expires by 30 June 2035	-	-	4,071,014	2,288,898
- expires by 30 June 2036	-	-	-	4,178,666
Other temporary differences	(1,888,275)	681,041	479,185	14,756,667
	14,281,480	19,394,232	22,368,622	37,091,463

Deferred tax assets have not been recognised in respect of these items as it is not probable that future taxable profits would be available against which the deductible temporary differences could be utilised.

Any unused tax losses shall be deductible for a maximum period of ten (10) consecutive years of assessment immediately following that year of assessment. Any amount which is not deducted at the end of the period of ten (10) years of assessment shall be disregarded.

13. OTHER INVESTMENTS

	2023 RM	2024 RM	2025 RM	2026 RM
Non-current assets				
Fair value through profit or loss				
Quoted equity investments	80,354	299,241	470,932	551,509
Current assets				
Fair value through profit or loss				
Short-term investment funds	-	35,431,502	51,137,716	49,345,390

(a) Other investments are classified as financial assets at fair value through profit or loss.

(b) Short-term investment funds of the Group represent highly liquid money market instruments, which are readily convertible to known amounts of cash and are subject to insignificant risk of changes in value.

(c) The fair values of quoted investments are determined by reference to the exchange quoted market bid prices at the close of the business at the end of each reporting period.

The fair values of short-term investment funds are determined by reference to the quoted prices at the close of business at the end of each reporting period.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906050013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

13. OTHER INVESTMENTS (continued)

(c) (continued)

The fair value of other investments of the Group are categorised as Level 1 in the fair value hierarchy. There is no transfer between levels in the hierarchy during the financial year.

(d) The Group has no intention and no historical trend of active trading in these quoted equity investment. Short term investment funds of the Group are exposed to changes in market quoted prices. However, the volatility of these funds prices is considered low. The Directors are of the opinion that the Group is not subject to significant exposure to price risk and accordingly, no sensitivity analysis is being presented at the end of each reporting period.

(e) Other investments are denominated in RM.

14. INVENTORIES

	2023 RM	2024 RM	2025 RM	2026 RM
At cost				
Raw materials	-	6,662,208	8,761,558	13,855,382
Packaging materials	-	1,495,131	1,342,070	4,502,779
Work-in-progress	-	1,373,853	1,992,815	2,970,282
Finished goods	286,696,014	499,256,071	685,806,308	890,477,866
	286,696,014	508,787,263	697,902,751	911,806,309

(a) Cost of finished goods are determined using a weighted average cost basis and stated at the lower of cost and net realisable value.

(b) Raw materials and packaging materials are determined using the first in, first out formula. Cost of work-in-progress included the cost of raw materials, direct labour, other direct cost and an appropriate portion of production overheads based on normal operating capacity of the production facilities.

(c) During the financial year, inventories of the Group recognised as cost of sales amounted to RM2,790,150,970 (2025: RM2,568,793,299, 2024: RM1,705,707,959, 2023: RM882,443,070).

(d) During the financial year, the Group had written down inventories amounted to RM6,683,385 (2025: RM2,259,576, 2024: RM379,882, 2023: RM357,416) which is recognised as cost of sales.

(e) During the financial year, the Group had written back inventories amounted to RM756,612 (2025: RM123,155, 2024: RM407,890, 2023: RM4,622,877), which is recognised as cost of sales.

(f) During the financial year, the Group had written off inventories amounted to RM531,635 (2025: RM1,569,881, 2024: RM120,062, 2023: RM Nil), which is recognised as cost of sales.

(g) The Group writes down its obsolete or slow-moving inventories based on assessment of their estimated net selling price. Inventories are written down when events or changes in circumstances indicate that the carrying amounts could not be recovered. Management specifically analyses sales trends and current economic trends when making this judgement to evaluate the adequacy of the write down for obsolete or slow-moving inventories. Where expectations differ from the original estimates, the differences would impact the carrying amount of inventories.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES

	2023 RM	2024 RM	2025 RM	2026 RM
Trade receivables				
Third parties	9,593,175	37,652,029	66,532,974	63,512,193
Related parties	15,525	2,963,351	8,673,779	12,628,342
	9,608,700	40,615,380	75,206,753	76,140,535
Less: impairment losses				
- third parties	(1,353,263)	(1,508,044)	(2,036,348)	(2,454,475)
- related parties	-	-	(183,371)	(39,741)
Trade receivables, net	8,255,437	39,107,336	72,987,034	73,646,319
Other receivables				
Other receivables	19,321,794	39,543,393	24,916,994	30,417,791
Amounts owing by related parties	3,808,989	3,808,989	1,163,498	61,123
Amount due from a corporate shareholder	826	826	-	-
Deposits	12,926,521	29,085,981	29,795,087	39,586,291
	36,058,130	72,439,189	55,875,579	70,065,205
Less: Impairment losses				
- other receivables	(199,144)	(124,657)	(844,035)	(1,038,298)
- related parties	-	-	(30,443)	-
Other receivables, net	35,858,986	72,314,532	55,001,101	69,026,907
Total receivables	44,114,423	111,421,868	127,988,135	142,673,226
Prepayments	2,810,279	24,821,810	18,057,216	18,808,032
Trade and other receivables	46,924,702	136,243,678	146,045,351	161,481,258

(a) Total receivables are classified as financial assets measured at amortised cost.

(b) Trade receivables are unsecured and interest-free with normal trade credit terms of 30 to 120 days (2025: 30 to 120 days, 2024: 30 to 90 days, 2023: 30 to 90 days). They are recognised at their original invoice amounts, which represent their fair values on initial recognition.

(c) Non-trade amounts owing by related parties and corporate shareholder represent advances and payments made on behalf, which are unsecured, interest-free and payable within the next twelve (12) months in cash and cash equivalents.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES (continued)

(d) Impairment for trade receivables including lease receivables that do not contain a significant financing component are recognised based on the simplified approach using the lifetime expected credit losses.

The Group applies the MFRS 9 simplified approach in measuring expected credit losses ("ECL") which uses a lifetime expected loss allowance for trade receivables. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted to reflect current and forward-looking information such as consumer price index affecting the ability of the customers to settle the receivables.

For trade receivables, which are reported net, such impairments are recorded in a separate impairment account with the loss being recognised within operating and administrative expenses in the consolidated statements of profit or loss. On confirmation that the trade receivable would not be collectable, the gross carrying value of the asset would be written off against the associated impairment.

Management exercised significant judgement in determining the probability of default by trade receivables, appropriate forward looking information.

Impairment for other receivables, amounts owing by corporate shareholder and related parties are recognised based on the general approach within MFRS 9 using the forward looking ECL. The methodology used to determine the amount of the impairment is based on whether there has been a significant increase in credit risk since initial recognition of the financial asset. For those in which the credit risk has not increased significantly since initial recognition of the financial asset, twelve-month ("12 month") expected credit losses along with gross interest income are recognised. For those in which credit risk has increased significantly, lifetime expected credit losses along with the gross interest income are recognised. For those that are determined to be credit impaired, lifetime ECL along with interest income on a net basis are recognised.

The probability of non-payment by other receivables, amounts owing by corporate shareholder and related parties is adjusted by forward looking information and multiplied by the amount of the expected loss arising from default to determine the twelve-month or lifetime expected credit loss for the other receivables, amounts owing by corporate shareholder and related parties.

It requires management to exercise significant judgement in determining the probability of default by other receivables, corporate shareholder and related parties, appropriate forward-looking information and significant increase in credit risk.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES (continued)

(e) Lifetime expected loss allowance for trade receivables are as follows:

	Gross carrying amount	Impairment loss	Net carrying amount
30 June 2023	**RM**	**RM**	**RM**
Current	3,947,425	-	3,947,425
1 to 30 days past due	1,677,731	-	1,677,731
31 to 60 days past due	826,066	(26,280)	799,786
61 to 90 days past due	201,570	-	201,570
91 to 120 days past due	226,369	-	226,369
More than 120 days past due	2,729,539	(1,326,983)	1,402,556
	5,661,275	(1,353,263)	4,308,012
	9,608,700	(1,353,263)	8,255,437
30 June 2024			
Current	16,880,345	-	16,880,345
1 to 30 days past due	6,580,791	-	6,580,791
31 to 60 days past due	4,914,013	-	4,914,013
61 to 90 days past due	2,282,111	-	2,282,111
91 to 120 days past due	1,039,667	(26,280)	1,013,387
More than 120 days past due	8,918,453	(1,481,764)	7,436,689
	23,735,035	(1,508,044)	22,226,991
	40,615,380	(1,508,044)	39,107,336
30 June 2025			
Current	29,903,558	(36,109)	29,867,449
1 to 30 days past due	20,878,019	(58,366)	20,819,653
31 to 60 days past due	11,602,719	(52,815)	11,549,904
61 to 90 days past due	6,621,712	(281,131)	6,340,581
91 to 120 days past due	698,409	(51,929)	646,480
More than 120 days past due	5,502,336	(1,739,369)	3,762,967
	45,303,195	(2,183,610)	43,119,585
	75,206,753	(2,219,719)	72,987,034

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES (continued)

(e) Lifetime expected loss allowance for trade receivables are as follows: (continued)

30 June 2026	**Gross carrying amount RM**	**Impairment loss RM**	**Net carrying amount RM**
Current	43,651,112	(263,725)	43,387,387
1 to 30 days past due	18,552,923	(33,326)	18,519,597
31 to 60 days past due	9,819,386	(19,313)	9,800,073
61 to 90 days past due	1,048,630	(4,700)	1,043,930
91 to 120 days past due	739,763	(20,160)	719,603
More than 120 days past due	2,328,721	(2,152,992)	175,729
	32,489,423	(2,230,491)	30,258,932
	76,140,535	(2,494,216)	73,646,319

(f) The reconciliation of movements in impairment loss for trade and other receivables at the end of each reporting period are as follows:

	Lifetime ECL allowance RM	**Credit impaired RM**	**Total allowance RM**
Trade receivables			
At 1 July 2022	50,791	1,684,593	1,735,384
Charge for the financial year	-	25,709	25,709
Reversal of impairment losses	-	(405,636)	(405,636)
Written off	-	(2,194)	(2,194)
At 30 June 2023	50,791	1,302,472	1,353,263
At 1 July 2023	50,791	1,302,472	1,353,263
Acquisition of subsidiaries	-	57,565	57,565
Charge for the financial year	-	227,420	227,420
Reversal of impairment losses	-	(7,299)	(7,299)
Written off	-	(122,905)	(122,905)
At 30 June 2024	50,791	1,457,253	1,508,044
At 1 July 2024	50,791	1,457,253	1,508,044
Acquisition of subsidiaries	-	357,481	357,481
Charge for the financial year	270,635	404,666	675,301
Reversal of impairment losses	(49,041)	(272,066)	(321,107)
At 30 June 2025	272,385	1,947,334	2,219,719

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES (continued)

(f) The reconciliation of movements in impairment loss for trade and other receivables at the end of each reporting period are as follows: (continued)

	Lifetime ECL allowance RM	Credit impaired RM	Total allowance RM
Trade receivables (continued)			
At 1 July 2025	272,385	1,947,334	2,219,719
Charge for the financial year	687,807	196,484	884,291
Reversal of impairment losses	(230,895)	(378,827)	(609,722)
Written off	-	(72)	(72)
At 30 June 2026	729,297	1,764,919	2,494,216
Other receivables			
At 1 July 2022	43,599	89,508	133,107
Charge for the financial year	581	73,781	74,362
Written off	(8,325)	-	(8,325)
At 30 June 2023	35,855	163,289	199,144
At 1 July 2023	35,855	163,289	199,144
Written off	-	(74,487)	(74,487)
At 30 June 2024	35,855	88,802	124,657
At 1 July 2024	35,855	88,802	124,657
Acquisition of subsidiaries	-	30,443	30,443
Charge for the financial year	149,795	603,763	753,558
Reversal of impairment losses	(34,180)	-	(34,180)
At 30 June 2025	151,470	723,008	874,478
At 1 July 2025	151,470	723,008	874,478
Charge for the financial year	505,409	2,582	507,991
Reversal of impairment losses	-	(3,316)	(3,316)
Written off	(149,831)	(191,024)	(340,855)
At 30 June 2026	507,048	531,250	1,038,298

Credit impaired refers to individually determined debtors who are in significant financial difficulties and have defaulted on payments to be impaired as at the financial year end.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

15. TRADE AND OTHER RECEIVABLES (continued)

(g) No ECL is recognised arising from corporate shareholder and related parties as it is negligible.

(h) As at the end of each reporting period, trade receivables of the Group are not secured by any collaterals. The Group did not renegotiate the terms of any trade receivables at the end of each reporting period.

(i) As at the end of each reporting period, the Group was not subject to significant concentration of credit risk.

(j) The currency exposure profile of receivables (excluding prepayments) are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Ringgit Malaysia ("RM")	43,500,580	103,552,349	113,918,173	137,650,665
Chinese Renminbi ("RMB")	-	50,100	851,237	23,063
United States Dollar ("USD")	486,067	405,339	8,085,816	3,529,600
Euro Dollar ("Euro")	23,890	27,278	1,252,107	616,227
Australian Dollar ("AUD")	-	277,950	277,950	-
Singapore Dollar ("SGD")	103,886	7,051,181	3,103,362	265,139
Brunei Dollar ("BND")	-	-	435,019	502,131
Japanese Yen ("JPY")	-	-	51,023	-
Thai Baht ("THB")	-	19,546	13,448	-
Indonesian Rupiah	-	38,125	-	-
New Zealand Dollar ("NZD")	-	-	-	86,401
	44,114,423	111,421,868	127,988,135	142,673,226

(k) Sensitivity analysis of RM against foreign currencies at the end of the reporting period of the Group, assuming that all other variables remain constant, are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Effects of 5% (2025: 5% ,2024: 5%, 2023: 5%) changes to RM against foreign currencies				
Profit after tax and equity				
RM/USD - strengthen	18,470	15,403	307,261	134,125
RM/USD - weaken	(18,470)	(15,403)	(307,261)	(134,125)
RM/SGD - strengthen	3,948	267,945	117,928	10,075
RM/SGD - weaken	(3,948)	(267,945)	(117,928)	(10,075)

The exposure of the Group to the other currencies are not significant, hence the effects of the changes in the exchange rates are not presented.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

16. CASH AND BANK BALANCES

	2023 RM	2024 RM	2025 RM	2026 RM
Cash and bank balances	27,763,993	159,476,121	280,072,752	280,704,480
Deposits with licensed banks	3,995,286	16,088,017	14,823,561	15,922,122
	31,759,279	175,564,138	294,896,313	296,626,602

(a) Cash and bank balances are classified as financial assets measured at amortised cost.

(b) No ECL is recognised arising from cash at banks and deposits with licensed banks because the probability of default by these financial institutions is negligible.

(c) Deposits placed with licensed banks of the Group has maturity periods of 1 month to 1 year (2025: 1 month to 1 year, 2024: 1 month to 1 year, 2023: 9 months to 1 year) with interest rate of 1.75% to 3.85% (2025: 1.83% to 4.95%, 2024: 2.04% to 4.05% and 2023: 1.80% to 4.15%) per annum.

(d) Certain deposits placed with licensed banks are pledged to financial institutions for banking facilities granted to the Group as disclosed in Note 19(b) to the consolidated financial statements.

(e) For the purpose of the consolidated statements of cash flows, cash and cash equivalents comprise the following as at the end of each reporting period:

	2023 RM	2024 RM	2025 RM	2026 RM
Cash and bank balances	27,763,993	159,476,121	280,072,752	280,704,480
Deposits with licensed banks	3,995,286	16,088,017	14,823,561	15,922,122
Short term investment funds (Note 13)	-	35,431,502	51,137,716	49,345,390
As per consolidated statements of financial position	31,759,279	210,995,640	346,034,029	345,971,992
Less: Pledged deposits placed with licensed bank for more than three (3) months	(2,902,496)	(15,112,770)	(13,096,406)	(14,084,469)
Less: Bank overdraft (Note 19)	(15,505)	(492,671)	(674,202)	(545,265)
As per consolidated statements of cash flows	28,841,278	195,390,199	332,263,421	331,342,258

(f) The currency exposure profile of cash and bank balances of the Group are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
RM	31,749,100	175,491,388	291,602,866	296,478,675
USD	10,179	66,465	1,949,353	26,439
THB	-	-	1,220,232	-
AUD	-	6,285	6,063	6,096
SGD	-	-	117,799	103,120
HKD	-	-	-	12,272
	31,759,279	175,564,138	294,896,313	296,626,602

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

Sensitivity analysis of RM against foreign currency for cash and bank balances is not presented as it is not material to the Group.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

17. SHARE CAPITAL

	2023		2024		2025		2026	
	Number of shares	RM	Number of shares	RM	Number of shares	RM	Number of shares	RM
Issued and fully paid ordinary shares with no par value:								
At the beginning of the financial year	135,200,000	28,414,365	135,200,000	28,414,365	163,500,000	238,414,515	169,782,217	251,606,291
Issuance of ordinary shares	-	-	28,300,000	210,000,150	6,282,217	13,191,776	-	-
At the end of the financial year	135,200,000	28,414,365	163,500,000	238,414,515	169,782,217	251,606,291	169,782,217	251,606,291

(a) The owners of the Company are entitled to receive dividends as and when declared by the Company and are entitled to one (1) vote per ordinary shares at meetings of the Company. All ordinary shares rank pari passu with regard to the residual assets of the Company.

(b) During the FYE 30 June 2024, the Company increased its issued share capital from RM28,414,365 to RM238,414,515 by way of issuance of 28,300,000 new ordinary shares for a total consideration of RM210,000,150.

(c) During the FYE 30 June 2025, the Company increased its issued and paid-up ordinary share capital from RM238,414,515 to RM251,606,291 by way of issuance of:

(i) 1,103,892 ordinary shares pursuant to the exercise of Employees' Share Options Scheme at an exercise price of RM7.40 per ordinary share for cash; and

(ii) 5,178,325 ordinary shares pursuant to the exercise of Employees' Share Options Scheme at an exercise price of RM0.97 per ordinary share for cash.

The newly issued shares rank pari passu in all respects with the existing ordinary shares of the Company. There were no other issues of shares during the financial year.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

18. RESERVES

	2023 RM	2024 RM	2025 RM	2026 RM
Non-distributable reserve:				
Share option reserve	2,028,854	2,113,389	-	-
Reorganisation reserve	(41,600)	(41,600)	(41,600)	(41,600)
Foreign exchange translation reserve	-	-	15,282	18,800
Distributable reserve:				
Retained earnings	105,255,918	121,816,412	170,501,805	204,467,686
	107,243,172	123,888,201	170,475,487	204,444,886

The movements in each category of reserves are disclosed in the consolidated statements of changes in equity.

The nature of reserve is as follows:

(a) Share option reserve

The share option reserve represents the effect of the equity-settled share option granted to employees. This reserve is made up of the cumulative value of services received from employees for the issue of share options.

(b) Reorganisation reserve

The reorganisation debit arose from the acquisition of subsidiaries based on the difference between the amount recorded as cost of merger and the nominal value of subsidiaries' share capital acquired under the pooling of interest method of accounting.

(c) Exchange translation reserve

The exchange translation reserve is used to record foreign currency exchange differences arising from the translation of the financial statements of foreign operations whose functional currencies are different from that of the presentation currency of the Group. It is also used to record the exchange differences arising from monetary items which form part of the net investment of the Group in foreign operations, where the monetary item is denominated in either the functional currency of the reporting entity or the foreign operation.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. BORROWINGS

	2023 RM	2024 RM	2025 RM	2026 RM
Non-current liabilities				
- Term loans	38,664,136	722,771,399	912,890,860	510,077,560
- Revolving credit	-	72,386,619	72,386,619	77,280,854
	38,664,136	795,158,018	985,277,479	587,358,414
Current liabilities				
- Term loans	3,704,641	15,785,254	15,405,400	480,028,409
- Bank overdraft	15,505	492,671	674,202	545,265
- Bankers' acceptances	84,667,000	79,800,000	140,530,442	186,461,238
- Invoice financing	-	-	4,625,249	-
- Revolving credit	27,943,898	67,991,294	184,670,690	105,852,084
	116,331,044	164,069,219	345,905,983	772,886,996
Total borrowings				
- Term loans	42,368,777	738,556,653	928,296,260	990,105,969
- Bank overdraft	15,505	492,671	674,202	545,265
- Bankers' acceptances	84,667,000	79,800,000	140,530,442	186,461,238
- Invoice financing	-	-	4,625,249	-
- Revolving credit	27,943,898	140,377,913	257,057,309	183,132,938
	154,995,180	959,227,237	1,331,183,462	1,360,245,410

(a) Borrowings are classified as financial liabilities measured at amortised cost.

(b) Borrowings are secured by freehold land and buildings, warehouse and capital work-in-progress, leasehold land and buildings and investment properties of the Group as disclosed in Notes 7(e), 8(c), 10(i) and 16(d) to the consolidated financial statements, joint and severally guarantee by the certain Directors of the Company, corporate guarantee by the Company and certain subsidiaries, corporate guarantee provided by a corporate shareholder of the Company, letter of undertaking issued by the Directors, Lee Meng Chuan and Lim Sin Yin and a corporate shareholder of the Company, against certain deposits with licensed banks of the Group as disclosed in Note 16(d) to the consolidated financial statements and memorandum of charge on shares of certain subsidiaries.

(c) Certain borrowings of the Group carry the following significant covenants:

(i) Consolidated Debt Service Coverage Ratio ("DSCR") is to be maintained at no less than 1.25 times throughout the financing tenure.

(ii) Consolidated net debt to EBITDA shall not exceed 4.0 times.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. BORROWINGS (continued)

(d) The term loans of the Group are repayable by monthly instalments ranging from 8 to 282 months (2025: 42 to 300 months, 2024: 42 to 300 months, 2023: 42 to 300 months).

(e) The revolving credit facilities of the Group are unsecured and repayable on demand. However, the Group has obtained confirmation from the lender that the facilities will be made available for a period exceeding 12 months from the reporting date. Included in revolving credit are RM41,998,500 and RM30,388,119 (2025: RM41,998,500, 2024: RM41,998,500, 2023: Nil) which were repayable by 1st instalment on 21 November 2026 and 19 October 2030 respectively.

(f) The carrying amounts of borrowings are reasonable approximation of fair value, either due to their short-term in nature or that floating rate instruments that are re-priced to market interest rates on or near the end of each reporting period.

The fair value for disclosure purpose of borrowings obligations is categorised as Level 3 in the fair value hierarchy, which is estimated based on expected future cash flows discounted at the market rate of interest as at the end of the reporting period. There is no transfer between levels in the fair value hierarchy during the financial year.

(g) Borrowings are denominated in RM.

(h) The following table sets out the carrying amounts as at the end of each reporting period and the remaining maturities of the borrowings of the Group that are exposed to interest rate risk:

	Within 1 year RM	1 - 2 years RM	2 - 5 years RM	More than 5 years RM	Total RM
30 June 2023					
Floating rates					
Term loans	3,704,641	3,996,701	8,462,692	26,204,743	42,368,777
Bank overdraft	15,505	-	-	-	15,505
Fixed rates					
Bankers' acceptances	84,667,000	-	-	-	84,667,000
Revolving credit	27,943,898	-	-	-	27,943,898
30 June 2024					
Floating rates					
Term loans	15,676,338	18,479,655	667,649,588	36,518,054	738,323,635
Bank overdraft	492,671	-	-	-	492,671
Revolving credit	67,991,294	5,000,000	10,000,000	57,386,619	140,377,913
Fixed rates					
Term loans	108,916	124,102	-	-	233,018
Bankers' acceptances	79,800,000	-	-	-	79,800,000
30 June 2025					
Floating rates					
Term loans	15,291,519	523,331,260	345,396,997	44,162,603	928,182,379
Bank overdraft	674,202	-	-	-	674,202
Bankers' acceptances	50,707,738	-	-	-	50,707,738
Revolving credit	184,670,690	10,000,000	10,000,000	52,386,619	257,057,309
Fixed rates					
Term loans	113,881	-	-	-	113,881
Bankers' acceptances	89,822,704	-	-	-	89,822,704
Invoice financing	4,625,249	-	-	-	4,625,249

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. BORROWINGS (continued)

(h) The following table sets out the carrying amounts as at the end of each reporting period and the remaining maturities of the borrowings of the Group that are exposed to interest rate risk: (continued)

	Within 1 year RM	1 - 2 years RM	2 - 5 years RM	More than 5 years RM	Total RM
30 June 2026					
Floating rates					
Term loans	480,028,409	105,141,196	304,681,514	100,254,850	990,105,969
Bank overdraft	545,265	-	-	-	545,265
Bankers' acceptances	175,393,667	-	-	-	175,393,667
Revolving credit	105,852,084	10,000,000	10,000,000	57,280,854	183,132,938
Fixed rates					
Bankers' acceptances	11,067,571	-	-	-	11,067,571

(i) The table below summarises the maturity profile of the borrowings of the Group at the end of each reporting period based on contractual undiscounted repayment obligations as follows:

	On demand or within one year RM	One to five years RM	Over five years RM	Total RM
30 June 2023				
Term loans	5,590,692	18,424,433	32,967,875	56,983,000
Bankers' acceptances	85,312,587	-	-	85,312,587
Revolving credit	28,051,839	-	-	28,051,839
Bank overdraft	16,247	-	-	16,247
	118,971,365	18,424,433	32,967,875	170,363,673
30 June 2024				
Term loans	67,712,211	793,714,507	61,246,698	922,673,416
Bankers' acceptances	80,394,902	-	-	80,394,902
Revolving credit	68,548,513	20,000,000	52,386,619	140,935,132
Bank overdraft	519,891	-	-	519,891
	217,175,517	813,714,507	113,633,317	1,144,523,341
30 June 2025				
Term loans	64,688,169	891,861,251	69,442,348	1,025,991,768
Bankers' acceptances	141,361,440	-	-	141,361,440
Revolving credit	185,689,720	20,000,000	52,386,619	258,076,339
Invoice financing	4,694,520	-	-	4,694,520
Bank overdraft	678,917	-	-	678,917
	397,112,766	911,861,251	121,828,967	1,430,802,984

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906050013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. BORROWINGS (continued)

(i) The table below summarises the maturity profile of the borrowings of the Group at the end of each reporting period based on contractual undiscounted repayment obligations as follows: (continued)

	On demand or within one year RM	One to five years RM	Over five years RM	Total RM
30 June 2026				
Term loans	525,149,393	455,102,620	131,894,323	1,112,146,336
Bankers' acceptances	187,433,906	-	-	187,433,906
Revolving credit	106,552,390	20,000,000	57,280,854	183,833,244
Bank overdraft	548,581	-	-	548,581
	819,684,270	475,102,620	189,175,177	1,483,962,067

(j) The weighted average effective interest rates per annum at the reporting date for borrowings are as follows:

	2023 %	2024 %	2025 %	2026 %
Fixed rates				
Bankers' acceptances	3.44 - 4.82	3.84 - 4.16	3.56 - 4.83	3.38 - 5.18
Term loans	-	3.50	3.50	-
Invoice financing	-	-	4.85	-
Floating rates				
Term loans	4.15 - 5.89	4.56 - 9.75	3.90 – 8.26	3.21 - 6.97
Revolving credit	4.76	4.46 - 5.03	4.26 - 4.93	4.41 - 5.10
Bank overdraft	4.70	5.42	7.35	7.13
Bankers' acceptances	3.44 - 4.82	3.84 - 4.16	4.22	3.14 - 3.63

(k) Sensitivity analysis of interest rate for the floating rate instruments at the end of the reporting period, assuming all other variables remain constant, is as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Effects of 100 basis point changes to profit after tax:				
Floating rate instruments	329,909	6,681,876	9,398,324	10,238,629

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

19. BORROWINGS (continued)

(l) Reconciliation of liabilities arising from financing activities

	Term loans RM	Bankers' acceptances RM	Revolving credit RM	Invoice financing RM	Total RM
As at 1 July 2022	46,182,579	38,015,000	17,800,000	-	101,997,579
Cash flows:					
- Drawdowns	-	81,949,000	13,303,000	-	95,252,000
- Repayments	(3,813,802)	(35,297,000)	(3,159,102)	-	(42,269,904)
As at 30 June 2023	42,368,777	84,667,000	27,943,898		154,979,675
As at 1 July 2023	42,368,777	84,667,000	27,943,898	-	154,979,675
Cash flows:					
- Drawdowns	646,798,402	81,760,000	125,377,975	-	853,936,377
- Repayments	(10,025,536)	(90,566,000)	(28,943,960)	-	(129,535,496)
Non-cash flow:					
Acquisition of subsidiaries	59,415,010	3,939,000	16,000,000	-	79,354,010
As at 30 June 2024	738,556,653	79,800,000	140,377,913	-	958,734,566
As at 1 July 2024	738,556,653	79,800,000	140,377,913	-	958,734,566
Cash flows:					
- Drawdowns	202,351,414	344,441,636	136,441,000	5,475,325	688,709,375
- Repayments	(16,831,613)	(284,382,194)	(19,761,604)	(2,699,199)	(323,674,610)
Non-cash flow:					
Acquisition of subsidiaries	4,219,806	671,000	-	1,849,123	6,739,929
As at 30 June 2025	928,296,260	140,530,442	257,057,309	4,625,249	1,330,509,260
As at 1 July 2025	928,296,260	140,530,442	257,057,309	4,625,249	1,330,509,260
Cash flows:					
- Drawdowns	82,885,000	665,266,408	20,894,234	-	769,045,642
- Repayments	(21,075,291)	(619,335,612)	(94,818,605)	(4,625,249)	(739,854,757)
As at 30 June 2026	990,105,969	186,461,238	183,132,938	-	1,359,700,145

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

20. TRADE AND OTHER PAYABLES

	2023 RM	2024 RM	2025 RM	2026 RM
Non-current liabilities				
Other payables				
Amounts owing to corporate shareholders	7,686,345	7,686,345	-	-
Amount owing to a related party	847,570	906,857	966,145	1,025,432
Contingent consideration	-	52,089,797	21,070,374	14,651,047
Provision for restoration cost	2,752,565	6,530,322	7,768,740	8,760,093
	11,286,480	67,213,321	29,805,259	24,436,572
Current liabilities				
Trade payables				
Third parties	153,495,851	433,488,712	556,035,587	638,607,053
Related parties	2,690,313	17,606,838	8,293,723	27,728,166
	156,186,164	451,095,550	564,329,310	666,335,219
Other payables				
Third parties	40,904,210	30,121,133	31,337,603	20,198,237
Accruals	19,216,868	53,462,864	55,857,311	84,175,279
Amounts owing to related parties	184,592	118,695	72,018	-
Amounts owing to Directors	270,501	13,436,219	90,000	2,000,002
Provision for restoration cost	7,860	7,860	619,945	699,529
Contingent consideration	-	19,660,903	96,730,118	162,648,431
Contract liabilities of:				
- unredeemed loyalty points	4,076,592	7,273,419	10,414,068	12,196,939
- unutilised treatment package	-	-	-	2,323,456
Dividend payable	-	-	7,300,000	-
Deposit received	-	22,756	2,341,559	4,016,652
	64,660,623	124,103,849	204,762,622	288,258,525
Total current payables	220,846,787	575,199,399	769,091,932	954,593,744
Total trade and other payables (non-current and current)	232,133,267	642,412,720	798,897,191	979,030,316

(a) Trade and other payables, excluding contingent consideration are classified as financial liabilities measured at amortised cost.

(b) Trade payables are non-interest bearing and the normal trade credit terms granted to the Group range from 7 to 120 days (2025: 7 to 120 days, 2024: 14 to 90 days, 2023: 14 to 90 days).

(c) Non-current amounts owing to corporate shareholders and related party represent advances, which are unsecured, interest-free and payable after twelve (12) months in cash and cash equivalents.

(d) Non-trade amounts owing to related parties and Directors represent advances and payments made on behalf, which are unsecured, interest-free and payable within the next twelve (12) months in cash and cash equivalents.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

20. TRADE AND OTHER PAYABLES (continued)

(e) Financial instruments that are not carried at fair values and whose carrying amounts are reasonable approximation of fair values, are as follows:

	2023		2024		2025		2026	
	Carrying amount RM	Fair value RM	Carrying amount RM	Fair value RM	Carrying amount RM	Fair value RM	Carrying amount RM	Fair value RM
Amounts owing to corporate shareholders	7,686,345	7,031,886	7,686,345	7,351,836	-	-	-	-
Amount owing to a related party	847,570	847,570	906,857	906,857	966,145	966,145	1,025,432	1,025,432

The fair value of amounts owing to corporate shareholders and a related party of the Group are estimated by discounting future contracted cash flows at the current market interest rate available to the Group for similar financial instruments.

Fair value of the amounts owing to corporate shareholders and a related party of the Group are categorised as Level 3 in the fair value hierarchy. There is no transfer between levels in the hierarchy during the financial year.

(f) The table below summarises the maturity profile of the trade and other payables (excluded contract liabilities) of the Group at the end of each reporting period based on contractual undiscounted repayment obligations as follows:

	On demand or within one year RM	One to five years RM	Over five years RM	Total RM
30 June 2023				
Trade and other payables	216,770,195	8,419,630	4,526,896	229,716,721
30 June 2024				
Trade and other payables	558,759,717	8,427,201	65,866,774	633,053,692
30 June 2025				
Trade and other payables	758,057,919	27,972,146	6,486,495	792,516,560
30 June 2026				
Trade and other payables	965,780,910	25,134,930	5,491,405	996,407,245

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

20. TRADE AND OTHER PAYABLES (continued)

(g) Provision for restoration cost

A reconciliation of restoration cost is as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Balance as at beginning of financial year	2,026,942	2,760,425	6,538,182	8,388,685
Acquisition from subsidiaries	-	3,100,000	-	-
Recognised in property, plant and equipment (Note 7(b))	774,226	798,765	-	-
Recognised in rights-of-use assets (Note 10)	-	-	796,393	2,524,993
Recognised in profit or loss:				
- Unwinding of discount on provision for restoration costs	-	-	293,342	310,632
- Under/(Over) provision of restoration costs	-	-	436,353	(1,925,328)
(Reversal)/Addition on provision for restoration costs	(40,743)	(84,300)	486,799	244,878
Utilised during the financial year	-	-	(162,384)	(84,238)
Written off	-	(36,708)	-	-
Balance as at end of financial year	2,760,425	6,538,182	8,388,685	9,459,622

Under the provision of lease agreements, the Group has an obligation to dismantle and remove refurbishments on the outlets and restore those outlets at the end of the term to an acceptable condition.

(h) Contract liabilities of unredeemed loyalty points

A reconciliation of unredeemed loyalty points is as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Balance as at beginning of financial year	2,734,913	4,076,592	7,273,419	10,414,068
Addition during the financial year	3,888,764	19,322,076	19,421,388	13,838,637
Recognised in profit or loss	(2,547,085)	(16,125,249)	(16,280,739)	(12,055,766)
Balance as at end of financial year	4,076,592	7,273,419	10,414,068	12,196,939

The Group maintains a customer loyalty program that allows its members to accumulate customer loyalty points on purchases of the products of the Group sold in its retail outlets. The members earn one (1) point for every RM1.00 spent on retail transactions. These customers' loyalty points are then converted into cash rebate when customers meet the minimum points.

Contract liabilities of unredeemed loyalty points have been recognised at the end of the reporting period for expected loyalty points to be redeemed based on past experience of the level of redemption.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

20. TRADE AND OTHER PAYABLES (continued)

(i) Contract liabilities of unutilised treatment package

A reconciliation of unutilised treatment package is as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Balance as at beginning of financial year	-	-	-	-
Cash received from sale of package	-	-	-	30,801,180
Recognised in revenue during the year	-	-	-	(28,477,724)
Balance as at end of financial year	-	-	-	2,323,456

Contract liabilities of unutilised treatment package comprise consideration received in advance from customers for physiotherapy treatment packages. The contract liabilities represent the Group's obligation to provide future treatment sessions under the packages purchased. Revenue is recognised as and when the treatment sessions are rendered to customers. Any unutilised sessions remaining upon expiry of the package validity period are recognised as revenue when the Group's obligation to provide further services ceases.

(j) The amount of RM10,414,068 (2025: RM7,273,419, 2024: RM4,076,592, 2023: RM2,734,913) included in contract liabilities at the beginning of the financial year has been recognised as revenue for the respective financial years.

(k) Revenue expected to be recognised in future relating to performance obligations that are unsatisfied (or partially satisfied) at the end of the reporting period, are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Within 1 year	4,076,592	7,273,419	10,414,068	14,520,395

(l) Contingent consideration

Contingent consideration are classified as financial liabilities measured at fair value through profit or loss.

In the financial year ended 30 June 2025, the contingent consideration in non-current liabilities represented the fair value of the expected consideration payable for the acquisition of the remaining equity interests from the vendors in the financial year ending 30 June 2028 in relation to the acquisition of TPH and Wellings. Contingent consideration in current liabilities represented the fair value of the 50% of remaining purchase consideration payable to the vendors in the financial year ended 30 June 2026 in relation to the acquisition of TPH, Wellings and certain subsidiaries of the Company as disclosed in Note 5 to the financial statements.

During the financial year ended 30 June 2026, the Group settled a total purchase consideration of RM78.4 million payable to the vendors in relation to the acquisitions of TPH and Wellings.

As at 30 June 2026, included in the contingent consideration is an amount of RM150.3 million, classified as current liabilities, representing the fair value of the estimated consideration payable for the anticipated acquisition of the remaining equity interests from the vendors of the Yanling Holdings Sdn. Bhd.. The initial recognition of the contingent consideration at fair value is grouped at Level 3 based on the degree to which the fair value is observable based on equity value of the subsidiary of the Group.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

20. TRADE AND OTHER PAYABLES (continued)

(l) Contingent consideration (continued)

The reconciliation of movements for contingent liabilities whose fair values have been classified in Level 3 of the fair value hierarchy at the end of each reporting period are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Balance as at 1 July	-	-	71,750,700	117,800,492
Additions	-	71,750,700	64,589,869	155,178,860
Recognised in profit or loss	-	-	1,120,826	10,519,961
Settlement	-	-	(19,660,903)	(106,199,835)
Balance as at 30 June	-	71,750,700	117,800,492	177,299,478

(m) The currency exposure profile of trade and other payables (excluded contract liabilities) of the Group are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
RM	226,706,114	626,427,903	769,133,560	948,079,560
RMB	1,223,852	1,535,859	1,275,048	-
USD	-	377,740	12,531,734	11,286,224
EURO	-	48,516	71,602	56,559
THB	-	-	4,927,350	5,063,762
AUD	-	7,281	294,728	7,281
SGD	126,709	6,742,002	249,101	16,535
	228,056,675	635,139,301	788,483,123	964,509,921

(n) Sensitivity analysis of RM against foreign currencies at the end of the reporting period of the Group, assuming that all other variables remain constant, are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Effects of 5% (2025: 5%, 2024: 5%, 2023: 5%) changes to RM against foreign currencies				
Profit after tax and equity				
RM/RMB - strengthen	46,506	58,363	48,452	-
RM/RMB - weaken	(46,506)	(58,363)	(48,452)	-
RM/THB - strengthen	-	-	187,239	192,423
RM/THB - weaken	-	-	(187,239)	(192,423)
RM/USD - strengthen	-	14,354	476,206	428,877
RM/USD - weaken	-	(14,354)	(476,206)	(428,877)
RM/SGD - strengthen	4,815	256,196	9,466	628
RM/SGD - weaken	(4,815)	(256,196)	(9,466)	(628)

The exposure of the Group to the other currencies are not significant, hence the effects of the changes in the exchange rates are not presented.

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

21. REVENUE

	2023 RM	2024 RM	2025 RM	2026 RM
Revenue from contracts with customers				
- Sale of goods	1,108,104,340	2,155,234,211	3,393,598,520	3,982,312,636
- Sale of services	-	-	2,147,397	29,623,116
- Revenue from customer loyalty points	2,547,085	16,125,249	16,280,739	12,055,766
	1,110,651,425	2,171,359,460	3,412,026,656	4,023,991,518
Timing of revenue recognition				
- Transferred at a point in time	1,110,651,425	2,171,359,460	3,412,026,656	4,023,991,518

Disaggregation of revenue from contracts with customers

Disaggregation of revenue from contract with customers has been presented in the operating segments, Note 6 to the consolidated financial statements, which has been presented based on nature of products and services from which the sale of transactions originated.

(a) Revenue from sale of goods is recognised at a point in time when the goods have been transferred to the customers and coincide with the delivery of products and acceptance by customers.

There is no material right of return and warranty provided to the customers on the sale of goods.

There is no significant financing component in the revenue arising from sale of goods and loyalty fees as the sales are made on the normal credit terms not exceeding twelve (12) months.

(b) The Group's loyalty points programme allows customers to accumulate points that can be redeemed for products.

The loyalty points give rise to a separate performance obligation as they provide a material right to the customer. A portion of the transaction price is allocated to the loyalty points awarded to customers based on relative stand-alone selling price and recognised as a contract liability until the points are redeemed. Revenue is recognised at a point in time upon redemption or expiry of the customer loyalty points by the customer.

When estimating the stand-alone selling price of the loyalty points, the Group considers the likelihood that the customer will redeem the points. The Group updates its estimates of the points that will be redeemed on a regular basis and any adjustments to the contract liability balance are charged against revenue.

(c) Revenue from services are recognised when services are being rendered to a customer and such customer receives and consume the benefits. The Group has a present right to payment for the services rendered respectively.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

22. FINANCE COSTS

	2023 RM	2024 RM	2025 RM	2026 RM
Interest expense on:				
- term loans	1,844,784	20,315,766	40,573,892	44,745,322
- lease liabilities	6,184,305	9,732,394	13,075,753	15,698,146
- bankers' acceptances	2,275,110	3,117,570	2,708,544	5,361,395
- revolving credit	8,475	935,723	7,576,508	11,229,840
- bank overdraft	923,152	1,280,787	132,378	63,720
- unwinding of discount on contingent consideration payable	-	-	-	10,519,961
- others	361,269	4,832,554	2,244,633	866,637
	11,597,095	40,214,794	66,311,708	88,485,021

23. PROFIT BEFORE TAX

(a) Other than those disclosed elsewhere in the consolidated financial statements, profit before tax is arrived at after charging/(crediting):

	2023 RM	2024 RM	2025 RM	2026 RM
Auditors' remuneration - BDO PLT:				
- statutory audit	450,000	890,500	1,295,000	1,428,900
- (over)/under provision in prior year	(9,000)	-	14,900	-
- assurance related services	-	-	117,000	-
Other auditors' remuneration:				
- under provision in prior year	-	-	-	10,563
- statutory audit	11,854	6,945	9,609	20,580
Bad debts written off	-	410,938	494,015	210,141
Prepayment written off	-	-	645,475	-
Gain on disposal of:				
- property, plant and equipment	-	(106,411)	(141,914)	(87,231)
- investment properties	-	-	(185,728)	-
- quoted equity instruments	-	-	(3,607)	(8,710)
Loss on foreign exchange:				
- realised	-	956,300	2,853	599,207
- unrealised	-	36,058	407,205	126,480
Gain on reassessment and modification of leases	-	-	(1,404,595)	(408,833)
Gain on fair value of quoted equity instruments	-	(218,887)	(32,960)	(74,152)
Gain on foreign exchange:				
- realised	(150,355)	(13,749)	(1,107,674)	(1,227,204)
- unrealised	-	(7,778)	(192,337)	(1,323,107)
Rebate and marketing income	(57,592,780)	(98,762,884)	(120,318,162)	(123,948,143)
Rental income	(152,067)	(1,137,551)	(2,186,751)	(2,567,143)
Waiver of debt	-	-	(280,000)	-
Interest income	(2,173,528)	(3,714,720)	(5,906,058)	(5,681,549)

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

23. PROFIT BEFORE TAX (continued)

(a) (continued)

(i) Interest income is recognised as it accrues, using the effective interest method.

(ii) Rental income is accounted for on a straight-line basis over the lease term of an ongoing lease.

(iii) Rebates and marketing income

The Group receives rebates and discounts from suppliers for various programmes, primarily volume rebates, prompt payment discounts and other purchase-related rebates. Rebates and discounts are recognised when the Group achieves the volume-purchase targets, and the related contractual conditions have been fulfilled in accordance with the terms stipulated in the trade agreements with vendors. These rebates and discounts that are directly attributable to the purchase of inventories are recognised as a deduction against cost of inventories. The rebates and discounts are recognised in cost of goods sold when the related goods are sold. Rebates and discounts relating to unsold inventories at the reporting date are deducted against inventories and subsequently recognised in the statement of profit or loss and other comprehensive income when the related goods are sold.

Marketing income and other incentives mainly comprise central distribution centre rebates ("CDC rebates"), in-store displays and promotions and advertisements for specific products. Incentives are recognised in the statement of profit or loss and other comprehensive income when the performance obligations have been fulfilled by the Group in accordance with the terms as stipulated in the agreements with vendors. These incentives are recognised as other operating income in the statement of profit or loss and other comprehensive income.

(b) Net (gain)/loss on impairment of financial assets recognised in profit or loss were as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Impairment loss on:				
- trade receivables	25,709	227,420	675,301	884,291
- other receivables	74,362	-	753,558	507,991
	100,071	227,420	1,428,859	1,392,282
Reversal of impairment loss on:				
- trade receivables	(405,636)	(7,299)	(321,107)	(609,722)
- other receivables	-	-	(34,180)	(3,316)
	(405,636)	(7,299)	(355,287)	(613,038)
Net (gain)/loss on impairment of financial assets	(305,565)	220,121	1,073,572	779,244

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

24. TAX EXPENSE

	2023 RM	2024 RM	2025 RM	2026 RM
Current tax expense based on profit for the financial year	15,793,972	33,360,698	77,873,933	119,971,546
(Over)/Under provision in prior years	(493,690)	273,123	1,424,336	(1,128,454)
	15,300,282	33,633,821	79,298,269	118,843,092
Deferred tax (Note 12):				
Relating to origination and reversal of temporary differences	2,187,198	(1,322,294)	(1,129,326)	(201,431)
Under/(Over) provision in prior years	159,061	713,334	(1,867,129)	1,718,568
	2,346,259	(608,960)	(2,996,455)	1,517,137
Real property gains tax	-	391,381	3,583	-
Capital gains tax	-	-	-	20,287
	17,646,541	33,416,242	76,305,397	120,380,516

(a) The Malaysian income tax is calculated at the statutory tax rate of twenty-four percent (24%) (2025: 24%, 2024: 24%, 2023: 24%) of the estimated taxable profits for the financial year.

(b) Numerical reconciliation between the tax expense and the product of accounting profit multiplied by the applicable tax rate of the Group are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Profit before tax	58,840,718	81,207,060	219,323,934	352,204,082
Tax at Malaysian statutory tax rate at 24% (2025: 24%, 2024: 24%, 2023: 24%)	14,121,772	19,489,694	52,637,744	84,528,980
Tax effects in respect of:				
- Non-taxable income	(204,756)	(473,687)	(808,225)	(3,108,503)
- Non-deductible expenses	2,527,708	11,795,337	24,201,234	35,234,058
- Movements of unrecognised deferred tax assets	1,536,446	1,227,060	713,854	3,115,580
	17,981,170	32,038,404	76,744,607	119,770,115
Real property gains tax	-	391,381	3,583	-
Capital gains tax	-	-	-	20,287
(Over)/Under provision in prior years				
- Income tax	(493,690)	273,123	1,424,336	(1,128,454)
- Deferred tax	159,061	713,334	(1,867,129)	1,718,568
	17,646,541	33,416,242	76,305,397	120,380,516

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

25. EARNINGS PER ORDINARY SHARE

(a) Basic

Basic earnings per ordinary share for the financial year has been calculated based on the consolidated profit for the financial year attributable to owners of the parent and the weighted average number of ordinary shares in issue during the financial year.

	2023	2024	2025	2026
Profit attributable to owners of the parent (RM)	37,020,402	37,222,550	122,294,436	191,631,878
Weighted average number of ordinary shares in issue (unit)	135,200,000	149,543,836	163,517,259	169,782,217
Basic earnings per ordinary share (sen)	27.38	24.90	74.80	112.87

(b) Diluted

Diluted earnings per ordinary share for the financial year has been calculated based on the consolidated profit for the financial year attributable to owners of the parents and the weighted average number of ordinary shares in issue during the financial year adjusted for the effects of dilutive potential ordinary shares.

	2023	2024	2025	2026
Profit attributable to owners of the parent (RM)	37,020,402	37,222,550	122,294,436	191,631,878
Weighted average number of ordinary shares in issue (unit)	135,200,000	149,543,836	163,517,259	169,782,217
Effect in dilution of share options (unit)	4,932,884	6,183,044	6,169,572	-
Adjusted weighted average number of ordinary shares in issue and issuable (unit)	140,132,884	155,726,880	169,686,831	169,782,217
Diluted earnings per ordinary share (sen)	26.42	23.90	72.07	112.87

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

26. DIVIDENDS

	2023		2024		2025		2026	
	Dividend per ordinary share RM	Amount of dividend RM	Dividend per ordinary share RM	Amount of dividend RM	Dividend per ordinary share RM	Amount of dividend RM	Dividend per ordinary share RM	Amount of dividend RM
First interim dividend	-	-	0.06	8,112,000	0.0446	7,300,000	0.1470	24,957,986
Second interim dividend	-	-	0.04	6,540,000	-	-	-	-
Third interim dividend	-	-	0.037	6,049,500	-	-	-	-
	-	-	0.137	20,701,500	0.0446	7,300,000	0.1470	24,957,986

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018325-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

27. EMPLOYEE BENEFITS

	2023 RM	2024 RM	2025 RM	2026 RM
Salaries, wages and bonuses	120,274,916	230,914,074	311,435,858	368,993,926
Contributions to defined contribution plan	14,064,490	28,315,321	43,533,023	55,851,014
Social security contributions	1,480,503	3,035,257	5,156,206	6,194,201
Other benefits	7,630,026	27,541,306	74,550,456	125,565,454
Share options vested under employees' share options scheme	190,205	77,919	2,089,363	-
	143,640,140	289,883,877	436,764,906	556,604,595

Included in employee benefits of the Group are Directors' remuneration as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Directors' fees	296,000	626,610	1,027,032	1,472,667
Salaries and bonuses	3,184,184	8,565,785	14,733,908	15,141,319
Contributions to defined contribution plan	434,942	1,302,649	2,221,176	2,339,933
Social security contributions	9,140	9,921	84,845	91,041
Other benefits	124,296	148,750	275,382	342,499
	4,048,562	10,653,715	18,342,343	19,387,459

28. EMPLOYEES' SHARE OPTIONS SCHEME ("ESOS")

The ESOS of the Company came into effect on 1 July 2019. The Company implements an ESOS, which is in force for a period of six (6) years until 25 June 2025 ("the extended option period"). The main features of the ESOS are as follows:

(a) the ESOS is made available to selected key employees who are confirmed employees of the Company and its subsidiaries as defined in the Companies Act 2016 in Malaysia, as amended from time to time, and any re-enactment thereof;

(b) the total number of shares offered under the ESOS shall not, in aggregate, exceed 5% of the issued and paid-up ordinary shares of the Company at any time during the existence of the ESOS;

(c) the option price under the ESOS shall be set at the Group's latest market valuation divided by the total number of shares issued at the date of valuation;

(d) the actual number of shares, which may be offered to any eligible employee shall be at the discretion of the Board of Directors;

(e) an option granted under the ESOS may be exercised by the grantee upon achieving the vesting conditions set by the Board;

(f) the shares issued and allotted shall rank pari passu in all respects with the then existing issued shares of the Company;

During the financial year ended 30 June 2025, the options were fully exercised or lapsed.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

28. EMPLOYEES' SHARE OPTIONS SCHEME ("ESOS") (continued)

The number of unissued ordinary shares under options at the respective option prices was as follows:

	[---------- Number of options over ordinary shares ----------]			
2023	**Balance as at 1.7.2022**	**Granted**	**Balance as at 30.6.2023**	**Exercisable as at 30.6.2023**
Option price:				
RM0.97	7,115,789	-	7,115,789	5,692,632

	[---------- Number of options over ordinary shares ----------]			
2024	**Balance as at 1.7.2023**	**Granted**	**Balance as at 30.6.2024**	**Exercisable as at 30.6.2024**
Option price:				
RM0.97	7,115,789	-	7,115,789	7,115,789

	[---------- Number of options over ordinary shares ----------]					
2025	**Balance as at 1.7.2024**	**Granted**	**Exercised**	**Lapsed**	**Balance as at 30.6.2025**	**Exercisable as at 30.6.2025**
Option price:						
First grant - 1 July 2019 RM0.97	7,115,789	-	(5,178,325)	(1,937,464)	-	-
Second grant - 31 July 2024 RM7.40	-	1,134,500	(1,103,892)	(30,608)	-	-

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

28. EMPLOYEES' SHARE OPTIONS SCHEME ("ESOS") (continued)

The fair value of share options granted was estimated by an independent professional valuer using the Binomial Lattice Option Pricing Model and Trinomial Option Pricing Model for the first and second grant, taking into account the terms and conditions upon which the options were granted. The risk-free rate is based on Malaysian Government Securities ('MGSs'). The fair value of share options measured at grant date and the assumptions are as follows:

First grant - Binomial Lattice Option Pricing Model	**1 July 2019**
Fair value of share options at the grant date (RM)	0.2970
Weighted average share price (RM)	0.97
Weighted average exercise price (RM)	0.97
Expected volatility (%)	24.46
Expected life (years)	6.00
Risk free rate of interest (%)	3.651

Second grant - Trinomial Option Pricing Model	**31 July 2024**
Fair value of share options at the grant date (RM)	1.5726
Weighted average share price (RM)	7.40
Weighted average exercise price (RM)	7.40
Expected volatility (%)	34.44
Expected life (years)	2.17
Risk free rate of interest (%)	3.453

29. CAPITAL COMMITMENTS

	2023 RM	**2024 RM**	**2025 RM**	**2026 RM**
Capital expenditure in respect of purchases of property, plant and equipment and investment property				
Approved and contracted for	1,678,333	5,093,400	26,794,200	4,720,000
Approved but not contracted for	-	-	775,391	48,000,000

30. RELATED PARTY DISCLOSURES

(a) Identities of related parties

Parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties could be individuals or other parties.

Related parties of the Group include:

(i) Subsidiaries of the Company as disclosed in Note 5 to the consolidated financial statements;

(ii) Corporate shareholders, Uptown Paradise Sdn. Bhd. and Iris Palida Sdn. Bhd.;

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018325-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

30. RELATED PARTY DISCLOSURES (continued)

(a) Identities of related parties (continued)

Related parties of the Group include: (continued)

(iii) Big Pharmacy Sdn. Bhd., a company in which Directors has substantial financial interests;

(iv) Companies in which the Directors of the Company and its subsidiaries have close familial relationships;

(v) Companies in which the shareholders of the Company and its subsidiaries have significant financial interest; and

(vi) Family members of shareholders and Directors.

(b) Significant related party transactions

In addition to the transactions and balances disclosed elsewhere in the consolidated financial statements, the Group had the following transactions with related parties during the financial year:

	2023 RM	2024 RM	2025 RM	2026 RM
Transaction with related parties:				
- Sales of goods	(26,814,073)	(33,703,499)	(26,855,331)	(34,073,512)
- Purchases	47,240,487	83,039,754	106,389,967	70,759,905
- Rental expenses	1,564,757	1,794,246	1,902,955	2,076,624
- Online advertisement and website management	158,904	192,241	84,170	-
Transactions with Directors				
- Rental expenses	-	-	-	464,427
- Disposal of motor vehicle	-	-	-	(60,000)

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

30. RELATED PARTY DISCLOSURES (continued)

(c) Compensation of key management personnel

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the entity, directly and indirectly, including any Director (whether executive or otherwise) of the Group.

The total remuneration of Directors and other key management personnel during the financial year was as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Directors' fees	296,000	626,610	1,027,032	1,472,667
Salaries and bonuses	3,184,184	8,565,785	17,382,612	16,957,556
Contributions to defined contribution plan	434,942	1,302,649	2,608,841	2,631,115
Social security contribution	9,140	9,921	93,657	95,799
Other benefits	124,296	148,750	336,826	444,917
	3,752,562	10,027,105	20,421,936	20,129,387
	4,048,562	10,653,715	21,448,968	21,602,054

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

31. CAPITAL AND FINANCIAL RISK MANAGEMENT

(a) Capital management

The primary objective of the Group's capital management is to ensure that it maintains a healthy capital ratio, in order to support the Group's businesses and maximise shareholders' value.

The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to its shareholders, return capital to its shareholder or issue new shares. No changes were made in objectives, policies or processes during the financial years ended 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026.

The Group is not subject to any externally imposed capital requirements.

The Group monitors capital utilisation using a total debt to total equity and gearing ratio. Total debt to total equity represents borrowings and lease liabilities owing to financial institutions divided by total equity whereas gearing ratio represents net debt divided by total equity plus net debt. The Group includes within its net debt, borrowings less short-term investment funds and cash and bank balances. The total debt to total equity and gearing ratios as at 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026 are as follows:

	2023 RM	2024 RM	2025 RM	2026 RM
Borrowings	154,995,180	959,227,237	1,331,183,462	1,360,245,410
Lease liabilities owing to financial institutions	1,059,251	2,361,828	3,666,374	2,583,226
Less: Short-term investment funds	-	(35,431,502)	(51,137,716)	(49,345,390)
Less: Cash and bank balances	(31,759,279)	(175,564,138)	(294,896,313)	(296,626,602)
Net debt	124,295,152	750,593,425	988,815,807	1,016,856,644
Total equity	159,131,741	419,288,516	528,780,749	559,130,381
Total equity and net debt	283,426,893	1,169,881,941	1,517,596,556	1,575,987,025
Total debt to total equity	98%	229%	252%	244%
Gearing ratio	44%	64%	65%	65%

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

31. CAPITAL AND FINANCIAL RISK MANAGEMENT (continued)

(b) Financial risk management

The overall financial risk management objective of the Group is to optimise its shareholders' value and not to engage in speculative transactions.

The Group is exposed to interest rate risk, credit risk, liquidity and cash flow risk, foreign currency risk and market price risk. Information on the management of the related exposure is detailed below:

(i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the financial instruments of the Group will fluctuate because of changes in market interest rates.

The exposure to interest rate risk of the Group for changes in interest rate relates primarily to the finance lease receivables, lease liabilities, and borrowings. The Group does not use derivative financial instruments to hedge its risk.

The interest rate profile and sensitivity analysis of interest rate risk have been disclosed in Note 10, Note 16 and Note 19 to the consolidated financial statements respectively.

(ii) Credit risk

Cash deposits and receivables may give rise to credit risk, which requires the loss to be recognised if a counterparty fails to perform as contracted. It is the policy of the Group to monitor the financial standing of these counterparties on an ongoing basis to ensure that the Group is exposed to minimal credit risk. The Group considers the risk of material loss in the event of non-performance by a financial counterparty to be unlikely.

Cash deposits are placed with or entered into with reputable financial institutions with high credit rating and has no history of default.

At the end of each reporting period, the maximum exposure of the Group to credit risk is represented by the carrying amount of each class of financial assets recognised in the consolidated statements of financial position.

Information regarding credit enhancements and exposure to concentration of credit risk are disclosed in Note 15 to the consolidated financial statements.

(iii) Liquidity and cash flow risk

The Group actively manages its debt maturity profile, operating cash flows and the availability of funding so as to ensure that all operating, investing and financing needs are met. In executing its liquidity and cash flow risk management strategy, the Group measures and forecasts its cash commitments and maintains a level of cash and cash equivalents deemed adequate to finance the activities of the Group.

Prudent liquidity risk management is applied by maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities. The Group aims at maintaining the flexibility in funding by keeping committed credit lines available.

The Group's current liabilities exceeded its current assets by RM423,219,140. The Group has sufficient cash flows from its business activities for the next twelve (12) months from the reporting date to meet its operating and financing obligations as and when they fall due.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

31. CAPITAL AND FINANCIAL RISK MANAGEMENT (continued)

(b) Financial risk management (continued)

(iii) Liquidity and cash flow risk (continued)

The analysis of financial instruments by remaining contractual maturities have been disclosed in Note 10, Note 15, Note 19 and Note 20 to the consolidated financial statements respectively.

(iv) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument would fluctuate because of changes in foreign exchange rates.

The Group is subject to foreign exchange fluctuations through the import of raw materials and finished goods. The Group monitors the movement in foreign currency exchange rates closely to ensure its foreign currency risk is minimised.

The foreign currency profile and sensitivity analysis have been disclosed in Note 15, Note 16 and Note 20 to the consolidated financial statements respectively.

(v) Market price risk

Market price risk is the risk that the fair value or future cash flows of the financial instruments of the Group would fluctuate because of changes in market prices (other than interest or exchange rates).

The Group is exposed to market price risk arising from its investments in short-term investment funds and quoted equity investments.

Sensitivity analysis of market price risk for quoted equity investments and short term investment funds is not presented as changes in market value will not have any significant impact to the financial statement of the Group.

32. SIGNIFICANT EVENTS DURING THE REPORTING PERIOD AND SUBSEQUENT TO THE END OF THE REPORTING PERIOD

(a) On 30 January 2026, the shareholders approved the conversion of the Company from a private limited liability company to a public limited liability company and the change of its name from Big Caring Group Sdn. Bhd. to Big Caring Group Bhd. The shareholders of the Company have also approved the adoption of a new Constitution to ensure compliance with the regulatory and governance requirements applicable to a public company. The above changes were undertaken as part of the Company's preparations for the proposed Initial Public Offering ("IPO") and listing exercise on the Main Market of Bursa Malaysia Securities Berhad.

(b) On 26 May 2026, a subsidiary of the Company, Big Pharmacy (Perak) Sdn. Bhd., entered into an asset purchase agreement with eleven (11) companies to acquire their assets for a total consideration of RM32,500,000. As at the end of the reporting period, a refundable deposit of RM3,250,000 had been paid with the balance payable upon completion. The acquisition has been completed as at the date of authorisation of these financial statements.


(c) On 14 October 2026, the Company entered into a sale and purchase agreement with the sole shareholder of Yeap Medical Supplies Pte. Ltd. ("YMS") to acquire a net 96% equity interest in YMS in three tranches of 76%, 10% and 10%, respectively. The consideration for each tranche is determined based on the normalised profit after tax of YMS, subject to the terms and adjustments stipulated in the agreement. The acquisition has not yet been completed as at the date of authorisation of these financial statements.

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
[201906000013 (LLP0018825-LCA) & AF 0206]
Chartered Accountants
Kuala Lumpur

STATEMENT BY DIRECTORS

We, Lee Meng Chuan and Lim Sin Yin, being two of the Directors of Big Caring Group Bhd state that, in the opinion of the Directors, the Consolidated Financial Statements set out on pages 4 to 161 are drawn up so as to give a true and fair view of the financial position of the Group as at 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026 and of the financial performance and cash flows of the Group for the financial years ended 30 June 2023, 30 June 2024, 30 June 2025 and 30 June 2026 in accordance with Malaysian Financial Reporting Standards and IFRS Accounting Standards and Chapter 10, Part II Division 1: Equity of the Prospectus Guidelines issued by the Securities Commission Malaysia.

Signed on behalf of the Board of Directors in accordance with a resolution dated 14 October 2026.



....

Lee Meng Chuan **Lim Sin Yin**
Director Director

14. REPORTING ACCOUNTANTS' REPORT ON THE PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026

BDO

Tel : +603 2616 2888
Fax : +603 2616 3190 / 3191
www.bdo.my

Level 8
BDO @ Menara CenTARa
360 Jalan Tuanku Abdul Rahman
50100 Kuala Lumpur
Malaysia

The Board of Directors
Big Caring Group Bhd
8, Jalan Astana 3/KU2,
Bandar Bukit Raja,
41050 Klang,
Selangor Darul Ehsan.

Date: 14 October 2026

Our Ref: BDO/LKH/TKY2/TTXW/AS

Dear Sir/Madam,

Big Caring Group Bhd ("BCG" or the "Company") and its subsidiaries ("Group")
Report on Compilation of the Pro Forma Consolidated Statements of Financial Position as at 30 June 2026 (this "Report")

We have completed our assurance engagement to report on the compilation of the pro forma Consolidated Statements of Financial Position of the Group as at 30 June 2026 ("Pro Forma Consolidated Financial Position") prepared by the Board of Directors of the Company ("Board of Directors"). The Pro Forma Consolidated Financial Position together with the accompanying notes thereon, for which we have stamped for the purpose of identification, have been prepared for inclusion in the prospectus of the Company ("the Prospectus") in connection with the listing of and quotation for the entire enlarged issued share capital of the Company on the Main Market of Bursa Malaysia Securities Berhad ("the Listing").

The applicable criteria on the basis of which the Board of Directors has compiled the Pro Forma Consolidated Financial Position are described in the Notes thereon to the Pro Forma Consolidated Financial Position and are in accordance with the Prospectus Guidelines issued by the Securities Commission Malaysia ("Prospectus Guidelines") and the Guidance Note for Issuers of Pro Forma Financial Information issued by the Malaysian Institute of Accountants.

The Pro Forma Consolidated Financial Position have been compiled by the Board of Directors to illustrate the impact of the events or transactions as set out in the Notes thereon to the Pro Forma Consolidated Financial Position as at 30 June 2026 as if the events have occurred or the transactions have been undertaken on 30 June 2026. As part of this process, information about the financial position of the Group has been extracted by the Board of Directors from the Company's audited consolidated financial statements for the financial year ended 30 June 2026, on which an auditors' report dated on 14 September 2026 has been published.

Directors' Responsibility for the Pro Forma Consolidated Statements of Financial Position

The Board of Directors is solely responsible for compiling the Pro Forma Consolidated Financial Position on the basis as described in the Notes thereon to the Pro Forma Consolidated Financial Position and in accordance with the requirements of the Prospectus Guidelines and the Guidance Note for Issuers of Pro Forma Financial Information issued by the Malaysian Institute of Accountants.

BDO PLT (201906000013 (LLP0018825-LCA) & AF 0206), Chartered Accountants, a Limited Liability Partnership, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

Our Independence and Quality Management

We are independent of the Group in accordance with the *By-Laws (on Professional Ethics, Conduct and Practice)* of the Malaysian Institute of Accountants ("By-Laws") and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* ("IESBA Code"), and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and the IESBA Code.

The firm applies Malaysian Approved Standard on Quality Management 1 (ISQM 1), *Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services Engagements*, which requires the firm to design, implement and operate a system of quality management including policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Reporting Accountants' Responsibility

Our responsibility is to express an opinion, as required by the Prospectus Guidelines, about whether the Pro Forma Consolidated Financial Position have been compiled, in all material respects, by the Board of Directors on the basis described in the Notes thereon to the Pro Forma Consolidated Financial Position.

We conducted our engagement in accordance with International Standard on Assurance Engagements (ISAE) 3420, *Assurance Engagements to Report on the Compilation of Pro Forma Financial Information Included in a Prospectus,* issued by the International Auditing and Assurance Standards Board and adopted by the Malaysian Institute of Accountants. This standard requires that we comply with ethical requirements and plan and perform procedures to obtain reasonable assurance about whether the Board of Directors has compiled, in all material respects, the Pro Forma Consolidated Financial Position on the basis set out in the Notes thereon to the Pro Forma Consolidated Financial Position and in accordance with the requirements of the Prospectus Guidelines and with the Malaysian Institute of Accountants' Guidance Note for Issuers of Pro Forma Financial Information.

For purposes of this engagement, we are not responsible for updating or reissuing any reports or opinions on any historical financial information used in compiling the Pro Forma Consolidated Financial Position, nor have we, in the course of this engagement, performed an audit or review of the financial information used in compiling the Pro Forma Consolidated Financial Position. In providing this opinion, we do not accept any responsibility for such reports or opinions beyond that owed to those to whom those reports or opinions were addressed by us at the dates of their issue.

The purpose for inclusion of the Pro Forma Consolidated Financial Position in the Prospectus is solely to illustrate the impact of significant events or transactions on unadjusted financial information of the entity as if the events had occurred or the transactions had been undertaken at an earlier date selected for purposes of the illustration. Accordingly, we do not provide any assurance that the actual outcome of the events or transactions at that date would have been as presented.

Reporting Accountants' Responsibility (continued)

A reasonable assurance engagement to report on whether the Pro Forma Consolidated Financial Position have been compiled, in all material respects, on the basis of the applicable criteria involves performing procedures to assess whether the applicable criteria used by the Board of Directors in the compilation of the Pro Forma Consolidated Financial Position provide a reasonable basis for presenting the significant effects directly attributable to the events or transactions, and to obtain sufficient appropriate evidence about whether:

- the related pro forma adjustments give appropriate effect to those criteria; and
- the Pro Forma Consolidated Financial Position reflect the proper application of those adjustments to the unadjusted financial information.

The procedures selected depend on our judgement, having regard to our understanding of the nature of the Group, the events or transactions in respect of which the Pro Forma Consolidated Financial Position have been compiled, and other relevant engagement circumstances.

The engagement also involves evaluating the overall presentation of the Pro Forma Consolidated Financial Position.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Opinion

In our opinion, the Pro Forma Consolidated Financial Position have been compiled, in all material respects, on the basis set out in the Notes thereon to the Pro Forma Consolidated Financial Position and in accordance with the requirements of the Prospectus Guidelines and with the Malaysian Institute of Accountants' Guidance Note for Issuers of Pro Forma Financial Information.

Other Matters

This Report, as defined above has been prepared solely for the purpose stated above, in connection with the Listing. As such, this Report should not be used for any other purpose without our prior written consent. Neither the Firm nor any member or employee of the Firm undertakes responsibility arising in any way whatsoever to any party in respect of this Report contrary to the aforesaid purpose.

Yours faithfully,

BDO PLT
201906000013 (LLP0018825-LCA) & AF 0206
Chartered Accountants

Law Kian Huat
02855/06/2028 J
Chartered Accountant

14. REPORTING ACCOUNTANTS' REPORT ON THE PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026 *(Cont'd)*

1. INTRODUCTION

The Pro Forma Consolidated Financial Position of Big Caring Group Bhd ("Company") and its subsidiaries (collectively referred to as the "Group") as at 30 June 2026 ("Pro Forma Consolidated SOFP") together with the notes thereon, for which the Directors of the Company are solely responsible, have been prepared for illustrative purposes only for the purpose of inclusion in the prospectus in connection with the listing of and quotation for the entire enlarged issued share capital of the Company on the Main Market of Bursa Malaysia Securities Berhad ("Listing").

2. MATERIAL TRANSACTIONS

2.1 Subdivision of Shares

In connection with the Listing, the Company carried out a subdivision of one ordinary share in the Company ("Shares") into 40 Shares which was completed on 6 August 2026 ("Share Split"). Upon completion of the Share Split, the total number of Shares increased from 169,782,217 Shares to 6,791,288,680 Shares.

2.2 Listing exercise

In conjunction with and as an integral part of the Listing, the Company has proposed to undertake the following transactions:

2.2.1 Initial Public Offering ("IPO")


The Company will undertake an IPO comprising of a public issue of 590,547,000 new Shares ("Public Issue") and an offer for sale of up to 1,291,821,000 existing Shares at a retail price of RM1.08 per Share. All proceeds from the offer for sale will accrue entirely to the selling shareholders. The selling shareholders will bear their own professional fees, placement fees and other miscellaneous expenses in respect of the offer for sale.

Upon completion of the Listing, the enlarged issued share capital of 7,381,835,680 Shares will be listed and quoted on the Main Market of Bursa Malaysia Securities Berhad.

2.2.2 Utilisation of proceeds

The proceeds from the Public Issue of approximately RM637.8 million are expected to be utilised as follows:

Details of utilisation	Estimated timeframe for utilisation upon Listing	RM'000	Percentage of gross proceeds %
(i) Repayment of the Group's existing bank borrowings*	Within 3 months	570,731	89.5
(ii) Establishment of a new distribution centre#	Within 36 months	30,000	4.7
(iii) Estimated listing expenses^	Immediate	37,060	5.8
		637,791	100.0



i

2. MATERIAL TRANSACTIONS (continued)

2.2 Listing exercise (continued)

2.2.2 Utilisation of proceeds (continued)

* The facility agreement for the syndicated term loan for the Caring Pharmacy Group Sdn. Bhd. and Medispec (M) Sdn. Bhd. ("MEM") acquisitions stipulates that the IPO is an event which the Group will be required to immediately repay the term loan via the IPO proceeds. Out of the total outstanding term loan as at 30 June 2026 of RM831,668,440, RM431,331,000 will be repaid through the utilisation of the IPO proceeds, while the remaining balance has been restructured into long-term borrowings.

The Group has utilised revolving credit facilities to part fund the acquisition of MEM and Your Physio Sdn. Bhd. and for working capital purposes. Total outstanding revolving credit as at 30 June 2026 of approximately RM96,441,000 will be repaid through the utilisation of the IPO proceeds.


The Group has utilised revolving credit facilities to part fund the acquisition of new outlets and Yanling Holdings Sdn. Bhd. Total outstanding revolving credit as at 30 June 2026, approximately RM42,959,000 will be repaid through the utilisation of the IPO proceeds.

Establishment of a new distribution centre is not adjusted in the Pro Forma III to the Pro Forma Consolidated SOFP as at 30 June 2026, as the Group has yet to enter into any agreement or issue any purchase order in relation to the proceeds earmarked.

^ The estimated listing expenses of approximately RM37,060,000 to be borne by the Company comprise amongst others, professional fees, regulatory fees, underwriting commission, brokerage fees and placement fees. Upon completion of the Listing, a total of RM12,457,000 is assumed to be directly attributable to the issuance of new Shares in connection with the IPO and as such, will be debited against the share capital of the Company. The remaining expenses of RM11,867,000 will be expensed off to the statement of profit or loss and other comprehensive income. Approximately RM12,031,000 and RM705,000 had been incurred and charged to the profit or loss of the Group as at 30 June 2026 and 30 June 2025 respectively.

The utilisation of proceeds will have the following impact on the Pro Forma Consolidated SOFP as at 30 June 2026:

	Effects on Total Assets RM	Effects on Equity and Liabilities RM
Cash and bank balances	(595,054,621)	-
Share capital	-	(12,457,000)
Reserves	-	(11,867,000)
Borrowings	-	(570,730,621)
	(595,054,621)	(595,054,621)



ii

3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026

The Pro Forma Consolidated SOFP of the Group as at 30 June 2026 have been prepared for illustrative purposes only to show the effects on the audited consolidated statements of financial position of the Group as at 30 June 2026 based on the assumptions that the transactions set out in Note 2 had been effected on 30 June 2026, and should be read in conjunction with the notes accompanying to the Pro Forma Consolidated SOFP.

	Note	As at 30 June 2026 RM	Adjustments for Subdivision of Shares RM	Pro Forma I After Subdivision of Shares RM	Adjustments for Public Issue RM	Pro Forma II After Pro Forma I and Public Issue RM	Adjustments for Utilisation of Proceeds RM	Pro Forma III After Pro Forma II and Utilisation of Proceeds RM
ASSETS								
Non-current assets								
Property, plant and equipment		281,026,525	-	281,026,525	-	281,026,525	-	281,026,525
Investment properties		28,859,414	-	28,859,414	-	28,859,414	-	28,859,414
Intangible assets		1,345,612,837	-	1,345,612,837	-	1,345,612,837	-	1,345,612,837
Investments in associates		5,918,155	-	5,918,155	-	5,918,155	-	5,918,155
Right-of-use assets		389,540,253	-	389,540,253	-	389,540,253	-	389,540,253
Deferred tax assets		4,399,923	-	4,399,923	-	4,399,923	-	4,399,923
Other investments		551,509	-	551,509	-	551,509	-	551,509
		2,055,908,616	-	2,055,908,616	-	2,055,908,616	-	2,055,908,616
Current assets								
Inventories		911,806,309	-	911,806,309	-	911,806,309	-	911,806,309
Trade and other receivables		161,481,258	-	161,481,258	-	161,481,258	-	161,481,258
Current tax assets		1,352,913	-	1,352,913	-	1,352,913	-	1,352,913
Other investments		49,345,390	-	49,345,390	-	49,345,390	-	49,345,390
Cash and bank balances	3.3.1	296,626,602	-	296,626,602	637,790,760	934,417,362	(595,054,621)	339,362,741
		1,420,612,472	-	1,420,612,472	637,790,760	2,058,403,232	(595,054,621)	1,463,348,611
TOTAL ASSETS		3,476,521,088	-	3,476,521,088	637,790,760	4,114,311,848	(595,054,621)	3,519,257,227

Stamped for the purpose of Identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026 (continued)

	Note	As at 30 June 2026 RM	Adjustments for Subdivision of Shares RM	Pro Forma I After Subdivision of Shares RM	Adjustments for Public Issue RM	Pro Forma II After Pro Forma I and Public Issue RM	Adjustments for Utilisation of Proceeds RM	Pro Forma III After Pro Forma II and Utilisation of Proceeds RM
EQUITY AND LIABILITIES								
Equity attributable to owners of the parent								
Share capital	3.3.3	251,606,291	-	251,606,291	637,790,760	889,397,051	(12,457,000)	876,940,051
Reserves	3.3.3	204,444,886	-	204,444,886	-	204,444,886	(11,867,000)	192,577,886
		456,051,177	-	456,051,177	637,790,760	1,093,841,937	(24,324,000)	1,069,517,937
Non-controlling interests		103,079,204	-	103,079,204	-	103,079,204	-	103,079,204
TOTAL EQUITY		559,130,381	-	559,130,381	637,790,760	1,196,921,141	(24,324,000)	1,172,597,141
Non-current liabilities								
Deferred tax liabilities		174,804,021	-	174,804,021	-	174,804,021	-	174,804,021
Lease liabilities		286,960,088	-	286,960,088	-	286,960,088	-	286,960,088
Borrowings		587,358,414	-	587,358,414	-	587,358,414	(37,958,621)	549,399,793
Other payables		24,436,572	-	24,436,572	-	24,436,572	-	24,436,572
		1,073,559,095	-	1,073,559,095	-	1,073,559,095	(37,958,621)	1,035,600,474

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

14. REPORTING ACCOUNTANTS' REPORT ON THE PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026 *(Cont'd)*

3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026 (continued)

	Note	As at 30 June 2026 RM	Adjustments for Subdivision of Shares RM	Pro Forma I After Subdivision of Shares RM	Adjustments for Public Issue RM	Pro Forma II After Pro Forma I and Public Issue RM	Adjustments for Utilisation of Proceeds RM	Pro Forma III After Pro Forma II and Utilisation of Proceeds RM
EQUITY AND LIABILITIES (continued)								
Current liabilities								
Trade and other payables		954,593,744	-	954,593,744	-	954,593,744	-	954,593,744
Lease liabilities		77,675,390	-	77,675,390	-	77,675,390	-	77,675,390
Borrowings	3.3.2	772,886,996	-	772,886,996	-	772,886,996	(532,772,000)	240,114,996
Current tax liabilities		38,675,482	-	38,675,482	-	38,675,482	-	38,675,482
		1,843,831,612	-	1,843,831,612	-	1,843,831,612	(532,772,000)	1,311,059,612
TOTAL LIABILITIES		2,917,390,707	-	2,917,390,707	-	2,917,390,707	(570,730,621)	2,346,660,086
TOTAL EQUITY AND LIABILITIES		3,476,521,088	-	3,476,521,088	637,790,760	4,114,311,848	(595,054,621)	3,519,257,227
Net assets (RM)		559,130,381		559,130,381		1,196,921,141		1,172,597,141
Number of ordinary shares assumed in issue		169,782,217		6,791,288,680		7,381,835,680		7,381,835,680
Net assets attributable to equity holders per ordinary share (RM)		3.29		0.08		0.16		0.16

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

14. REPORTING ACCOUNTANTS' REPORT ON THE PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026 *(Cont'd)*

3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026 (continued)

3.1 Basis of preparation

The applicable criteria on the basis of which the Board of Directors of the Company ("Board of Directors") have compiled the Pro Forma Consolidated SOFP are as described below. The Pro Forma Consolidated SOFP are prepared in accordance with the requirements of the Prospectus Guidelines and the Guidance Note for Issuers of Pro Forma Financial Information issued by the Malaysian Institute of Accountants.

The Pro Forma Consolidated SOFP have been prepared based on the audited consolidated financial statements of the Company for the financial year ended 30 June 2026 which were prepared in accordance with MFRS Accounting Standards as issued by the Malaysian Accounting Standards Board ("MFRS Accounting Standards") and IFRS Accounting Standards issued by the International Accounting Standards Board ("IFRS Accounting Standards"), on which an auditors' report dated 14 September 2026 has been issued. The auditors' report was not subject to any qualification, modification or disclaimer of opinion.

The Pro Forma Consolidated SOFP have been prepared in a manner consistent with the format of the financial statements and the accounting policies adopted by the Group and adjusted for the events and transactions detailed in Note 2. The Pro Forma Consolidated SOFP does not include the effects of the adoption of MFRS Accounting Standards which are effective for the annual period beginning on 1 July 2026.

The Pro Forma Consolidated SOFP is not necessarily indicative of the financial position that would have been attained had the events and transactions detailed in Note 2 actually occurred at the respective dates. The Pro Forma Consolidated SOFP have been prepared for illustrative purposes only and do not include the effects of borrowing costs associated with the acquisition of assets by Big Pharmacy (Perak) Sdn. Bhd., a subsidiary of the Company, from eleven (11) companies under an asset purchase agreement completed on 1 September 2026 as the impact of such borrowing costs is immaterial and the acquisition is not material to the Group as a whole.

3.2 Pro Forma adjustments to the Pro Forma Consolidated SOFP

3.2.1 Pro Forma I


Pro Forma I incorporates the effects of the Subdivision of Shares as set out in Note 2.1.

3.2.2 Pro Forma II

Pro Forma II incorporates the effects of Pro Forma I and Public Issue as set out in Note 2.2.1.

3.2.3 Pro Forma III

Pro Forma III incorporates the effects of Pro Forma II and Utilisation of Proceeds as set out in Note 2.2.2.



3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026 (continued)

3.3 Notes to the Pro Forma Consolidated SOFP

3.3.1 Cash and bank balances

	RM
As at 30 June 2026, **Pro Forma I**	296,626,602
Adjustments for Public Issue	637,790,760
Pro Forma II	934,417,362
Adjustments for Utilisation of Proceeds	(595,054,621)
Pro Forma III	339,362,741

3.3.2 Borrowings

Non-current liabilities	
As at 30 June 2026, **Pro Forma I** and **Pro Forma II**	587,358,414
Adjustments for Utilisation of Proceeds	(37,958,621)
Pro Forma III	549,399,793
Current liabilities	
As at 30 June 2026, **Pro Forma I** and **Pro Forma II**	772,886,996
Adjustments for Utilisation of Proceeds	(532,772,000)
Pro Forma III	240,114,996

Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201905000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

3. PRO FORMA CONSOLIDATED SOFP AS AT 30 JUNE 2026 (continued)

3.3 Notes to the Pro Forma Consolidated SOFP (continued)

3.3.3 Share capital and reserves

	Share capital RM	Translation reserve RM	Reorganisation reserve RM	*Distributable* Retained earnings RM	Total attributable to owners of the parent RM	Non-controlling interests RM	Total equity RM
Balance as at 30 June 2026, **Pro Forma I**	251,606,291	18,800	(41,600)	204,467,686	456,051,177	103,079,204	559,130,381
Public Issue	637,790,760	-	-	-	637,790,760	-	637,790,760
Pro Forma II	889,397,051	18,800	(41,600)	204,467,686	1,093,841,937	103,079,204	1,196,921,141
Estimated listing expenses attributable to the Public Issue	(12,457,000)	-	-	-	(12,457,000)	-	(12,457,000)
Estimated other listing expenses	-	-	-	(11,867,000)	(11,867,000)	-	(11,867,000)
	(12,457,000)	-	-	(11,867,000)	(24,324,000)	-	(24,324,000)
Pro Forma III	876,940,051	18,800	(41,600)	192,600,686	1,069,517,937	103,079,204	1,172,597,141


Stamped for the purpose of identification only
14 OCT 2026
BDO PLT
(201906000013 (LLP0018825-LCA) & AF 0206)
Chartered Accountants
Kuala Lumpur

14. REPORTING ACCOUNTANTS' REPORT ON THE PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026 *(Cont'd)*

APPROVAL BY THE BOARD OF DIRECTORS

Approved and adopted by the Board of Directors of Big Caring Group Bhd in accordance with a resolution dated 14 October 2026.

Signed on behalf of the Board of Directors,



.....
Lee Meng Chuan
Director



.....
Lim Sin Yin
Director

Kuala Lumpur

15. ADDITIONAL INFORMATION

15.1 SHARE CAPITAL

(i) No securities will be allotted or issued on the basis of this Prospectus later than six months after the date of issue of this Prospectus.

(ii) As at the LPD, we have only one class of shares in our Company, namely ordinary shares, all of which rank equally with one another. There are no special rights attached to our Shares.

(iii) Save for the new Shares issued pursuant to (i) the ESOS as disclosed in Section 6.1.1 of this Prospectus; (ii) the Caring Acquisition to UPSB and IPSB as disclosed in Section 6.1.1 of this Prospectus; (iii) the Subdivision as disclosed in Section 6.1.2 of this Prospectus; and (iv) our Public Issue as disclosed in Section 4 of this Prospectus, no shares, warrants, options, convertible securities or uncalled capital of our Company and our Subsidiaries have been issued or are proposed to be issued during the Financial Years Under Review and from 1 July 2026 up to the date of this Prospectus.

(iv) As at the date of this Prospectus, save for our Issue Shares reserved for subscription by the Eligible Persons as disclosed in Section 4.1.2 of this Prospectus, there is currently no other scheme involving our employees and Directors in the share capital of our Company or any of our Subsidiaries.

(v) Save for the put and call options as disclosed in Section 6.3 of this Prospectus, none of the share capital of our Company or any of our Subsidiaries is under option or agreed conditionally or unconditionally to be put under option.

(vi) Save as disclosed in this Prospectus, and save as provided for under our Constitution as reproduced in Section 15.2 below and the Act, there are no other restrictions on the holding or voting or transfer of our Shares.

15.2 EXTRACTS OF OUR CONSTITUTION

The following provisions are reproduced from our Constitution and are qualified in its entirety by reference to our Constitution and by applicable law. The words, terms and expressions appearing in the following provisions shall bear the same meanings used in our Constitution unless they are otherwise defined or the context otherwise requires.

15.2.1 Remuneration of Directors

The provisions in our Constitution dealing with remuneration of Directors are as follows:

Clause 93 - Directors' remuneration

The fees and benefits payable to the Directors including compensation for loss of employment of a Director or a former Director of the Company shall be subject to annual Members approval in a general meeting and shall (unless such resolution otherwise provides) be divisible among the Directors as they may agree PROVIDED ALWAYS that:

(a) salaries payable to executive Directors may not include a commission on or percentage of turnover; and

(b) fees payable to non-executive Directors shall be a fixed sum and not by a commission on or percentage of profits or turnover.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 94 - Reimbursement of expenses

94.1 The Directors shall be paid all their travelling and other expenses properly and necessarily expended by them in and about the business of the Company including their travelling and other expenses incurred in attending board meetings or of any committee of the Directors or general meetings or otherwise howsoever in or about the business of the Company in the course of the performance of their duties as Directors.

94.2 If by arrangement with the Directors, any Director shall perform or render any special duties or services outside his ordinary duties as a Director in particular without limiting to the generality of the foregoing if any Director being willing shall be called upon to perform extra services or to make any special efforts in going or residing away from his usual place of business or residence for any of the purposes of the Company or in giving special attention to the business of the Company as a member of a committee of Directors, the Company may remunerate the Director so doing a special remuneration in addition to his Director's fees and such special remuneration may be by way fixed sum or otherwise as may be arranged.

Clause 115 - Alternate Director

115.1 A Director may appoint any person to act as his alternate PROVIDED ALWAYS that:

(a) such person is not an existing director of the Company;

(b) such person does not act as an alternate for more than one Director of the Company;

(c) the appointment is approved by a majority of the other members of the Board; and

(d) any fee paid by the Company to an alternate director shall be deducted from that Director's remuneration,

and at his discretion by way of a notice to the Company to remove such alternate Director from office.

115.2 An alternate Director shall (except as regards power to appoint an alternate Director and remuneration) be subject in all respects to the terms and conditions existing with reference to the other Directors and shall be entitled to receive notices of all meetings of the Directors and to attend, speak and vote at any such Director's meeting at which his appointer is not present.

115.3 Any appointment or removal of an alternate Director may be made by cable, telegram, facsimile, telex or in any other manner approved by the Directors. Any cable or telegram shall be confirmed as soon as possible by letter but may be acted upon by the Company meanwhile.

115.4 If a Director making any such appointment as aforesaid shall cease to be a Director (otherwise than by reason of vacating his office at a general meeting of the Company at which he is re-elected), the person appointed by him as an alternative Director shall thereupon cease to be an alternate Director.

115.5 An alternate Director shall not be taken into account in reckoning the minimum or maximum number of Directors allowed for the time being but he shall be counted for the purpose of reckoning whether a quorum is present at any meeting of the Directors attended by him at which he is entitled to vote.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 117 - Remuneration of Managing Director

The remuneration of a managing director or managing directors shall be fixed by the Directors and may be by way of salary or commission or participation in profits or otherwise or by any or all of these modes but shall not include a commission on or percentage of turnover but it may be a term of his appointment that he shall receive pension, gratuity, or other benefits upon his retirement.

15.2.2 Voting and borrowing powers of Directors

The provisions in our Constitution dealing with voting powers of our Directors in the proposals, arrangements, or contracts in which they are interested in and the borrowing powers exercisable by them and how such borrowing powers can be varied are as follows:

Clause 96 - General power of the Company vested in Directors

The business of the Company shall be managed by the Directors who may, in addition to the powers and authorities conferred upon them by this Constitution or otherwise, pay all expenses incurred in promoting and registering the Company, and exercise all such powers of the Company as are not, by the Act or this Constitution, required to be exercised by the Company in a general meeting, subject nevertheless to this Constitution, the provisions of the Act, and to such resolutions (not being inconsistent with this Constitution or the Act) as may be prescribed by the Company in a general meeting. However, no resolution made by the Company in a general meeting shall invalidate any prior act of the Directors that would have been valid if that resolution had not been made or passed. The general powers given by this Clause shall not be limited or restricted by any special authority or power given to the Directors by any other Constitution. Any sale or disposal by the Directors of a substantial portion of the Company's main undertaking or property shall be subject to the prior approval of shareholders in general meeting.

Clause 97 - Limitation on Directors' powers

The Directors shall not without the prior approval of the Company in a general meeting:

(a) exercise any power of the Company to issue shares unless otherwise permitted under the Act;

(b) carry into effect any proposal or execute any transaction for the acquisition of an undertaking or property of a substantial value, or the disposal of a substantial portion of the Company's undertaking or property; and

(c) subject to the Act, enter into any arrangement or transaction with a Director of the Company or its holding company or with a person connected with such a Director, to acquire from or dispose to such a Director or person, any shares or non-cash assets of the requisite value.

Clause 98 - Directors' borrowing powers

The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property and uncalled capital, or any part thereof and to issue debentures and other securities whether outright or as security for any debt, liability or obligation of the Company or subsidiary company or of any related third party subject to the law, including but not limited to the provisions of the Act and the Listing Requirements, as they may think fit.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 111 - Chairman of the Directors' meeting to have a casting vote

111.1 Subject to this Constitution any question arising at any meeting of the Directors shall be decided by a majority of votes, each Director having one vote and a determination by a majority of the Directors shall for all purposes be deemed a determination of the Directors.

111.2 In case of an equality of votes, the Chairman of the meeting shall have a second or casting vote except where only two Directors form a quorum and only such Directors are present at the meeting or where only two Directors are competent to vote on the question at issue, in which case the Chairman shall not have a casting vote and the resolution shall be deemed not to have been passed, without affecting any other businesses at the meeting.

Clause 113 - Disclosure of interest and restriction on discussion and voting

Every Director shall declare his interest in the Company and his interest in any contract or proposed contract with the Company as may be required by law. Subject to Section 222 of the Act, a Director shall not participate in any discussion or vote in respect of any contract or proposed contract or arrangement in which he has directly or indirectly an interest and if he shall do so his vote shall not be counted. A Director shall, notwithstanding his interest, be counted in the quorum for any meeting where a decision is to be taken upon any contract or proposed contract or arrangement in which he is in any way interested PROVIDED ALWAYS that he has complied with Section 221 of the Act and all other relevant provisions of the Act and this Constitution.

Clause 114 - Power to vote

Without prejudice to the provisions of any other Constitution, the Act and the Listing Requirements, a Director may vote in respect of:

(a) any arrangement for giving the Director himself or any other Director any security or indemnity in respect of money lent by him to or obligations undertaken by him for the benefit of the Company; or

(b) any arrangement for the giving by the Company of any security to a third party in respect of a debt or obligation of the Company for which the Director himself or any other Director has assumed responsibility in whole or in part under a guarantee or indemnity or by the deposit of security.

Clause 115 - Alternate Director

115.2 An alternate Director shall (except as regards power to appoint an alternate Director and remuneration) be subject in all respects to the terms and conditions existing with reference to the other Directors and shall be entitled to receive notices of all meetings of the Directors and to attend, speak and vote at any such Directors' meeting at which his appointer is not present.

Clause 119 - Power of Directors to establish committees

119.1 The Directors may delegate any of their powers to committees consisting of such members as they think fit, and may from time to time revoke such delegation or alter or vary any of such powers and discharge any such committee in whole or in part. Any committee so formed shall in the exercise of the powers so delegated, conform to any terms, conditions, restrictions and regulations that may from time to time be imposed on it by the Directors.

15. ADDITIONAL INFORMATION *(Cont'd)*

15.2.3 Transfer of Securities

The provisions in our Constitution dealing with transfer of shares are as follows:

Clause 31 - Transfer of Deposited Securities

31.1 Subject to the restriction imposed by this Constitution, the Listing Requirements, the Central Depositories Act and the Rules (with respect to transfer of Deposited Security), the transfer of any listed security or class of listed security of the Company, shall be by way of book entry by the Depository in accordance with the Rules and, notwithstanding Sections 105, 106 or 110 of the Act, but subject to subsection 148(2) of the Act and any exemption that may be made from compliance with subsection 148(1) of the Act, the Company shall be precluded from registering and effecting any transfer of the listed securities.

31.2 The Depository may, in its absolute discretion, refuse to register any transfer Deposited Security where the reason for transfer does not fall within any approved reasons provided for in the Rules or does not comply with the Rules.

31.3 Subject to the provisions of the Act, the Listing Requirements and the Rules, there shall be no restriction on the transfer of fully paid securities except where required by law or transfer is in respect of the partly paid Shares in respect of which a call has been made and is unpaid.

Clause 32 - Transfer of Shares (Non-Deposited Securities)

32.1 Subject to the provisions of the Act and this Constitution, any Member may transfer all or any of his Shares (which are not Deposited Securities) by a duly executed and stamped instrument in writing. The instrument shall be executed by or on behalf of the transferor and the transferor shall remain the holder of the Shares transferred until the transfer is registered and the name of the transferee is entered in the Register of Members in respect thereof.

32.2 The instrument of transfer must be left for registration at the Office of the Company together with such fee not exceeding RM1.00 as the Directors from time to time may require accompanied by the certificate of the Shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer, and thereupon the Company shall subject to the powers vested in the Directors by this Constitution register the transferee as a shareholder and retain the instrument of transfer.

32.3 Subject to the Act, the Directors may in their discretion through passing of a resolution to decline or delay registering any transfer of Shares (which is non-Deposited Security) to a person of whom they do not approve, whether or not being fully paid Shares or Shares on which the Company has a lien, within 30 days from the date of receipt the instrument of transfer.

32.4 Neither the Company nor its Directors nor any of its officers shall incur any liability for any transfer of shares apparently made by sufficient parties, although the same may, by reason of any fraud or other cause not known to the Company or its Directors or other officers be legally inoperative or insufficient to pass the property in the Shares proposed or professed to be transferred and although transferred, the transfer may, as between the transferor and transferee be liable to be set aside and notwithstanding that the Company may have notice of such transfer. And in every such case, the transferee, his executors, administrators and assignees alone shall be entitled to be recognised as the holder of such Shares and the previous holder shall so far as the Company is concerned, be deemed to have transferred his whole title hereto.

32.5 Subject to any written law, no Shares shall in any circumstances be transferred to any infant, bankrupt or person of unsound mind.

32.6 Subject to the provisions of this Constitution, the Directors may at any time after the allotment of any Share but before any person has been entered in the Register of Members as the holder recognise a renunciation of any Shares by the allottee thereof in favour of some other person and may accord to any allottee of a Share a right to effect such renunciation on such terms and conditions as the Directors may determine.

32.7 All instruments of transfer which shall be registered shall be retained by the Company but any instrument of transfer which the Directors may decline or refuse to register shall on demand be returned to the person depositing the same. All powers of attorney granted by members for purpose, inter-alia, of transferring Shares which may be lodged, produced or exhibited to the Company or any of its proper officers shall as between the Company and the grantor of such powers be taken and deemed to continue and remain in full force and effect and the same may be acted upon until such time as express notice in writing of the revocation of the same shall have been given and lodged at the registered office of the Company.

15.2.4 Changes in capital and variation of class rights, preferences and restrictions attached to each class of securities relating to voting, dividend, liquidation and any rights

The provisions in our Constitution pertaining to the changes in capital and variation of class rights, preferences and restrictions attached to each class of securities relating to voting, dividend, liquidation and any rights are as follows:

Clause 8 – Power to issue of shares

Without prejudice to any special rights previously conferred on the holders of any existing Shares or class of Shares, but subject to the Act, the Listing Requirements, any other statutory requirements, and to conditions, restrictions and limitations expressed in this Constitution, the Directors may allot, issue or grant rights to subscribe for or otherwise dispose of unissued shares in the Company to such persons, at such time and on such terms and conditions, with such preferred, deferred or other special rights or such restrictions, whether in regard to dividend, voting, return of capital or otherwise as they deem proper, but the Directors in making any such issue of shares shall comply with the following conditions:

(a) No Shares shall be issued at a discount except in compliance with the provisions of the Act and Listing Requirements;

(b) The rights attaching to shares of a class other than ordinary shares, shall be expressed in this Constitution, the respective term sheets and/or subscription agreement;

(c) No issue of Shares shall be made without the prior approval of the members of the Company in a general meeting; and

(d) No Director shall participate in a scheme that involves a new issuance of Shares or other convertible securities to employees unless the Members in a general meeting have approved the specific allotment to be made to such Director and such Director must not vote on the resolution approving the said allotment.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 9 - Rights of preference shareholders

9.1 Subject to the Act, the Listing Requirements and term sheet and/or subscription agreement, any other relevant authority for the time being in force, and the conditions, restrictions and limitations expressed in this Constitution, any preference shares may, with the sanction of an ordinary resolution, be issued on the terms that they are, or at the option of the Company are liable, to be redeemed and the Company has the power to issue such preference capital ranking equally with, or in priority to preference shares already issued.

9.2 Subject to the Act, the Listing Requirements and term sheet and/or subscription agreement, a holder of preference shares must have a right to vote in meetings of holders of their respective class of shares in each of the following circumstances:

(a) when the dividend or part of the dividend on the share is in arrears for more than six months;

(b) on a proposal to reduce the Company's share capital;

(c) on a proposal for the disposal of the whole of the Company's property, business and undertaking;

(d) on a proposal that affects the rights attached to the preference shares;

(e) on a proposal to wind up the Company;

(f) during the winding up of the Company; and

(g) the Company shall not, without the consent of the existing preference members at a class meeting, issue further preference capital ranking in priority above preference share already issued.

9.3 Subject to this Constitution and/or term sheet and/or subscription agreement, a holder of preference shares shall be entitled to the same rights as a holder of ordinary shares in relation to receiving notices, reports, audited financial statements, and attending general meetings.

9.4 The Company shall not allot any preference shares or convert any issued shares into preference shares unless in accordance with the right of the Members with respect to repayment of capital, participation in surplus assets and profits, cumulative or non-cumulative dividends, voting and priority of payment of capital and dividend in relation to other Shares and other classes of preference shares as set out in this Constitution and/or term sheet and/or subscription agreement.

Clause 10 - Repayment of preference capital

The repayment of preference share capital, other than redeemable preference shares or any alteration of preference shareholders' rights, shall only be made pursuant to a special resolution of the preference shareholders concerned PROVIDED ALWAYS that where the necessary majority for such a special resolution is not obtained at the class meeting, consent in writing obtained from the holders of three-fourths (3/4) of the preference capital concerned within two months of the class meeting shall be as valid and effectual as a special resolution carried at the meeting.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 11 - Modification of class rights

Subject to the provisions of the Act, if at any time the share capital is divided into different classes of Shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may, whether or not the Company is being wound up, be varied or abrogated with the consent in writing of the holders of three-fourths (3/4) of the issued shares of that class or with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of that class. To every such separate general meeting the provisions of this Constitution relating to general meetings shall *mutatis mutandis* apply so that the necessary quorum shall be two persons at least holding or representing by proxy one-third of the issued shares of the class (excluding any shares of that class held as treasury shares) and that any holder of shares of the class present in person or by proxy may demand a poll. To every such special resolution the provisions of Section 292 of the Act shall apply with such adaptations as are necessary.

Clause 12 - Alteration of rights by issuance of new Shares

The rights conferred upon the holders of the Shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the Shares of that class, be deemed to be varied by the creation or issue of further Shares ranking as regards participation in the profits or assets of the Company in some or in all respects *pari passu* therewith.

Clause 52 - Power to increase capital

Subject to the Act, this Constitution, the Central Depositories Act, the Rules, the Listing Requirements, any other relevant authority for the time being in force, and the conditions, restrictions and limitations expressed in this Constitution, the Company may from time to time, whether all the shares for the time being authorised shall have been issued or all the shares for the time being issued shall have been fully called up or not, by ordinary resolution increase its share capital by the creation and issue of new shares, such new capital to be of such amount and to be divided into shares of such respective amounts and to carry such rights or to be subject to such conditions or restrictions in regard to dividend, return of capital or otherwise as the Company by the resolution authorising such increase may direct.

Clause 53 - Issue of new Shares to the Member

Subject to any direction to the contrary that may be given by the Company in general meeting, all new Shares or other convertible securities shall, before issue, be offered to such persons as at the date of the offer are entitled to receive notices from the Company of general meetings in proportion as nearly as the circumstances admit, to the amount of the existing Shares or securities to which they are entitled. The offer shall be made by notice specifying the number of Shares or securities offered, and limiting a time within which the offer, if not accepted, will be deemed to be declined, and, after the expiration of that time or on the receipt of an intimation from the person to whom the offer is made that he declines to accept the Shares or securities offered, the Directors may dispose of those Shares or securities in such manner as they think most beneficial to the Company. The Directors may likewise also dispose of any new Shares or securities which (by reason of the ratio which the new Shares or securities bear to Shares or securities held by persons entitled to an offer of new Shares or securities) cannot, in the opinion of the Directors, be conveniently offered under this Constitution.

15. ADDITIONAL INFORMATION *(Cont'd)*

Clause 54 - Ranking of new Shares

Except so far as otherwise provided by the conditions of issue in this Constitution, any share capital raised by the creation of new Shares shall be considered as part of the original share capital of the Company and shall be subject to the same provisions with reference to the allotments, the payment of calls and instalments, lien, transfer, transmission, forfeiture and otherwise as the original share capital.

Clause 55 - Power to alter capital

The Company may by ordinary resolution and subject to the Act, the Central Depositories Act, the Rules, the Listing Requirements, any other relevant authority for the time being in force, and the conditions, restrictions and limitations expressed in this Constitution:

55.1 consolidate and divide all or any of its share capital into Shares of larger amount than its existing Shares;

55.2 subdivide its share capital or any part thereof into Shares of smaller amount, subject nevertheless to the provisions of the Act and so that as between the resulting Shares, one or more of such shares may, by the resolution by which such subdivision is effected, be given any preference or advantage as regards dividend, return of capital, voting or otherwise over the others or any other of such Shares;

55.3 cancel Shares which at the date of the passing of the resolution in that behalf have not been taken or agreed to be taken by any person or which have been forfeited and diminish the amount of its share capital by the amount of the shares so cancelled; or

55.4 convert and/or reconvert and/or re-classify any class of Shares into any other class of Shares.

Clause 56 - Power to reduce capital

The Company may by special resolution, subject to the provisions of the Act, the Central Depositories Act, the Rules, the Listing Requirements, any other relevant authority for the time being in force, and the conditions, restrictions and limitations expressed in this Constitution, reduce its share capital, any capital redemption reserve fund or any reserve account in any manner authorised by the Act and subject to any consent required by law.

15.3 DEPOSITED SECURITIES AND RIGHTS OF DEPOSITORS

As our Shares are proposed for quotation on the Official List, such Shares must be prescribed as shares required to be deposited with Bursa Depository. Upon such prescription, a holder of our Shares must deposit his Shares with Bursa Depository on or before the date fixed, failing which our Share Registrar will be required to transfer his Shares to the Minister of Finance and such Shares may not be traded on Bursa Securities.

Dealing in our Shares deposited with Bursa Depository may only be effected by a person having a securities account with Bursa Depository ("**Depositor**") by means of entries in the securities account of that Depositor.

A Depositor whose name appears in the Record of Depositors maintained by Bursa Depository in respect of our Shares shall be deemed to be a shareholder of our Company and shall be entitled to all rights, benefits, powers and privileges and be subject to all liabilities, duties and obligations in respect of, or arising from, such Shares.

15. ADDITIONAL INFORMATION *(Cont'd)*

15.4 LIMITATION ON THE RIGHT TO HOLD SECURITIES AND/OR EXERCISE VOTING RIGHTS

Subject to Section 15.2 which have been reproduced above from our Constitution and Section 15.3 of this Prospectus, there is no limitation on the right to own our Shares, including any limitation on the right of a non-resident or non-Malaysian shareholder to hold or exercise voting rights on our Shares which is imposed by Malaysian law or by our Constitution.

15.5 REPATRIATION OF CAPITAL, REMITTANCE OF PROFIT AND TAXATION

As at the LPD, we are not subject to governmental laws, decrees, regulations and/or other requirements which may affect the repatriation of capital and remittance of profits by our Company to our shareholders, and our Subsidiaries to our Company.

(i) Malaysia

Generally, dividends distributed by Malaysian companies are not subject to further Malaysian income tax under the single-tier dividend system, and no withholding tax is imposed on such dividends. However, effective from the year of assessment 2025, a 2.0% dividend tax will apply on annual dividend income exceeding RM100,000 received by both resident and non-resident individual shareholders.

Gains from disposal of listed shares are generally not subject to capital gains tax in Malaysia. However, where a company carries on a business of trading in shares as its principal activity, profits derived therefrom would be taxable as business income at the prevailing corporate tax rate.

(ii) Singapore

Singapore adopted the one-tier corporate tax system from 1 January 2003. Under the one-tier corporate tax system, the tax paid by a Singapore resident company on its corporate profits is a final tax. Dividends payable by the Singapore resident company are exempt from Singapore income tax in the hands of the shareholders, regardless of whether the shareholder is a company or an individual and whether or not the shareholder is a Singapore tax resident. There is no withholding tax on the dividend payments to both resident and non-resident shareholders of Singapore.

15.6 MATERIAL CONTRACTS

Save as disclosed below, our Group has not entered into any material contracts that are not in the ordinary course of our Group's business during the Financial Years Under Review, and from 1 July 2026 up to the date of this Prospectus:

(i) Share purchase agreement dated 17 January 2023 in respect of the acquisition of 70.0% equity interest in Ting Pharmacy

On 17 January 2023, BP (Sarawak), our subsidiary, (as purchaser) entered into a share purchase agreement with Susie Ting Fung Yin, Alex Chin Yang Chung and John Ting Meng Hong (as vendors) (collectively, "**Ting Pharmacy Vendors**") to acquire 700,000 ordinary shares in Ting Pharmacy, representing 70.0% equity interest in Ting Pharmacy, for a final adjusted total cash consideration of RM27,964,176.00. The acquisition was completed and the shares were transferred on 22 August 2023.

15. ADDITIONAL INFORMATION *(Cont'd)*

(ii) Sale and purchase agreement dated 15 August 2023 in respect of the acquisition of 60.0% equity interest in Yanling Holdings

On 15 August 2023, Yanling Assets, our subsidiary, (as purchaser) entered into a sale and purchase agreement with Goh Ching Yang and Sin Laik Choo (as vendors) to acquire 60 ordinary shares in Yanling Holdings, representing 60.0% equity interest in Yanling Holdings, for a total cash consideration of RM63.0 million. The acquisition was completed and the shares were transferred on 30 October 2023.

(iii) Sale and purchase agreement dated 21 September 2023 in respect of the acquisition of 100.0% equity interest in Caring

On 21 September 2023, our Company (as purchaser) entered into a sale and purchase agreement with Convenience Shopping (Sabah) Sdn Bhd and Motivasi Optima Sdn Bhd (as vendors) to acquire 217,706,400 ordinary shares in Caring, representing 100.0% equity interest in Caring, for a total cash consideration of RM888,330,927.00. The acquisition was completed and the shares were transferred on 23 January 2024.

(iv) Share purchase agreement dated 24 January 2025 in respect of the acquisition of 89.3% equity interest in Medispec

On 24 January 2025, our Company (as purchaser) entered into a share purchase agreement with Premier Vitality Sdn Bhd, Heng Thin Fook and Ong Lian Hong (as vendors) to acquire 892,572 ordinary shares in Medispec, representing 89.3% equity interest in Medispec, for a total cash consideration of RM249,441,000.00. The acquisition was completed and the shares were transferred on 21 March 2025.

(v) Sale and purchase agreement dated 20 March 2025 in respect of the acquisition of 57.1% equity interest in Your Physio

On 20 March 2025, our Company (as purchaser) entered into a sale and purchase agreement with Tan Kuen Wei, Lee Choon Yik and Cheen Lee Pheng (as vendors) to acquire 180,570 ordinary shares in Your Physio, representing 57.1% equity interest in Your Physio, for a total cash consideration of RM32,760,000.00. The acquisition was completed and the shares were transferred on 16 June 2025.

(vi) Sale and purchase agreement dated 18 July 2025 in respect of the acquisition of 30.0% equity interest in Ting Pharmacy

On 18 July 2025, BP (Sarawak), our subsidiary, (as purchaser) entered into a share purchase agreement with the Ting Pharmacy Vendors (as defined in Section 15.6(i) of this Prospectus above) to acquire 300,030 ordinary shares in Ting Pharmacy, representing 30.0% equity interest in Ting Pharmacy, for a total cash consideration of RM17,522,630.00. The acquisition was completed and the shares were transferred on 11 September 2025.

(vii) Share sale agreement dated 21 January 2026 in respect of the acquisition of 29.0% equity interest in Wellings Pharmacy

On 21 January 2026, CPRM, our subsidiary, (as purchaser) entered into a share sale agreement with Mah Choon Leng (as vendor) to acquire 290,000 ordinary shares in Wellings Pharmacy, representing 29.0% equity interest in Wellings Pharmacy, for a total cash consideration of RM36,116,800.00. The acquisition was completed and the shares were transferred on 13 March 2026.

15. ADDITIONAL INFORMATION *(Cont'd)*

(viii) 12 asset sale agreements dated 15 May 2023 in respect of the acquisition of stocks, fixtures and fittings

On 15 May 2023, Ting Pharmacy, our subsidiary, (as purchaser) entered into 12 asset sale agreements with the following operating entities (as vendors) owned or otherwise controlled, singly or collectively, directly or indirectly, by the Ting Pharmacy Vendors (as defined in Section 15.6(i) of this Prospectus above) for the acquisition of stocks, fixtures and fittings of these operating entities:

(a) Antares Pharma Sdn Bhd, for a total cash consideration of RM5,955,730.00;

(b) Antares Pharma (Betong) Sdn Bhd, for a total cash consideration of RM324,582.00;

(c) Antares Pharma (Bintulu) Sdn Bhd, for a total cash consideration of RM498,075.00;

(d) Antares Pharma (Limbang) Sdn Bhd, for a total cash consideration of RM511,238.00;

(e) Antares Pharma (MJC) Sdn Bhd, for a total cash consideration of RM384,392.00;

(f) Antares Pharma (Mukah) Sdn Bhd, for a total cash consideration of RM352,528.00;

(g) Antares Pharma (Samarindah) Sdn Bhd, for a total cash consideration of RM337,274.00;

(h) Antares Pharma (Saratok) Sdn Bhd, for a total cash consideration of RM339,235.00;

(i) Antares Pharma (Sarikei) Sdn Bhd, for a total cash consideration of RM498,013.00;

(j) Sejingkat Pharmacy, for a total cash consideration of RM210,444.00;

(k) Antares Pharma (Sri Aman) Sdn Bhd, for a total cash consideration of RM482,496.00; and

(l) Ting Pharmacy Sdn Bhd, for a total cash consideration of RM453,166.00.

The acquisitions were completed on 18 July 2023.

(ix) Assets transfer agreement dated 26 April 2023 in respect of the acquisition of stocks, fixtures and fittings

On 26 April 2023, BP (Perak), our subsidiary (as purchaser) entered into an assets transfer agreement with Caribbean Healthcare Sdn Bhd (as vendor) for the acquisition of stocks, fixtures and fittings of Caribbean Healthcare Sdn Bhd, for a total cash consideration of RM7,191,484.00. BP (Perak) has obtained control over the stocks, fixtures and fittings of Caribbean Healthcare Sdn Bhd on 9 April 2023.

(x) Shareholders' agreement dated 15 August 2023 in respect of Yanling Holdings

On 15 August 2023, Yanling Assets, our subsidiary, entered into a shareholders' agreement with Goh Ching Yang and Sin Laik Choo to govern the relationship as shareholders of Yanling Holdings whereby Yanling Assets holds 60.0% of the equity interest in Yanling Holdings and Goh Ching Yang and Sin Laik Choo hold the remaining 40.0% of the equity interest in equal proportions.

15. ADDITIONAL INFORMATION *(Cont'd)*

(xi) Shareholders' agreement dated 27 January 2025 in respect of Medispec

On 27 January 2025, our Company entered into a shareholders' agreement with Virapatna Thakolsri to govern the relationship as shareholders of Medispec, and the management and operations of Medispec whereby our Company holds 89.3% of the equity interest in Medispec and Virapatna Thakolsri holds the remaining 10.7% of the equity interest in Medispec.

(xii) Asset purchase agreement dated 26 May 2026 in respect of the acquisition of businesses and assets

On 26 May 2026, BP (Perak), our subsidiary (as purchaser) entered into an asset purchase agreement with the following operating entities (as vendors) owned by Chuah Chong Ee and Tan Pei Wen for the acquisition of businesses and assets of these operating entities, for a total cash consideration of RM32,500,000.00:

(a) Icare RX Holdings Sdn Bhd;

(b) Icare RX Sdn Bhd;

(c) Icare RX (Kamunting) Sdn Bhd;

(d) Icare RX (Parit Buntar) Sdn Bhd;

(e) Icare RX (Simpang) Sdn Bhd;

(f) Icare RX (Aulong) Sdn Bhd;

(g) Icare RX (Kota Kinabalu) Sdn Bhd;

(h) Pharmorix (M) Sdn Bhd;

(i) Icare RX (Gunung Rapat) Sdn Bhd;

(j) Icare RX (Pokok Assam) Sdn Bhd; and

(k) Icare RX (Bagan Serai) Sdn Bhd.

Subsequently, on 6 July 2026, BP (Perak), our subsidiary (as purchaser) entered into an asset purchase agreement with Icare Physiotherapy Sdn Bhd (as vendor) owned by Chuah Chong Ee and Tan Pei Wen for the acquisition of businesses and assets of Icare Physiotherapy Sdn Bhd, for a total cash consideration of RM20,000.00.

The acquisitions were completed on 1 September 2026.

(xiii) Sale and purchase agreement dated 14 October 2026

On 14 October 2026, our Company (as purchaser) entered into a sale and purchase agreement with Yeap Chee Kiong, Victor (Ye Zhiqiang, Victor) (as vendor) to acquire 96,000 ordinary shares in YMS, representing 96.0% equity interest in YMS in three tranches of 76.0%, 10.0%, and 10.0%, respectively. The consideration for each tranche is determined based on the normalised profit after tax of YMS, subject to the terms and adjustments stipulated in the agreement. The acquisition is pending completion as at the LPD. Please refer to Section 7.3.1 of this Prospectus for further details of the YMS Acquisition.

(xiv) Retail underwriting agreement dated 14 October 2026

Retail Underwriting Agreement dated 14 October 2026 entered into between our Company, our Joint Managing Underwriters and our Joint Underwriters for the underwriting of 267,638,000 Issue Shares under the Retail Offering, subject to the clawback and reallocation provisions as set out in Section 4.1.3 of this Prospectus and upon the terms and subject to the conditions of the Retail Underwriting Agreement. Details of the underwriting commission are set out in Section 4.6.2 of this Prospectus.

(xv) Master cornerstone placement agreement dated 14 October 2026

Master Cornerstone Placement Agreement dated 14 October 2026 entered into between our Company, the Selling Shareholders, our Joint Global Coordinators, our Joint Bookrunners and the Cornerstone Investors, under which the Cornerstone Investors agree to acquire an aggregate of 665,500,000 IPO Shares, representing approximately 9.0% of our enlarged issued Shares, pursuant to the Institutional Offering at the Institutional Price on the terms and subject to the conditions as set out in the Master Cornerstone Placement Agreement and the relevant individual cornerstone placement agreements.

(xvi) Lock-up agreement dated 14 October 2026 in relation to our IPO and Listing

Lock-up agreement dated 14 October 2026 entered into between our Company and our Joint Bookrunners in relation to the lock-up agreement for our IPO and Listing, details of which are set out in Section 4.7.3 of this Prospectus.

15.7 MATERIAL LITIGATION

As at the LPD, our Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, including those relating to bankruptcy, receivership or similar proceedings which has a material adverse effect on the business or financial position of our Group, and our Directors confirm that there are no legal proceedings pending or threatened, or of any fact likely to give rise to any proceedings which might materially and adversely affect our financial or business position.

15.8 CONSENTS

The Joint Principal Advisers, Joint Global Coordinators, Joint Bookrunners, Joint Managing Underwriters, Joint Underwriters, legal advisers, Share Registrar, Issuing House and company secretaries have given their respective written consents for the inclusion in this Prospectus of their names in the form and context in which their names appear before the issuance of this Prospectus, and such consents have not subsequently been withdrawn.

Our Auditors and Reporting Accountants have given written consent for the inclusion in this Prospectus of its name, Accountants' Report, the Reporting Accountants' report on the pro forma consolidated statement of financial position as at 30 June 2026 and all references thereto in the form and context in which they are contained in this Prospectus before the issuance of this Prospectus, and such consent has not subsequently been withdrawn.

Our IMR has given its written consent for the inclusion in this Prospectus of its name, the IMR Report and all references thereto in the form and context in which they are contained in this Prospectus before the issuance of this Prospectus, and such consent has not subsequently been withdrawn.

15. ADDITIONAL INFORMATION *(Cont'd)*

15.9 DOCUMENTS AVAILABLE FOR INSPECTION

Copies of the following documents may be inspected at our registered office during office hours for a period of six months from the date of this Prospectus:

(i) our Constitution;

(ii) our material contracts as referred to in Section 15.6 of this Prospectus;

(iii) our audited consolidated financial statements for the Financial Years Under Review;

(iv) audited financial statements of each of our Subsidiaries for the Financial Years Under Review;

(v) Reporting Accountants' report on the pro forma consolidated statement of financial position as at 30 June 2026 as included in Section 14 of this Prospectus;

(vi) Accountants' Report as included in Section 13 of this Prospectus;

(vii) IMR Report as included in Section 8 of this Prospectus; and

(viii) letters of consent referred to in Section 15.8 of this Prospectus.

16. PROCEDURES FOR APPLICATION

THIS SUMMARY OF PROCEDURES FOR APPLICATION AND ACCEPTANCE DOES NOT CONTAIN THE DETAILED PROCEDURES AND FULL TERMS AND CONDITIONS AND YOU CANNOT RELY ON THIS SUMMARY FOR PURPOSES OF ANY APPLICATION FOR OUR IPO SHARES. YOU MUST REFER TO THE DETAILED PROCEDURES AND TERMS AND CONDITIONS AS SET OUT IN THE "DETAILED PROCEDURES FOR APPLICATION AND ACCEPTANCE" ACCOMPANYING OUR ELECTRONIC PROSPECTUS ON THE WEBSITE OF BURSA SECURITIES. YOU SHOULD ALSO CONTACT THE ISSUING HOUSE FOR FURTHER ENQUIRIES.

Unless otherwise defined, all words and expressions used in this Section shall carry the same meaning as ascribed to them in this Prospectus.

Unless the context otherwise requires, words used in the singular include the plural, and vice versa.

16.1 OPENING AND CLOSING OF APPLICATIONS

OPENING OF THE APPLICATION PERIOD: 10:00 A.M., 29 OCTOBER 2026

CLOSING OF THE APPLICATION PERIOD: 5:00 P.M., 5 NOVEMBER 2026

In the event there is any change to the dates and times stated above, we will advertise the notice of changes in widely circulated daily English and Bahasa Malaysia newspapers within Malaysia and make an announcement on the website of Bursa Securities.

Late Applications will not be accepted.

16.2 METHODS OF APPLICATION

All Applications must accord with this Prospectus and our Constitution. The submission of an Application Form does not mean that the Application will succeed.

Types of Application and category of investors	Application method
Applications by Malaysian Public:	
(i) Individuals	White Application Form or Electronic Share Application or Internet Share Application
(ii) Non-individuals	White Application Form only
Applications by Eligible Persons	Pink Application Form only
Applications by institutional and selected investors	Our Joint Global Coordinators and Joint Bookrunners will contact the selected investors directly. They should follow our Joint Global Coordinators' and Joint Bookrunners' instructions
Applications by Bumiputera investors approved by MITI	MITI will contact the Bumiputera investors directly. They should follow MITI's instructions

16. PROCEDURES FOR APPLICATION *(Cont'd)*

16.3 ELIGIBILITY

16.3.1 General

You must have a CDS account and a correspondence address in Malaysia. If you do not have a CDS account, you may open a CDS account by contacting any of the ADAs set out in the list of ADAs accompanying our Electronic Prospectus on the website of Bursa Securities. The CDS account must be in your own name. Invalid, nominee or third party CDS accounts will not be accepted for the Applications.

Only **ONE** Application Form for each category from each applicant will be considered and **APPLICATIONS MUST BE FOR AT LEAST 100 ISSUE SHARES OR MULTIPLES OF 100 ISSUE SHARES.**

MULTIPLE APPLICATIONS WILL NOT BE ACCEPTED UNLESS EXPRESSLY ALLOWED IN THESE TERMS AND CONDITIONS. AN APPLICANT WHO SUBMITS MULTIPLE APPLICATIONS IN HIS OWN NAME OR BY USING THE NAME OF OTHERS, WITH OR WITHOUT THEIR CONSENT, COMMITS AN OFFENCE UNDER SECTION 179 OF THE CMSA AND IF CONVICTED, MAY BE PUNISHED WITH A MINIMUM FINE OF RM1,000,000 AND A JAIL TERM OF UP TO 10 YEARS UNDER SECTION 182 OF THE CMSA.

AN APPLICANT IS NOT ALLOWED TO SUBMIT MULTIPLE APPLICATIONS IN THE SAME CATEGORY OF APPLICATION. PERSONS SUBMITTING APPLICATION BY WAY OF APPLICATION FORMS MAY NOT SUBMIT APPLICATIONS BY WAY OF ELECTRONIC SHARE APPLICATION OR INTERNET SHARE APPLICATION AND VICE VERSA.

AN APPLICANT WHO WISHES TO SUBMIT APPLICATIONS USING A JOINT BANK ACCOUNT MUST CONTACT THE FINANCIAL INSTITUTION HANDLING THE APPLICATIONS TO ENSURE THAT THE NAME ON THE JOINT BANK ACCOUNT MATCHES THE NAME ON THEIR CDS ACCOUNT. THIS STEP MINIMISES THE RISK OF REJECTION OF IPO APPLICATIONS DUE TO NAME DISCREPANCIES. OUR COMPANY, JOINT PRINCIPAL ADVISERS AND ISSUING HOUSE ARE NOT RESPONSIBLE FOR ANY ISSUES ARISING THEREAFTER.

16.3.2 Application by Malaysian Public

You can only apply for our Issue Shares if you fulfil all of the following:

(i) you must be one of the following:

  (a) a Malaysian citizen who is at least 18 years old as at the date of the Application; or

  (b) a corporation/institution incorporated in Malaysia with a majority of Malaysian citizens on your board of directors/trustees and if you have a share capital, more than half of the issued share capital, excluding preference share capital, is held by Malaysian citizens; or

  (c) a superannuation, co-operative, foundation, provident, pension fund established or operating in Malaysia;

(ii) you must not be a director or employee of the Issuing House or an immediate family member of a director or employee of the Issuing House; and

(iii) you must submit the Application by using only one of the following methods:

  (a) White Application Form;

  (b) Electronic Share Application; or

  (c) Internet Share Application.

16. PROCEDURES FOR APPLICATION *(Cont'd)*

16.3.3 Application by Eligible Persons

Eligible Persons (including any entities, wherever established) will be provided with Pink Application Forms and letters from us detailing their respective allocation. The applicants must follow the notes and instructions in the said documents and where relevant, in this Prospectus. All duly completed Pink Application Forms should be submitted to our Group's Human Resources Department.

Eligible Persons may request for a copy of the printed Prospectus from our Company at no cost and are given an option to have the printed Prospectus delivered to them free of charge, or to obtain the printed Prospectus from our Company, the Issuing House, participating organisations of Bursa Securities and Members of the Association of Banks in Malaysia or Malaysian Investment Banking Association.

Eligible Persons who have made applications using the Pink Application Form may still apply for our Issue Shares allocated to the Malaysian Public using the White Application Form or through the Electronic Share Application or the Internet Share Application.

16.4 APPLICATIONS USING APPLICATION FORMS

The Application Form must be completed in accordance with the notes and instructions contained in the respective category of the Application Form. Applications made on the incorrect type of Application Form or which do not conform **STRICTLY** to the terms of this Prospectus or the respective category of Application Form or notes and instructions or which are illegible will not be accepted.

The FULL amount payable is RM1.08 for each Issue Share.

Payment must be made out in favour of "**MIH SHARE ISSUE ACCOUNT NO. 712**" and crossed "**A/C PAYEE ONLY**" and endorsed on the reverse side with your name and address.

Each completed Application Form, accompanied by the appropriate remittance and legible photocopy of the relevant documents may be submitted using one of the following methods:

(i) despatch by **ORDINARY POST** in the official envelopes provided to the following address:

Malaysian Issuing House Sdn Bhd
11th Floor, Menara Symphony
No. 5, Jalan Prof. Khoo Kay Kim
Seksyen 13
46200 Petaling Jaya
Selangor Darul Ehsan

or

P.O. Box 00010
Pejabat Pos Jalan Sultan
46700 Petaling Jaya
Selangor Darul Ehsan

(ii) **DELIVER BY HAND AND DEPOSIT** in the drop-in boxes provided at the front portion of Menara Symphony, No. 5, Jalan Prof. Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan,

so as to arrive not later than 5:00 p.m. on 5 November 2026 or such other date and time specified in any changes to the date or time for closing.

16. PROCEDURES FOR APPLICATION *(Cont'd)*

We, together with the Issuing House, will not issue any acknowledgement of the receipt of your Application Forms or Application monies. Please direct all enquiries in respect of the Application Form to the Issuing House.

The abovementioned methods are not applicable to the submission of Pink Application Forms. All duly completed Pink Application Forms should be submitted to our Group's Human Resources Department.

16.5 APPLICATION USING ELECTRONIC SHARE APPLICATION

Only Malaysian individuals may apply for our Issue Shares offered to the Malaysian Public by way of Electronic Share Application.

Electronic Share Applications may be made through the ATM of the following Participating Financial Institutions and their branches, namely Affin Bank Berhad, Alliance Bank Malaysia Berhad, AmBank (M) Berhad, CIMB Bank Berhad, Malayan Banking Berhad, Public Bank Berhad and RHB Bank Berhad. A processing fee will be charged by the respective Participating Financial Institutions (unless waived) for each Electronic Share Application.

The exact procedures, terms and conditions for Electronic Share Application are set out on the ATM screens of the relevant Participating Financial Institutions.

16.6 APPLICATION BY WAY OF INTERNET SHARE APPLICATION

Only Malaysian individuals may use the Internet Share Application to apply for our Issue Shares offered to the Malaysian Public.

Internet Share Applications may be made through an internet financial services website of the Internet Participating Financial Institutions or Participating Securities Firms, namely Affin Bank Berhad, Alliance Bank Malaysia Berhad, CGS International Securities Malaysia Sdn Bhd, Hong Leong Investment Bank Berhad, iFAST Capital Sdn Bhd, Kenanga Investment Bank Berhad, Malacca Securities Sdn Bhd, Malayan Banking Berhad, Moomoo Securities Malaysia Sdn Bhd, Public Bank Berhad, RHB Bank Berhad, TA Securities Holdings Berhad and UOB Kay Hian (M) Sdn Bhd. A processing fee will be charged by the respective Internet Participating Financial Institutions or Participating Securities Firms (unless waived) for each Internet Share Application.

The exact procedures, terms and conditions for Internet Share Application are set out on the internet financial services website of the respective Internet Participating Financial Institutions or Participating Securities Firms.

16.7 AUTHORITY OF OUR BOARD AND THE ISSUING HOUSE

The Issuing House, on the authority of our Board, reserves the right to:

(i) reject the Applications which:

  (a) do not conform to the instructions of this Prospectus, Application Forms, Electronic Share Application and Internet Share Application (where applicable); or

  (b) are illegible, incomplete or inaccurate; or

  (c) are accompanied by an improperly drawn up, or improper form of, remittance; or

(ii) reject or accept any Application, in whole or in part, on a non-discriminatory basis without the need to give any reason; and

(iii) bank in all Application monies (including those from unsuccessful/partially successful applicants) which would subsequently be refunded, where applicable (without interest), in accordance with Section 16.9 of this Prospectus.

If you are successful in your Application, our Board reserves the right to require you to appear in person at the registered office of the Issuing House at any time within 14 days of the date of the notice issued to you to ascertain that your Application is genuine and valid. Our Board shall not be responsible for any loss or non-receipt of the said notice nor shall it be accountable for any expenses incurred or to be incurred by you for the purpose of complying with this provision.

16.8 OVER / UNDER-SUBSCRIPTION

In the event of over-subscription, the Issuing House will conduct a ballot in the manner approved by our Directors to determine the acceptance of Applications in a fair and equitable manner. In determining the manner of balloting, our Directors will consider the desirability of allotting and allocating our Issue Shares to a reasonable number of applicants for the purpose of broadening the shareholding base of our Company and establishing a liquid and adequate market for our Shares.

The basis of allocation of our Issue Shares and the balloting results in connection therewith will be furnished by the Issuing House to the SC, Bursa Securities, all major English and Bahasa Malaysia newspapers as well as posted on the Issuing House's website at www.mih.com.my within one Market Day after the balloting event.

Pursuant to the Listing Requirements, we are required to have at least 25.0% of our total number of Shares for which listing is sought to be held by a minimum of 1,000 public shareholders holding not less than 100 Shares each upon our admission to the Official List and completion of our IPO. We expect to achieve this at the point of our Listing. In the event this requirement is not met, we may not be allowed to proceed with our Listing. In the event thereof, monies paid in respect of all Applications will be returned in full (without interest or any share of revenue or benefits arising therefrom) and if such monies are not returned in full within 14 days after our Company becomes liable to do so, the provision of Section 243(2) of the CMSA shall apply accordingly.

In the event of an under-subscription of the Retail Offering, subject to the clawback and reallocation provisions as set out in Section 4.1.3 of this Prospectus, any of the aforementioned Issue Shares not applied for will then be subscribed by our Joint Managing Underwriters and Joint Underwriters subject to the terms and conditions of the Retail Underwriting Agreement.

16.9 UNSUCCESSFUL / PARTIALLY SUCCESSFUL APPLICANTS

If you are unsuccessful/partially successful in your Application, your Application monies (without interest) will be refunded to you in the following manner:

16.9.1 For applications by way of Application Form

(i) The Application monies or the balance of it, as the case may be, will be returned to you through the self-addressed and stamped Official "A" envelope you provided by ordinary post (for fully unsuccessful Applications) or by crediting into your bank account (the same bank account you have provided to Bursa Depository for the purposes of cash dividend/distribution) or if you have not provided such bank account information to Bursa Depository, the balance of Application monies will be refunded via banker's draft sent by ordinary/registered post to your last address maintained with Bursa Depository (for partially successful Applications) within 10 Market Days from the date of the final ballot at your own risk.

16. PROCEDURES FOR APPLICATION *(Cont'd)*

(ii) If your Application is rejected because you did not provide a CDS account number, your Application monies will be refunded via banker's draft sent by ordinary/registered post to your address as stated in the NRIC or any official valid temporary identity document issued by the relevant authorities from time to time or the authority card (if you are a member of the armed forces or police) at your own risk.

(iii) A number of Applications will be reserved to replace any successfully balloted Applications that are subsequently rejected pursuant to Bursa Depository's verification. The Application monies relating to these Applications which are subsequently rejected or unsuccessful or only partly successful will be refunded (without interest) by the Issuing House as per items (i) and (ii) above (as the case may be).

(iv) The Issuing House reserves the right to bank into its bank account all Application monies from unsuccessful applicants. These monies will be refunded (without interest) within 10 Market Days from the date of the final ballot by crediting into your bank account (the same bank account you have provided to Bursa Depository for the purposes of cash dividend/distribution) or by issuance of banker's draft sent by registered post to your last address maintained with Bursa Depository if you have not provided such bank account information to Bursa Depository or as per item (ii) above (as the case may be).

16.9.2 For applications by way of Electronic Share Application and Internet Share Application

(i) The Issuing House shall inform the Participating Financial Institutions or Internet Participating Financial Institutions or Participating Securities Firms of the unsuccessful or partially successful Applications within two Market Days after the balloting date. The full amount of the Application monies or the balance of it will be credited without interest into your account with the Participating Financial Institutions or Internet Participating Financial Institutions or Participating Securities Firms (or arranged with the Authorised Financial Institution) within two Market Days after the receipt of confirmation from the Issuing House.

(ii) You may check your account on the fifth Market Day from the balloting date.

(iii) A number of Applications will be reserved to replace any successfully balloted Applications that are subsequently rejected pursuant to Bursa Depository's verification. The Application monies relating to these Applications which are subsequently rejected will be refunded (without interest) by the Issuing House by crediting into your account with the Participating Financial Institutions or Internet Participating Financial Institutions or Participating Securities Firms (or arranged with the Authorised Financial Institution) not later than 10 Market Days from the date of the final ballot. For Applications that are held in reserve and which are subsequently unsuccessful or partially successful, the relevant Participating Financial Institutions or Internet Participating Financial Institutions or Participating Securities Firms will be informed of the unsuccessful or partially successful Applications within two Market Days after the date of the final ballot.

The Participating Financial Institutions or Internet Participating Financial Institutions or Participating Securities Firms will credit the Application monies or any part thereof (without interest) within two Market Days after the receipt of confirmation from the Issuing House.

16. PROCEDURES FOR APPLICATION *(Cont'd)*

16.10 SUCCESSFUL APPLICANTS

If you are successful in your Application:

(i) Our Issue Shares allotted to you will be credited into your CDS account.

(ii) A notice of allotment will be despatched to you at your last address maintained with the Bursa Depository, at your own risk, before our Listing. This is your only acknowledgement of acceptance of your Application.

(iii) In accordance with Section 14(1) of the SICDA, Bursa Securities has prescribed our Shares as prescribed securities. As such, our IPO Shares issued/offered through this Prospectus will be deposited directly with Bursa Depository and any dealings in these Shares will be carried out in accordance with the SICDA and Rules of Bursa Depository.

(iv) In accordance with Section 29 of the SICDA, all dealings in our Shares will be by book entries through CDS accounts. No physical share certificates will be issued to you and you shall not be entitled to withdraw any deposited securities held jointly with Bursa Depository or its nominee as long as our Shares are listed on Bursa Securities.

(v) In the event that the Final Retail Price is lower than the Retail Price, the difference will be refunded to you without any interest thereon. The refund will be credited into your bank account for purposes of cash dividend/distribution if you have provided such bank account information to Bursa Depository or despatched, in the form of cheques, by ordinary post to your address maintained with Bursa Depository if you have not provided such bank account information to Bursa Depository, or by crediting into your account with the Participating Financial Institutions for applications made via the Electronic Share Application or by crediting into your account with the Internet Participating Financial Institutions or Participating Securities Firms for applications made via the Internet Share Application, within 10 Market Days from the date of the final ballot, at your own risk.

16.11 ENQUIRIES

Enquiries in respect of the Applications may be directed as follows:

Mode of Application	Parties to direct the queries
Application Form	Issuing House Enquiry Services Telephone at 03-7890 4700
Electronic Share Application	Participating Financial Institutions
Internet Share Application	Internet Participating Financial Institutions or Participating Securities Firms or Authorised Financial Institutions

You may also check the status of your Application at the Issuing House's website at www.mih.com.my, by entering your CDS Account Number on the website after 3:00 p.m. on the allotment date. Alternatively, you may contact any of the ADAs set out in the **"Detailed Procedures for Application and Acceptance"** accompanying our Electronic Prospectus on the website of Bursa Securities.

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS

Details of the major licences, permits and approvals obtained by our Group for our operations and the status of compliance as at the LPD are as follows:

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
1.	CPRM	Drug Control Authority, NPRA ("**DCA**")	Wholesaler licence to sell wholesale or supply registered products including scheduled poisons, as stated in the list attached to the licence at BRDC.	MALLB20262043A	Issue date 15 January 2026 Validity period 15 January 2026 to 31 December 2026	(i) Compliance with the Control of Drugs and Cosmetics Regulations 1984 ("**Drugs Regulations**") and requirements of Good Manufacturing Practice and/or Good Distribution Practice and/or other requirements as prescribed by the DCA	Complied
						(ii) For products to which the Drugs Regulations apply, CPRM is allowed to sell by wholesale the registered products as listed in the register of products provided under Regulation 9(1) of the Drugs Regulations	Complied
2.	CPRM	Klang Royal City Council	Temporary business licence in respect of BRDC for: (i) wholesale and store pharmaceutical drugs; (ii) office; and (iii) advertisement.	0052025032296359	Issue date 22 October 2025 Validity period 22 October 2025 to 31 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
3.	Yanling Natural Hygiene	MITI	Manufacturing licence in respect of No. 6, 8, 10, 12, 12A, 16, 18, 20 & 22, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for health medicaments, traditional medicaments and functional supplements.	A022581	Issue date 11 August 2020 Validity period Not applicable	(i) MITI and Malaysian Investment Development Authority ("**MIDA**") shall be notified of the sale of shares in Yanling Natural Hygiene	Noted
						(ii) Yanling Natural Hygiene shall train its Malaysian employees to ensure that the transfer of technology and expertise can be channelled at all levels of positions	Complied
						(iii) Yanling Natural Hygiene shall comply with the capital investment requirements per employee (CIPE) of at least RM140,000.00	Complied
						(iv) The total number of full-time employees of Yanling Natural Hygiene shall consist of at least 80.0% Malaysian citizens. The hiring of foreign employees hired through external sources, is subject to current policies	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
4.	Yanling Natural Hygiene	MITI	Manufacturing licence in respect of Lot 2 & 2A, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for health medicaments, traditional medicaments and functional supplements.	A027183	Issue date 18 November 2025 Validity period Not applicable	(i) MITI and MIDA shall be notified of the sale of shares in Yanling Natural Hygiene	Noted
						(ii) Yanling Natural Hygiene shall train its Malaysian employees to ensure that the transfer of technology and expertise can be channelled at all levels of positions	Complied
						(iii) Yanling Natural Hygiene shall comply with the capital investment requirements per employee (CIPE) of at least RM140,000.00	Complied
						(iv) The total number of full-time employees of Yanling Natural Hygiene shall consist of at least 80.0% Malaysian citizens. The hiring of foreign employees hired through external sources, is subject to current policies	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
5.	Yanling Natural Hygiene	DCA	Manufacturer's licence to manufacture the products specified in the list attached to the licence and to sell by wholesale or to supply the said products at the Manufacturing Facility. Address of stores: Lot 13, 15, 17, 19 & 21, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	MALLP20260946	Issue date 24 November 2025 Validity period 1 January 2026 to 31 December 2026	(i) Compliance with the Drugs Regulations and requirements of Good Manufacturing Practice and/or Good Distribution Practice and/or other requirements as prescribed by the DCA	Complied
						(ii) For products to which the Drugs Regulations apply, Yanling Natural Hygiene is allowed to manufacture only the registered products as approved by the DCA	Complied
						(iii) According to the Drugs Regulations, Yanling Natural Hygiene is only permitted to manufacture registered products listed in the schedule attached to the licence for the following scope of activities (non-sterile): (a) Pharmaceutical (X): capsules (hard shell), capsules (soft shell), powders, tablets;	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
						(b) Health supplements: capsules (hard shell), capsules (soft shell), powders, tablets; and	
						(c) Traditional: capsules (hard shell), liquid for internal use, powders, tablets	
6.	Yanling Natural Hygiene	Fisheries Development Authority of Malaysia	Licence for fish processing at the Manufacturing Facility.	0000560	Issue date 23 February 2026 Validity period 23 February 2026 to 31 March 2027	(i) No person shall deal with, process, export or import any fish unsafe to be consumed by human without a written consent from the Fisheries Development Authority of Malaysia	Complied
						(ii) No person shall deal with, process, export or import any fish which is illegally obtained or caught or in contravention of the law	Complied
						(iii) Dealings and processing shall only be carried out at the permitted premises	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
						(iv) Yanling Natural Hygiene shall retain relevant documents such as delivery notes, invoices, product-related certificates and submit them to the authorities upon request	Complied
7.	Yanling Natural Hygiene	MOH	Certificate of Registration for food premises involved in manufacturing of food.	FSSM031200337-01	Issue date 12 January 2024 Validity period 11 March 2024 to 11 March 2027	Nil	Not applicable
8.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 2 & 2A, (Grd Floor & 1st Floor), Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for: (i) manufacturing / processing pharmaceutical drugs and related products (factory processing health products and supplements); and	202600005587	Issue date 15 October 2025 Validity period 15 October 2025 to 31 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
			(ii) wholesale / storage of pharmaceutical drugs and related products (storage of packaged goods and raw materials, food products and health supplements).				
9.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 6 & 8, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for: (i) manufacturing / processing pharmaceutical drugs and related products as well as traditional medicines and health supplements; and (ii) wholesale / storage of plastic and PVC goods (storage of packaged goods and raw materials, traditional medicine and health supplements).	202600008306	Issue date 17 November 2025 Validity period 17 November 2025 to 31 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
10.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 16 & 16-1, 18 & 18-1, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for: (i) manufacturing / processing pharmaceutical drugs and related products as well as chinese traditional medicines; and (ii) advertisement.	202600001657	Issue date 17 November 2025 Validity period 17 November 2025 to 31 December 2026	Nil	Not applicable
11.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 19, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for wholesale / storage of pharmaceutical drugs and related products (storage of packaged goods, traditional herbal medicine, health supplements and cosmetic products).	202600013960	Issue date 17 November 2025 Validity period 17 November 2025 to 31 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
12.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 19-1, No. 21-1, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for: (i) office; (ii) warehouse / cold room (wholesale / storage); (iii) storage of packaged goods, traditional medicine, herbal and health supplements; and (iv) advertisement.	202600005316	Issue date 17 November 2025 Validity period 17 November 2025 to 31 December 2026	Nil	Not applicable
13.	Yanling Natural Hygiene	Selayang Municipal Council	Business licence in respect of No. 20, Jalan SB Jaya 11, Taman Industri SB Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan for: (i) manufacturing / processing pharmaceutical drugs and related products (factory processing traditional medicine and supplements); and	202600004319	Issue date 17 November 2025 Validity period 17 November 2025 to 31 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
			(ii) manufacturing / processing pharmaceutical drugs and related products (factory processing traditional herbal medicine and supplements).				
14.	Yanling Natural Hygiene	Department of Occupational Safety and Health ("**DOSH**")	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for goods hoist in respect of No. 3, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMA-SL/A26-569188	Issue date 13 July 2026 Validity Period 13 July 2026 to 8 October 2027	Nil	Not applicable
15.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for goods hoist in respect of No. 10, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMA-SL/A25-515891	Issue date 13 October 2025 Validity Period 13 October 2025to 29 December 2026	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
16.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for goods hoist in respect of No. 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMA-SL/A25-515902	Issue date 13 October 2025 Validity Period 13 October 2025 to 29 December 2026	Nil	Not applicable
17.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for goods hoist in respect of Lot 22, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMA-SL/A26-563202	Issue date 19 June 2026 Validity Period 19 June 2026 to 17 September 2027	Nil	Not applicable
18.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for electric steam boiler in respect of No. 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMD-SL/A26-578200	Issue date 16 August 2026 Validity Period 16 August 2026 to 2 November 2027	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
19.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for air compressor in respect of No. 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMT-SL/A25-515901	Issue date 13 October 2025 Validity Period 13 October 2025 to 29 December 2026	Nil	Not applicable
20.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for vertical air receiver tank in respect of No. 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMT-SL/A26-563234	Issue date 19 June 2026 Validity Period 19 June 2026 to 17 September 2027	Nil	Not applicable
21.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for vertical vacuum/receiver in respect of Lot 22, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMT-SL/A26-563203	Issue date 19 June 2026 Validity Period 19 June 2026 to 17 September 2027	Nil	Not applicable

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
22.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for autoclave in respect of No. 11, 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMD-SL/A26-564166	Issue date 24 June 2026 Validity Period 24 June 2026 to 17 September 2027	Nil	Not applicable
23.	Yanling Natural Hygiene	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA 1994 for autoclave in respect of No. 11, 16 & 18, Jalan S.B Jaya 11, Taman Industri S.B Jaya, 47000 Sungai Buloh, Selangor Darul Ehsan.	PMD-SL/A26-577322	Issue date 13 August 2026 Validity Period 13 August 2026 to 14 October 2027	Nil	Not applicable
24.	Quantum Upstream	DCA	Wholesaler licence to sell wholesale or supply registered products other than scheduled poisons as defined under the PA 1952, as stated in the list attached to the licence at No. 66A-2, Jalan Cerdas, Taman Connaught Cheras, 56000 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur.	MALLB20260810	Issue date 30 October 2025 Validity period 1 January 2026 to 31 December 2026	(i) Compliance with the Drugs Regulations, and the requirements of Good Manufacturing Practice and/or Good Distribution Practice, and/or other requirements as prescribed by the DCA	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
						(ii) For products to which the Drugs Regulations apply, Quantum Upstream is permitted to sell by wholesale the registered products as listed in the register of products provided under Regulation 9(1) of the Drugs Regulations	Complied
25.	Medispec	DCA	Import licence to import, sell by retail or wholesale, or supply the registered products including scheduled poisons, as stated in the list attached to the licence at No. 55 & 57, Lorong Sempadan 2 (Off Boundary Road), 11400 Ayer Itam, Pulau Pinang. Address of stores: No. 49M, Lorong Sempadan 2, Off Boundary Road, 11400 Ayer Itam, Pulau Pinang.	MALLI20260520A	Issue date 8 October 2025 Validity period 1 January 2026 to 31 December 2026	(i) A certified true copy of the invoice and certificate of analysis for each batch of imported goods must be submitted to the authority immediately upon receipt of each consignment	Complied
						(ii) Compliance with the Drugs Regulations, and the requirements of Good Manufacturing Practice and/or Good Distribution Practice and/or other requirements as prescribed by the DCA	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
26.	Medispec	DCA	Import licence to import, sell by retail or wholesale, or supply the registered products including scheduled poisons, as stated in the list attached to the licence at Lot 07, 08, 09 & 10, Block B, Jalan SS 25/22, Mayang Avenue, Taman Mayang, 47301 Petaling Jaya, Selangor Darul Ehsan.	MALLI20260565A	Issue date 9 October 2025 Validity period 1 January 2026 to 31 December 2026	(i) A certified true copy of the invoice and certificate of analysis for each batch of imported goods must be submitted to the authority immediately upon receipt of each consignment	Complied
						(ii) Compliance with the Drugs Regulations, and the requirements of Good Manufacturing Practice and/or Good Distribution Practice and/or other requirements as prescribed by the DCA	Complied
27.	Medispec	DCA	Wholesaler licence to sell by wholesale or supply registered products including scheduled poisons, as stated in the list attached to the licence at No. 55 & 57, Lorong Sempadan 2 (Off Boundary Road), 11400 Ayer Itam, Pulau Pinang. Address of stores: No. 49M, Lorong Sempadan 2, Off Boundary Road, 11400 Ayer Itam, Pulau Pinang.	MALLB20260545A	Issue date 8 October 2025 Validity period 1 January 2026 to 31 December 2026	(i) Compliance with the Drugs Regulations, and the requirements of Good Manufacturing Practice and/or Good Distribution Practice, and/or other requirements as prescribed by the DCA	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
						(ii) For products to which the Drugs Regulations apply, Medispec is permitted to sell by wholesale the registered products as listed in the register of products provided under Regulation 9(1) of the Drugs Regulations	Complied
28.	Medispec	DCA	Wholesaler licence to sell wholesale or supply registered products including scheduled poisons, as stated in the list attached to the licence at Lot 07, 08, 09 & 10, Block B, Jalan SS 25/22, Mayang Avenue, Taman Mayang, 47301 Petaling Jaya, Selangor Darul Ehsan.	MALLB20260544A	Issue date 8 October 2025 Validity period 1 January 2026 to 31 December 2026	(i) Compliance with the Drugs Regulations, and the requirements of Good Manufacturing Practice and/or Good Distribution Practice, and/or other requirements as prescribed by the DCA	Complied
						(ii) For products to which the Drugs Regulations apply, Medispec is permitted to sell by wholesale the registered products as listed in the register of products provided under Regulation 9(1) of the Drugs Regulations	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
29.	Medispec	MDA	(i) Establishment licence as authorised representative. Responsible person: Heng Thin Fook	MDA-8373-W125	Issue date 20 February 2026 Validity period 20 February 2026 to 19 February 2029	(i) Medispec shall submit all information within the prescribed period upon request by the MDA	Noted
						(ii) Medispec shall comply with all instructions issued by MDA from time to time	Noted
30.	Medispec	MDA	(ii) Establishment licence as distributor. Responsible person: Heng Thin Fook	MDA-8441-D125	Issue date 5 May 2025 Validity period 5 May 2025 to 4 May 2028	(iii) The MDA reserves the right to conduct visit or inspection to Medispec at any time without prior notice	Noted
31.	Medispec	MDA	(iii) Establishment licence as importer. Responsible person: Heng Thin Fook	MDA-8440-P125		(iv) The MDA may suspend or revoke the establishment licence or take legal action if Medispec fails to comply with any of the requirements of the establishment licence	Noted
						(v) Establishment licence issued by the MDA shall not be transferred	Noted
						(vi) Establishment licence shall be visibly displayed and shall be presented upon request by any authorised officer	Complied

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
						(vii) Medispec may apply for renewal of establishment licence not later than 90 days prior to expiry of licence	Noted
						(viii) Medispec shall not import, export and place in market an unauthorised medical device from the manufacturer or the authorised representative	Complied
						(ix) Any changes or amendments to the information concerning licence shall be notified to the MDA	Noted
						(x) The validity period of the licence certificate is subject to the validity period and conditions of the Quality Management System certificate issued by the Conformity Assessment Body	Noted

ANNEXURE A: OUR MAJOR LICENCES, PERMITS AND APPROVALS *(Cont'd)*

No.	Licensee	Approving authority/ Issuer	Description of licence, permit or approval	Licence no. / Permit no. / Application no. / Serial no.	Issuance date / Validity period	Major conditions imposed	Status of compliance
32.	Medispec	Petaling Jaya City Council	Trade, business and industrial licence in respect of Lot 07, 08, 09 & 10, Block B, Jalan SS 25/22, Mayang Avenue, Taman Mayang, 47301 Petaling Jaya, Selangor Darul Ehsan for: (i) drugs distributor; (ii) advertisement; (iii) office; and (iv) store.	L100000102241	Issue date 2 October 2025 Validity Period 1 January 2026 to 31 December 2026	Nil	Not applicable
33.	Medispec	DOSH	Certificate of Fitness and Inspections pursuant to the OSHA for goods hoist in respect of B-01-10, Block B, Jalan SS25/22, Mayang Avenue, Taman Mayang, 47301 Petaling Jaya, Selangor Darul Ehsan.	PMA-SL/A25-523779	Issue date 25 November 2025 Validity Period 25 November 2025 to 23 February 2027	Nil	Not applicable

As at the LPD, all of the retail outlets operated by our Group have valid annual certificates for body corporate issued by the Registrar of the Pharmacy Board. Further, our Group's licensed pharmacists at our Licensed Pharmacies have valid annual retention certificates and Type A licences issued by the Registrar of the Pharmacy Board and Pharmacy Enforcement Division and the MOH, respectively.

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT

B.1 MATERIAL PROPERTIES OWNED BY OUR GROUP

Details of the material properties owned by our Group as at the LPD are as follows:

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
BRDC							
1.	Registered owner BIG Pharmacy Healthcare Title details H.S.(D) 139753, PT 69180, Mukim Kapar, Daerah Klang, Negeri Selangor Postal address No. 8, Jalan Astana 3/KU2, Bandar Bukit Raja, 41050 Klang, Selangor Tenure Freehold	Description An industrial building structure comprising one unit of three-storey warehouse, three-storey office and other ancillary facilities Existing use Used as our headquarters and distribution centre of our Group	27 April 2026	Built-up area 22,449 Land area 19,021	Category of land use Industry Express condition Industry Restriction in interest Nil	Charged to Maybank Islamic Berhad vide presentation number 001SC34620/2022 registered on 4 April 2022	68,685
Medispec Buildings							
2.	Registered owner Medispec Title details GRN 219648, Lot 49694, Seksyen 39, Bandar Petaling Jaya, Daerah Petaling, Negeri Selangor	Description A unit of three and half storey office shoplot Existing use Used as office and store	14 January 2026 and 19 January 2026	Built-up area 801 Land area 240	Category of land use Building Express condition Commercial building Restriction in interest Nil	Charged to OCBC Bank (Malaysia) Berhad vide presentation number 001SC111332/2022 registered on 19 October 2022	1,804

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
	Postal address No. B-1-07, B-2-07, B-3-07, B-4-07, Block B, Mayang Avenue, Jalan SS 25/22, Taman Mayang, 47301, Petaling Jaya, Selangor Tenure Freehold						
3.	Registered owner Medispec Title details GRN 219649, Lot 49695, Seksyen 39, Bandar Petaling Jaya, Daerah Petaling, Negeri Selangor Postal address No. B-1-08, B-2-08, B-3-08, B-4-08, Block B, Mayang Avenue, Jalan SS 25/22, Taman Mayang, 47301, Petaling Jaya, Selangor Tenure Freehold	Description A unit of three and half storey office shoplot Existing use Used as office and store	14 January 2026 and 19 January 2026	Built-up area 801 Land area 229	Category of land use Building Express condition Commercial building Restriction in interest Nil	Charged to CIMB Bank Berhad vide presentation number 001SC61379/2021 registered on 3 September 2021	1,578
4.	Registered owner Medispec Title details GRN 219650, Lot 49696, Seksyen 39, Bandar Petaling Jaya, Daerah Petaling, Negeri Selangor	Description A unit of three and half storey office shoplot Existing use Used as office and store	14 January 2026 and 19 January 2026	Built-up area 683 Land area 195	Category of land use Building Express condition Commercial building Restriction in interest Nil	Charged to OCBC Bank (Malaysia) Berhad vide presentation number 001SC97966/2021 registered on 3 December 2021	1,508

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
	Postal address No. B-1-09, B-2-09, B-3-09, B-4-09, Block B, Mayang Avenue, Jalan SS 25/22, Taman Mayang, 47301, Petaling Jaya, Selangor Tenure Freehold						
5.	Registered owner Medispec Title details GRN 219651, Lot 49697, Seksyen 39, Bandar Petaling Jaya, Daerah Petaling, Negeri Selangor Postal address No. B-1-10, B-2-10, B-3-10, B-4-10, Block B, Mayang Avenue, Jalan SS 25/22, Taman Mayang, 47301, Petaling Jaya, Selangor Tenure Freehold	Description A unit of three and half storey office shoplot Existing use Used as office and store	14 January 2026 and 19 January 2026	Built-up area 535 Land area 153	Category of land use Building Express condition Commercial building Restriction in interest Nil	Charged to OCBC Bank (Malaysia) Berhad vide presentation number 001SC97966/2021 registered on 3 December 2021	1,390

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
Yanling Facilities							
6.	Registered owner Yanling Natural Hygiene Title details HSD 36933, PT 32, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 1, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Intended use Manufacturing facility for pharmaceutical drugs and health-related products	12 December 2025	Built-up area 1,568 Land area 312	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC80320/2020 registered on 20 November 2020	1,940
7.	Registered owner Yanling Natural Hygiene Title details HSD 36912, PT 11, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 2, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 474 Land area 237	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Public Bank Berhad vide presentation number 001SC5542/2015 registered on 22 January 2015	1,211

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
	Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)						
8.	Registered owner Yanling Natural Hygiene Title details HSD 36913, PT 12, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 2A, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC26036/2016 registered on 30 March 2016, presentation number 001SC41392/2016 registered on 16 May 2016 and presentation number 001SC47963/2017 registered on 13 June 2017	298
9.	Registered owner Yanling Natural Hygiene Title details HSD 36932, PT 31, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 3, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan	Description One unit of two-storey terrace factory Intended use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	12 December 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC98822/2021 registered on 7 December 2021	1,029

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
	Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)						
10.	Registered owner Yanling Natural Hygiene Title details HSD 36914, PT 13, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 6, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	(i) Private caveat lodged by Hong Leong Islamic Bank Berhad vide presentation number 001B26952/2017 registered on 13 June 2017 (ii) Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC66618/2017 registered on 11 August 2017	783

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
11.	Registered owner Yanling Natural Hygiene Title details HSD 36915, PT 14, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 8, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC66619/2017 registered on 11 August 2017	783
12.	Registered owner Yanling Natural Hygiene Title details HSD 36919, PT 18, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 16, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Manufacturing facility for pharmaceutical drugs and health-related products	12 December 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC26032/2016 registered on 30 March 2016, presentation number 001SC41393/2016 registered on 16 May 2016 and presentation number 001SC47964/2017 registered on 13 June 2017	251

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
13.	Registered owner Yanling Natural Hygiene Title details HSD 36920, PT 19, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 18, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Nil	251
14.	Registered owner Yanling Natural Hygiene Title details HSD 36924, PT 23, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 19, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is used as office	12 December 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC48389/2021 registered on 24 June 2021	1,108

ANNEXURE B: OUR MATERIAL PROPERTIES AND EQUIPMENT *(Cont'd)*

No.	Registered owner / Title details / Postal address / Tenure	Description / Existing use / Intended use	Date of issuance of CCC or equivalent	Built-up area / Land area (approximate) (sq. m. unless otherwise stated)	Category of land use / Express condition / Restriction in interest	Encumbrances on property	Audited NBV as at 30 June 2026 (RM'000)
15.	Registered owner Yanling Natural Hygiene Title details HSD 36921, PT 20, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 20, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is manufacturing facility for pharmaceutical drugs and health-related products	3 June 2025	Built-up area 372 Land area 186	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC26033/2016 registered on 30 March 2016, presentation number 001SC41391/2016 registered on 16 May 2016 and presentation number 001SC47962/2017 registered on 13 June 2017	689
16.	Registered owner Yanling Natural Hygiene Title details HSD 36923, PT 22, Pekan Sungai Buloh, Daerah Gombak, Negeri Selangor Postal address No. 21, Jalan S.B. Jaya 11, Taman Industri S.B. Jaya, 47000 Sg. Buloh, Selangor Darul Ehsan Tenure 99 years expiring on 17 May 2100 (approximately 74 years unexpired lease term)	Description One unit of two-storey terrace factory Existing use Ground floor is used for storage and first floor is used as office	12 December 2025	Built-up area 610 Land area 305	Category of land use Industry Express condition Industry Restriction in interest This land shall not be transferred, leased or mortgaged in any manner without the consent of the state authority	Charged to Hong Leong Islamic Bank Berhad vide presentation number 001SC48383/2021 registered on 24 June 2021	1,754

Save as disclosed in Section 7.15 of this Prospectus, none of the material properties owned as disclosed under Section B.1 above are in breach of any land use conditions and/or are in non-compliance with current statutory requirements, land rules or building regulations which will have a material adverse impact on our operations or the utilisation of our assets on the said properties. No valuations have been conducted on any of the properties disclosed above.

B.2 MATERIAL PROPERTIES TENANTED BY OUR GROUP

(i) Outlets

As at the LPD, we operate a total of 668 retail outlets in shopping centres, high streets or as a standalone building, of which 654 retail outlets are rented by our Group.

(ii) Material properties

As at the LPD, there are no material properties rented or leased by our Group for our business operations.

B.3 MATERIAL EQUIPMENT

As at the LPD, our Group does not have any material equipment.

ANNEXURE C: OUR MATERIAL TRADEMARKS

C. MATERIAL TRADEMARKS

Save as disclosed below, as at the LPD, we do not have any other material trademarks, brand names and other intellectual property rights in Malaysia:

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
1.	AHC AHC	AHC Medical Supplies	07014733	30 July 2027	Class 10: Nursing appliances; Appliances for physical exercise [for medical use]; Machines for physical exercise [medical use]; Physical exercise apparatus for medical purposes; Crutches; Commode chairs; Electric massage chairs; Electric massage beds; Mattresses for medical use; Oxygen concentration analyzers and monitors for medical use; Apparatus for producing oxygen for medical use; Parts and fittings for all the aforesaid goods; All included in Class 10.
2.	AHC	AHC Medical Supplies	2016072538	30 November 2036	Class 35: Retail or wholesale services of medical supplies; Online promotion on a computer network; All included in Class 35.
3.	BIG PHARMACY	BCG	2014056647	8 May 2034	Class 35: Advertising; Retailing and wholesaling services relating to healthcare supplements, cosmetic, skincare products, toiletries, vitamin preparations, cleaning preparations, polishing preparations, scouring preparations and abrasive preparations and substances; Marketing and promotional services using the global communications network; Automated and computerized retail and wholesale services for others relating to healthcare supplements, cosmetic, skincare products, toiletries, vitamin preparations, cleaning preparations, polishing preparations, scouring preparations and abrasive preparations and substances, provided over a global communication information network; Online retail store services featuring health care supplements and cosmetic and skincare products; The bringing together, for the benefit of others, of a variety of goods (excluding the transport thereof) namely, healthcare supplements, cosmetic and skincare products, enabling customers to conveniently view and purchase those goods from general merchandise catalogue by mail order or by means telecommunications; All included in Class 35.
4.	BIG REHAB ONE STOP SOLUTIONS BIG REHAB	BCG	TM2024025219	The status is Provisional Refusal (Objection) – Hearing(1)	Class 35: Advertising, promotion and marketing; Business management of wholesale and retail outlets; Advertising services to promote public awareness on healthcare issues; Online retail store services featuring medical apparatus; Online retail store services featuring medical instruments; Online retail store services featuring physical therapy equipment; Online retail store services featuring hygienic implements for humans; Online retail store services featuring metal hardware; Online wholesale store services featuring physical therapy equipment; Online wholesale store services featuring hygienic implements for humans; Online wholesale store services featuring medical apparatus; Online wholesale store services featuring medical instruments;

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
					Online wholesale store services featuring metal hardware; Online wholesale store services featuring sanitary installations; Online wholesale store services featuring sanitation equipment; Retail services for physical therapy equipment; Wholesale services for physical therapy equipment; Retail services in relation to medical apparatus; Wholesale services for medical apparatus; Retail services in relation to medical instruments; Wholesale services in relation to medical instruments; Retail and wholesale services for mobility aids; Retail or wholesale services for medical supplies; Retail and wholesale services for therapeutic and assistive devices adapted for the disabled; Retail and wholesale services for diagnostic pharmaceutical products and diagnostic substances for medical use; Retail and wholesale services for diagnostic substances for medical use, radiopharmaceuticals for clinical and medical purposes; Retail and wholesale services for massage apparatus; Retail and wholesale services for medical apparatus for measuring bone density; Retail and wholesale services for mobile x-ray apparatus; Retail and wholesale services for orthopaedic articles; Retail or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Retail and wholesale services in relation to systems comprising medical apparatus and accessories for administering measured doses of pharmaceutical preparations; Wholesale and retail store services featuring beauty and personal care products; Wholesale distributorship services featuring beauty, personal care and wellness products; Wholesale services through direct solicitation by distributors directed to end-users featuring beauty and personal care products; Providing business administration and management of housing facilities for the elderly or disabled persons.
			TM2024025223	The status is Provisional Refusal (Objection) – Hearing(1)	Class 44: Medical evaluation services for patients receiving rehabilitation for purposes of guiding treatment and assessing effectiveness; Medical advice for individuals with disabilities; Occupational therapy and rehabilitation; Physical rehabilitation; Providing physical rehabilitation facilities; Health care consultancy services [medical services]; Advisory services relating to medical apparatus and instruments; Providing information relating to the rental of medical machines and apparatus; Rental of medical apparatus and installations; Rental of medical machines and apparatus; Medical equipment rental; Services for the provision of medical facilities.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
5.		BCG	TM2026001627	Provisional Refusal (Objected)(2)	Class 44: Medical, medicinal and pharmaceutical consultancy; Advisory services relating to pharmacies; Dispensing of pharmaceuticals; Dispensing of dietary supplements; Providing information relating to dietary and nutritional supplements; Individual medical counseling services provided to patients; Lifestyle counseling and consultancy services for medical purposes; Medical evaluation services; Medical information; Providing medical information from a web site; Providing online information about medical services; Medical, hygienic and beauty care; Consultancy relating to pharmaceutical and medical products; Preparation of prescriptions by pharmacists; Providing medical information in the field of pharmacological treatment; Services of pharmacists being prescription analysis and validation; Services of pharmacists being the preparation and dispensing of medications; Health care consultancy services [medical services]; Medical evaluation services for patients receiving rehabilitation for purposes of guiding treatment and assessing effectiveness; Occupational therapy and rehabilitation; Physical rehabilitation; Providing physical rehabilitation facilities; Advisory services relating to medical apparatus and instruments; Providing information relating to the rental of medical machines and apparatus; Services for the provision of medical facilities.
			TM2026001628	Provisional Refusal (Objected)(2)	Class 35: Advertising, promotion and marketing; Advertising services relating to the commercialization of new products; Advertising services to promote public awareness on healthcare issues; Advertising services to promote public awareness of medical conditions; Advertising services in the field of pharmaceuticals; Business management of wholesale and retail outlets; Online retail store services featuring medical apparatus; Online retail store services featuring medical instruments; Online wholesale store services featuring medical apparatus; Online wholesale store services featuring medical instruments; Retail services in relation to medical apparatus; Wholesale services for medical apparatus; Retail services in relation to medical instruments; Wholesale services in relation to medical instruments; Retail or wholesale services for medical supplies; Retail and wholesale services for pharmaceuticals; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Online retail store services featuring dietary supplements; Online wholesale store services featuring dietary supplements; Retail services for dietary supplements; Wholesale services for dietary supplements; Retail and wholesale services for sanitary preparations for medical purposes, dietetic food and substances adapted for medical or veterinary use; Retail and wholesale services for systems comprising medical apparatus and accessories for administering measured doses of pharmaceutical preparations.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
6.		BCG	TM2026001625	Provisional refusal (Objection) - Hearing[3]	Class 35: Advertising, promotion and marketing; Advertising services relating to the commercialization of new products; Advertising services to promote public awareness on healthcare issues; Advertising services to promote public awareness of medical conditions; Advertising services in the field of pharmaceuticals; Business management of wholesale and retail outlets; Online retail store services featuring medical apparatus; Online retail store services featuring medical instruments; Online wholesale store services featuring medical apparatus; Online wholesale store services featuring medical instruments; Retail services in relation to medical apparatus; Wholesale services for medical apparatus; Retail services in relation to medical instruments; Wholesale services in relation to medical instruments; Retail or wholesale services for medical supplies; Retail and wholesale services for pharmaceuticals; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Online retail store services featuring dietary supplements; Online wholesale store services featuring dietary supplements; Retail services for dietary supplements; Wholesale services for dietary supplements; Retail and wholesale services for sanitary preparations for medical purposes, dietetic food and substances adapted for medical or veterinary use; Retail and wholesale services for systems comprising medical apparatus and accessories for administering measured doses of pharmaceutical preparations.
			TM2026001629	Provisional refusal (Objection) - Hearing[3]	Class 16: Medical journals; Pharmaceutical information leaflets; Mounts for x-ray negatives for non-medical purposes; Paper bags for use in the sterilisation of medical instruments; Paper for medical examination tables; Artificial limbs for medical instruction purposes [teaching materials, except apparatus]; Artificial bones for medical instruction purposes [teaching materials, except apparatus]; Adhesive labels to be printed with an individual's medical and personal information [not of textile]; Plastic film roll stock for packaging pharmaceuticals; Leaflets; Brochures; Printed promotional material; Information booklets.
7.	Be In Goodhealth	BCG	TM2023027321	Provisional Refusal (Objection) – Appeal[4]	Class 16: Adhesive labels [not of textile] to be printed with an individual's medical and personal information; Adhesive labels to be printed with an individual's medical and personal information [not of textile]; Artificial bones for medical instruction purposes [teaching materials, except apparatus]; Artificial limbs for medical instruction purposes [teaching materials, except apparatus]; Medical journals; Mounts for x-ray negatives for non-medical purposes; Paper bags for use in the sterilisation of medical instruments; Paper bags for use in the sterilization of medical instruments; Paper for medical examination tables; Pediatric measuring and medication dosage information charts; Pharmaceutical information leaflets; Plastic film roll stock for packaging pharmaceuticals.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
			TM2023027322	Provisional Refusal (Objection) - Appeal[4]	Class 35: Administrative management of health care clinics; Administrative services for medical referrals; Advertising services to promote public awareness of medical conditions; Advertising services to promote public awareness of medical issues; Advertising services to promote public awareness on health issues; Advertising services to promote public awareness on healthcare issues; Business administration services in the field of healthcare; Compilation of medical reports; Data processing services in the field of healthcare; Electronic data processing services relating to health care information; Maintaining a registry of certified medical technical professionals; Maintaining files and records concerning the medical condition of individuals; Maintaining patient medical records and files; Maintaining personal medical history records and files; Medical billing; Promoting the commercial and business interests of professionals in the mobile software application development provided by an association for its members; Promoting the commercial and business interests of professionals of the healthcare industry provided by an association for its members.
			TM2023027411	Provisional Refusal (Objected)[4]	Class 5: Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for human beings and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax.
8.	BIG CARING GROUP BIG CARING GROUP	CPRM	TM2025042284	2 December 2035	Class 35: Advertising; Advertising services relating to the sale of goods; Business information; Providing business information via a web site; Demonstration of goods; Distribution of samples; Direct mail advertising; Marketing; Online advertising on a computer network; Provision of an online marketplace for buyers and sellers of goods and services; Outdoor advertising; Presentation of goods on communication media, for retail purposes; Sales promotion for others; The bringing together, for the benefit of others, of a variety of goods, excluding the transport thereof, enabling customers to conveniently view and purchase those goods; Business management of retail outlets; Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Business consultancy in the field of pharmaceutical leads; Retail and wholesale services for pharmaceuticals; Retail services provided by pharmacies.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
			TM2025042287	2 December 2035	Class 44: Health care; Health centre services; Health counselling; Medical assistance; Medical screening; Nursing, medical; Pharmacy advice; Physiotherapy; Preparation of prescriptions by pharmacists; Therapy services; Visagists' services; Medical services; Pharmaceutical consultancy services; Medical and pharmaceutical consultation; Medical, hygienic or beauty care services for human beings; Consultancy relating to pharmaceutical and medical products; Health care consultancy services being medical services; Medical care services.
9.	CARING PHARMACY CARING PHARMACY	CPRM	09016571	24 September 2029	Class 35: Retailing services in relation to medicines, pharmaceutical goods and services and all other goods commonly sold in pharmacies; All included in Class 35.
10.	康寧心 CARING 專業情 is our Profession 康寧心 CARING 專業情 is our Profession	CPRM	2012058811	7 November 2032	Class 35: Retailing services in relation to medicines, pharmaceutical goods and services and all other goods commonly sold in pharmacies; All included in Class 35.
11.	CARING	CPRM	TM2020007982	5 May 2030	Class 3: Abrasive paper; After-shave lotions; Almond oil; Almond soap; Almond milk for cosmetic purposes; Aloe vera preparations for cosmetic purposes; Antiperspirant soap; Antiperspirants [toiletries]; Aromatics [essential oils]; Astringents for cosmetic purposes; Baby wipes impregnated with cleaning preparations; Bath preparations, not for medical purposes; Beauty masks; Bleaching preparations [decolorants] for cosmetic purposes; Bleaching preparations [decolorants] for household purposes; Cleaning preparations; Preparations for cleaning dentures; Cleansers for intimate personal hygiene purposes, non medicated; Cleansing milk for toilet purposes; Collagen preparations for cosmetic purposes; Cotton swabs for cosmetic purposes; Cotton wool for cosmetic purposes; Deodorant soap; Deodorants for human beings or for animals; Dry shampoos; Hair conditioners; Hair straightening preparations; Make-up removing preparations; Massage gels, other than for medical purposes; Mouthwashes, not for medical purposes; Petroleum jelly for cosmetic purposes; Shampoos; Soap; Soap for brightening textile; Soap for foot perspiration; Sunscreen preparations; Teeth whitening strips; Tissues impregnated with cosmetic lotions; Tissues impregnated with make-up removing preparations; Vaginal washes for personal sanitary or deodorant purposes.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
			TM2020007984	5 May 2030	Class 5: Absorbent cotton; Acne treatment preparations; Adhesive plasters; Adhesive tapes for medical purposes; Adhesives for dentures; Air purifying preparations; Air deodorizing preparations; Alcohol for pharmaceutical purposes; Aloe vera preparations for pharmaceutical purposes; Amino acids for medical purposes; Analgesics; Antibacterial soap; Antibacterial handwashes; Antioxidant pills; Antiseptics; Babies' diapers; Babies' diaper-pants; Balms for medical purposes; Balsamic preparations for medical purposes; Bandages for dressings; Bath preparations for medical purposes; Breast-nursing pads; Bunion pads; Preparations for callouses; Candy, medicated; Candy for medical purposes; Castor oil for medical purposes; Charcoal for pharmaceutical purposes; Cod liver oil; Collagen for medical purposes; Compresses; Cooling sprays for medical purposes; Corn rings for the feet; Corn remedies; Cotton for medical purposes; Cotton swabs for medical purposes; Diapers for incontinence; Dietary fibre; Dietary supplements with a cosmetic effect; Dietetic foods adapted for medical purposes; Dietetic beverages adapted for medical purposes; Dietetic substances adapted for medical use; Digestives for pharmaceutical purposes; Disinfectant soap; Disinfectants for hygiene purposes; Disinfectants for chemical toilets; Disinfectants; Dressings, medical; Enzyme preparations for medical purposes; Enzyme dietary supplements; Enzymes for medical purposes; Eyepatches for medical purposes; First-aid boxes, filled; Food for babies; Gauze for dressings; Glucose for medical purposes; Glucose dietary supplements; Glycerine for medical purposes; Haemorrhoid preparations; Herbal teas for medicinal purposes; Herbal extracts for medical purposes; Infant formula; Laxatives; Lecithin for medical purposes; Lecithin dietary supplements; Linseed for pharmaceutical purposes; Linseed meal for pharmaceutical purposes; Linseed dietary supplements; Linseed oil dietary supplements; Liquorice for pharmaceutical purposes; Lotions for pharmaceutical purposes; Medicated shampoos; Medicated toiletry preparations; Medicated hair lotions; Medicated dry shampoos; Medicated soap; Medicinal tea; Medicinal herbs; Medicinal roots; Medicines for alleviating constipation; Medicines for human purposes; Mouthwashes for medical purposes; Nicotine gum for use as an aid to stop smoking; Nicotine patches for use as aids to stop smoking; Nutritional supplements; Ointments for pharmaceutical purposes; Pants, absorbent, for incontinence; Panty liners [sanitary]; Petroleum jelly for medical purposes; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for skin care; Pharmaceutical preparations for treating dandruff; Propolis dietary supplements; Protein dietary supplements; Salts for mineral water baths; Sanitary panties; Sanitary tampons; Sanitary towels; Personal sexual lubricants; Slimming pills; Sunburn ointments; Suppositories; Surgical dressings; Vitamin preparations; Vitamin supplement patches; Yeast dietary supplements.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
12.		CPRM	TM2024030353	1 October 2034	Class 35: Advertising; Advertising services relating to the sale of goods; Business information; Providing business information via a web site; Demonstration of goods; Distribution of samples; Direct mail advertising; Marketing; Online advertising on a computer network; Provision of an online marketplace for buyers and sellers of goods and services; Outdoor advertising; Presentation of goods on communication media, for retail purposes; Sales promotion for others; The bringing together, for the benefit of others, of a variety of goods, excluding the transport thereof, enabling customers to conveniently view and purchase those goods; Business management of retail outlets; Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Business consultancy in the field of pharmaceutical leads; Retail and wholesale services for pharmaceuticals; Retail services provided by pharmacies.
			TM2024030355	1 October 2034	Class 44: Health care; Health centre services; Health counselling; Medical assistance; Medical screening; Nursing, medical; Pharmacy advice; Physiotherapy; Preparation of prescriptions by pharmacists; Therapy services; Visagists' services; Medical services; Pharmaceutical consultancy services; Medical and pharmaceutical consultation; Medical, hygienic or beauty care services for human beings; Consultancy relating to pharmaceutical and medical products; Health care consultancy services being medical services; Medical care services.
13.		CPRM	TM2024030356	1 October 2034	Class 35: Advertising; Advertising services relating to the sale of goods; Business information; Providing business information via a web site; Demonstration of goods; Distribution of samples; Direct mail advertising; Marketing; Online advertising on a computer network; Provision of an online marketplace for buyers and sellers of goods and services; Outdoor advertising; Presentation of goods on communication media, for retail purposes; Sales promotion for others; The bringing together, for the benefit of others, of a variety of goods, excluding the transport thereof, enabling customers to conveniently view and purchase those goods; Business management of retail outlets; Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Business consultancy in the field of pharmaceutical leads; Retail and wholesale services for pharmaceuticals; Retail services provided by pharmacies.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
			TM2024030358	1 October 2034	Class 44: Health care; Health centre services; Health counselling; Medical assistance; Medical screening; Nursing, medical; Pharmacy advice; Physiotherapy; Preparation of prescriptions by pharmacists; Therapy services; Visagists' services; Medical services; Pharmaceutical consultancy services; Medical and pharmaceutical consultation; Medical, hygienic or beauty care services for human beings; Consultancy relating to pharmaceutical and medical products; Health care consultancy services being medical services; Medical care services.
14.	medispec caring for health & wellness medispec caring for health & wellness	Medispec	2014053022	3 March 2034	Class 5: Pharmaceutical; Medicines for human use; Veterinary preparations; Dietetic supplements adapted for medical purposes; Food supplements; Herbal supplements, vitamins and mineral preparations; All included in Class 05.
15.	Resurge	Quantum Upstream	2018061333	31 May 2028	Class 5: Dietary fibre / dietary fiber; Dietetic beverages adapted for medical purposes; Nutraceutical preparations for therapeutic or medical purposes; Nutritional supplements; Protein dietary supplements; Vitamin preparations; All included in Class 5.
16.	QUANTUM UPSTREAM QUANTUM UPSTREAM QUANTUM UPSTREAM	Quantum Upstream	TM2021018967	9 July 2031	Class 35: Advertising; Advertising and marketing services provided by means of social media; Advertising of business web sites; Advertising services for the promotion of goods; Demonstration of goods; Demonstration of goods and services by electronic means; Demonstration of goods for advertising purposes; Direct mail advertising; distribution of samples; Distribution of samples for advertising purposes; Distribution of samples for publicity purposes; Distribution of samples, Directly or through the post; import-export agency services; Marketing; Marketing analysis; Online advertising; On-line advertising and marketing services; Presentation of goods on communication media, For retail purposes; Provision of information and advisory services relating to E-Commerce; Provision of an online marketplace for buyers and sellers of goods and services; Publicity; Publicity and sales promotion relating to goods and services; Publicity and sales promotion relating to goods and services available on-line; Online retail services relating to pharmaceutical, veterinary and sanitary preparations and medical supplies, dietary fibre, dietetic beverages, nutritional supplements, protein dietary supplements, vitamin preparations, collagen, food and beverages, beauty care products, personal care products, oral care products, traditional medicines, health supplements.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
			TM2022014561	14 June 2032	Class 5: Dietary fibre; Dietetic beverages adapted for medical purposes; Nutraceutical preparations for therapeutic or medical purposes; Nutritional supplements; Protein dietary supplements; Vitamin preparations; Dietetic substances adapted for medical use; Collagen for medical purposes; Greases for medical purposes; Dietetic foods adapted for medical purposes.
17.	RESURGE GOLD	Quantum Upstream	TM2024009326	1 April 2034	Class 5: Dietary food supplements in the nature of powdered drink mixes; Dietary food supplements in the nature of powdered drink mixes, not for medical purposes; Nutritional supplements in the nature of powdered drink mixes; Nutritional supplements in the nature of powdered drink mixes for medical purposes; Beverages adapted for medical purposes; Dietetic beverages adapted for medical use; Dietetic food and beverages adapted for medical purposes; Malted milk beverages for medical purposes; Medicated beverages; Nutritionally fortified beverages for medical purposes; Preparations for making medicated beverages; Dietetic substances consisting of vitamins, minerals and trace elements, either individually or in combination; Vitamin formulations for human consumption; Vitamin fortified beverages for medical purposes; Powdered nutritional supplement drink mix; Dietary food supplements in the nature of powdered drink mixes for medical purposes; Dietary supplement drinks; Nutritional drinks being dietary food supplements; Nutritional drinks for dietary purposes; Powdered plant-based protein dietary supplements; Protein dietary supplements; Protein supplements for humans; Pharmaceutical preparations for regulating the immune system.
18.	RESURGE DM	Quantum Upstream	TM2024009327	1 April 2034	Class 5: Dietary food supplements in the nature of powdered drink mixes; Dietary food supplements in the nature of powdered drink mixes, not for medical purposes; Nutritional supplements in the nature of powdered drink mixes; Nutritional supplements in the nature of powdered drink mixes for medical purposes; Beverages adapted for medical purposes; Dietetic beverages adapted for medical use; Dietetic food and beverages adapted for medical purposes; Malted milk beverages for medical purposes; Nutritionally fortified beverages for medical purposes; Preparations for making medicated beverages; Dietetic substances consisting of vitamins, minerals and trace elements, either individually or in combination; Vitamin formulations for human consumption; Vitamin fortified beverages for medical purposes; Powdered nutritional supplement drink mix; Dietary food supplements in the nature of powdered drink mixes for medical purposes; Dietary supplement drinks; Nutritional drinks being dietary food supplements; Nutritional drinks for dietary purposes; Pharmaceutical preparations and substances for the prevention of diabetes; Pharmaceutical preparations and substances for the treatment of diabetes; Dietary supplements for controlling cholesterol; Medicated beverages.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
19.	QUANTUM UPSTREAM	Quantum Upstream	TM2026011113	The status is Under Substantive Examination(5)	Class 3: baby wipes; cosmetic preparations for the care of mouth and teeth; dental care preparations; dental rinses, not for medical purposes; dentifrices; dentifrices and mouthwashes; dentifrices in the form of chewing gum; dentifrices in the form of solid tablets; denture polishes; moist wipes for sanitary and cosmetic purposes; non-medicated dental care preparations; polishing pastes for the teeth; preparations for cleaning teeth; teeth whitening preparations; teeth whitening strips impregnated with teeth whitening preparations; cosmetics
			TM2026011115		Class 10: medical apparatus and instruments; surgical apparatus and instruments; disposable gloves for medical purposes; condoms; blood pressure measuring apparatus; hearing aids; hospital beds; walking aids for medical purposes; face masks for medical purposes; body massagers; physical therapy equipment; elastic bandages, not for dressings; baby bottles
			TM2026011122		Class 20: shower seats; grab bars, not of metal; mattresses; air mattresses, not for medical purposes; armchairs; baby furniture; pillows; beds; seating furniture; cushions; portable baby bath seats for use in bath tubs; furniture for babies; furniture for bathrooms; furniture for children; storage drawers [furniture]; chairs adapted for use by those with mobility difficulties
			TM2026011121		Class 29: milk; milk substitutes; soy milk; milk of plant origin; beverages consisting primarily of milk; lactose-free milk; processed nuts; dried fruits; processed fruits; prepared vegetables; nut-based snack bars; dairy products and dairy substitutes; dairy products based on milk substitutes; dried milk-based products for use as meal replacements; snack foods consisting primarily of nuts; toasted nuts; milk enriched with protein
			TM2026011124		Class 30: bread; cereal-based snack foods; processed cereals; rice; coffee; tea; cocoa; honey; sugar; salt; processed grains; grain based snacks
20.	Georgetown Pharmacy	TPHP	2011050657	4 April 2031	Class 35: Pharmacy retail services; retailing store, wholesale, distribution services in respect of household products, arranging exhibitions for advertising purposes; billboard advertising; demonstration of goods for advertising purposes, dissemination of advertising matter; distribution of advertising material; All included in Class 35.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
21.		TPHP	TM2025035502	10 October 2035	Class 35: Retail services provided by pharmacies; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising relating to pharmaceutical products and in-vivo imaging products; Management services provided to pharmacies for controlling drug inventories; Providing administrative assistance to pharmacies for managing drug inventories; Business administration of pharmacy reimbursement programs and services; Business consultancy in the field of pharmaceutical leads; Providing marketing leads for the pharmaceutical industry; Business management advice and assistance; Business management of retail outlets; Retail services for physical therapy equipment; Online retail store services featuring dietary supplements; Online retail store services featuring dietetic preparations; Online retail store services featuring disposable paper products; Online retail store services featuring medical apparatus; Online retail store services featuring medical instruments; Online retail store services featuring physical therapy equipment; Online retail store services featuring cosmetic and beauty products.
			TM2025035503	10 October 2035	Class 44: Pharmacy advice; Pharmacy dispensary services; Preparation and dispensing of medications; Providing information relating to the preparation and dispensing of medications; Pharmaceutical consultancy services; Consultancy and information services relating to pharmaceutical products; Consultancy relating to health care; Preparation of prescriptions in pharmacies; Health counselling; Medical, hygienic or beauty care services for human beings; Blood pressure screening services; Cholesterol testing; Providing information relating to dietary and nutritional supplements; Physiotherapy.
22.		Wellings Pharmacy	2014069263	19 December 2034	Class 35: Pharmacy retail services in Class 35.
23.		Wellings Pharmacy	TM2024031955	16 October 2034	Class 44: Advisory services relating to pharmacies; Consultancy relating to pharmacies; Preparation of prescriptions in pharmacies; Pharmacy advisory services; Pharmacy dispensary services.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
24.		Yanling Natural Hygiene	2013016438	2 December 2033	Class 5: Pharmaceutical preparations; Dietetic substances adapted for medical use; All included in class 5.
			2013016439	2 December 2033	Class 16: Letterheads, printed matters and paper articles; Cardboard and cardboard articles; Plastic materials for packaging; All included in class 16.
25.		Yanling Natural Hygiene	95004840	23 May 2032	Class 16: Letterheads, printed matters and paper articles; Cardboard and cardboard articles; Plastic materials for packaging; All included in Class 16.
			95004841	23 May 2032	Class 5: Pharmaceutical and dietic substances adapted for medical use included in Class 05.
26.	ICARERX	Icare RX Holdings[6]	TM2022025405	28 September 2032	Class 5: Pharmaceutical preparations and substances; Pharmaceutical drugs; Pharmaceutical preparations for health care; Dietary and nutritional supplements; Herbal dietary supplements; Nutritional supplements; Protein supplements for humans; Vitamin and mineral dietary supplements; Dietary food supplemental drinks for medical purposes; Dietary food supplements; Dietary food supplements in powder form; Food supplements in capsule form.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

No.	Trademark	Registered owner / Applicant	Registration / Application no.	Expiry date / Status (if not registered)	Class/ Description of trademark
					Class 35: Retail services provided by drugstores; Retail services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising; Advisory services relating to the operation of franchises; Providing assistance in the management of franchised businesses; Business administration; Administration of loyalty programmes involving discounts or incentives; Goods import-export agency services; Business management of retail outlets; Marketing; Online advertising on a computer network; Providing information and advice to consumers regarding the selection of products and items to be purchased; Providing information in the field of marketing; On-line retail store services featuring cosmetic and beauty products; On-line retail store services featuring dietary supplements; On-line retail store services featuring dietetic preparations; On-line retail store services featuring foodstuffs; Retail or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; The bringing together, for the benefit of others, of a variety of goods, excluding the transport thereof, enabling customers to conveniently view and purchase those goods. Class 44: Pharmacy advice; Consultancy and information services provided via the internet relating to pharmaceutical products; Medical, medicinal and pharmaceutical consultancy; Providing pharmaceutical information; Leasing of medical equipment; Provision of information relating to the rental of medical machines and apparatus.
27.		Chuah Chong Ee trading as Icare Pharmacy(7)	2016063043	19 July 2036	Class 35: Pharmacy retail services; Retail or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising; Administration of the business affairs of franchises; Business management; Discount services (retail, wholesale, or sales promotion services); Distribution of goods (not being transport services) (agent, wholesale, representative services, by any means); Promotion and sale of naming and product supply rights (for others); Management of a retail enterprise for others; Marketing; Retailing of goods (by any means); The bringing together, for the benefit of others, a variety of goods (excluding the transport thereof), enabling customers to conveniently view and purchase the goods; all included in class 35.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

Notes:

(1) The applications for the registration of these trademarks have been submitted on 20 August 2024. On 19 February 2025, our Company received provisional refusal (objected) by the MyIPO in respect of the said registration applications on the grounds that the trademark does not have distinctive character pursuant to Section 23(1)(b) of the Trademarks Act 2019. On 18 April 2025, our Company had submitted an application for ex-parte hearing to appeal in response to the provisional refusal. The hearing was subsequently held on 24 September 2026 and the outcome of the hearing remains pending with the MyIPO as at the LPD.

(2) The applications for the registration of these trademarks have been submitted on 15 January 2026. On 23 July 2026, our Company received provisional refusal (objected) by the MyIPO in respect of the said registration application on the grounds that the trademark is similar to an earlier trademark and is to be registered for goods or services identical with or similar to the earlier trademark pursuant to Section 24(2)(b) of the Trademarks Act 2019. On 15 September 2026, our Company had submitted an appeal in response to the provisional refusal and is awaiting the response from the MyIPO on the appeal as at the LPD.

(3) The applications for the registration of these trademarks have been submitted on 15 January 2026. On 23 July 2026, our Company received provisional refusal (objected) by the MyIPO in respect of the said registration application on the grounds that the trademark does not have distinctive character pursuant to Section 23(1)(b) of the Trademarks Act 2019 and the trademark consist of signs or indications which may serve in trade, to designate the kind, quality, intended purpose or other characteristics of goods or services pursuant to Section 23(1)(c) of the Trademarks Act 2019. On 12 October 2026, our Company had submitted an application for hearing in response to the provisional refusal and is awaiting the response from the MyIPO on the hearing as at the LPD.

(4) The applications for the registration of these trademarks have been submitted on 9 September 2023 and 11 September 2023. On 19 January 2024, our Company received provisional refusal (objected) by the MyIPO in respect of the said registration applications on the grounds that the trademark does not have distinctive character pursuant to Section 23(1)(b) of the Trademarks Act 2019 and the trademark consist of signs or indications which may serve in trade, to designate the kind, quality, intended purpose or other characteristics of goods or services pursuant to Section 23(1)(c) of the Trademarks Act 2019. On 17 May 2024, our Company had submitted an appeal in response to the provisional refusal and is awaiting the response from the MyIPO on the appeal as at the LPD.

(5) The applications for the registration of these trademarks have been submitted on 3 April 2026 and is pending registration as at the LPD.

(6) Pursuant to the deed of assignment dated 26 May 2026 between Icare RX Holdings ("**Assignor**"), and BP (Perak) ("**Assignee**"), the Assignor has agreed to assign the Assignee the entire right, title and interest in and to the trademark. As at the LPD, the trademark has yet to be registered in the name of BP (Perak) with the MyIPO.

(7) Pursuant to the deed of assignment dated 26 May 2026 between Chuah Chong Ee, trading as Icare Pharmacy ("**Assignor**"), and BP (Perak) ("**Assignee**"), the Assignor has agreed to assign the Assignee the entire right, title and interest in and to the relevant trademarks. As at the LPD, the trademark has yet to be registered in the name of BP (Perak) with the MyIPO.

ANNEXURE C: OUR MATERIAL TRADEMARKS *(Cont'd)*

Out of the 27 material trademarks, five material trademarks are still pending registrations in Malaysia. There are no specific requirements under any prescribed law for our Group to register any of the material trademarks above. Hence, the non-registration of the material trademarks above is not expected to have a material adverse effect on the business or operations of our Group as we can continue to use such trademarks.